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Abstract 
The bacterial cell envelope heteropolymer, peptidoglycan (PG), is essential for maintaining 
the osmotic stability and shape of most bacteria. PG biosynthesis is the target of our most 
successful antibiotics, the β-lactams and glycopeptides. However, the spread of antibiotic 
resistant strains highlights the need for novel antibiotic targets.  
Gram-negative bacteria possess a mainly single layered PG, which is enlarged in growing and 
dividing bacteria by the coordinated action of PG synthases and hydrolases. PG synthesis in 
Gram-negative bacteria is regulated from the cytoplasmic membrane (CM), by prokaryotic 
cytoskeletal elements, and from the outer membrane (OM) by the lipoproteins, LpoA and 
LpoB. LpoA/B interact with, and are essential for the in vivo activity of, the major PG 
synthases PBP1A and PBP1B, respectively. While the regulation of PG synthesis has been 
well studied in recent years, the mechanisms of PG hydrolysis regulation in E. coli remain 
poorly understood. E. coli possesses ~30 PG hydrolases with relatively few known regulators.  
In this work, we have structurally characterised LpoA from E. coli using nuclear magnetic 
resonance (NMR) spectroscopy of the N-terminal domain and use this to further the 
understanding of the in vitro and in vivo interaction of LpoA/PBP1A. We also studied PBP1A 
and LpoA in Haemophilus influenzae; in this species LpoA is essential.   
In a search for novel LpoA interaction partners we discovered the in vitro and in vivo 
interaction with the PG hydrolase, PBP4 and show that PBP4 also interacts with PBP1A. 
Subsequently, we optimised a process for the rapid identification of in vitro interactions and 
identified >20 interactions between PG synthases, PG hydrolases and other cell envelope 
proteins. We therefore present a putative PG hydrolysing complex with direct associations to 
the PG synthesis machinery.  
Through direct functional interactions with at least five PG hydrolases, we present the 
characterisation of the OM-anchored lipoprotein NlpI, of currently unknown cellular function, 
as a regulator of hydrolase activity. We show the in vitro regulation of activity by NlpI and 
the in vivo relevance of these interactions using a β-lactamase induction assay.  
This work significantly enhances our understanding of how PG synthesis and hydrolysis are 
coordinated as multi-enzyme complexes and presents the characterisation of a novel regulator 
of hydrolase activity, NlpI. 
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1.1 Growth and morphogenesis of Escherichia coli 
Most bacteria proliferate by binary fission, replicating genetic and proteinaceous material 
before dividing into two, usually identical, daughter cells [1]. Rod-shaped bacteria, such as 
the model organisms Escherichia coli and Bacillus subtilis grow by alternating phases of cell 
elongation and division. These processes must ensure doubling of cell length, replication and 
segregation of genetic material, and cell division at the centre of the newly elongated 
structure, without losing structural integrity [2]. 
The peptidoglycan (PG) sacculus is the component of the bacterial cell wall crucial for 
resisting internal osmotic challenges and protection from bursting due to turgor [3,4]. This 
continuous, macromolecular, net-like structure encompasses the cytoplasmic membrane of the 
majority of bacteria and maintains cell morphology. Exceptions include the mollicutes, for 
example the mycoplasma and phytoplasma, which live intracellularly where the internal 
turgor is the same as the external and do not possess a cell wall, using cytoskeletal elements to 
maintain cell shape [3-5]. The essentiality of the sacculus necessitates highly coordinated 
growth and division, but how the cell accomplishes this whilst maintaining morphology and 
structural integrity is a poorly understood process.  
Bacteria can be characterised based on the layers and thickness of the cell envelope, including 
the PG. The monoderm Gram-positive and diderm Gram-negative bacteria (Gram, 1884) both 
have a cytoplasmic membrane (CM), composed of phospholipids and proteins, encasing the 
cytoplasm. The CM is ~7 nm thick and its primary roles are to control the influx and efflux of 
metabolites and to maintain membrane potential [7,8]. Gram-positive bacteria possess up to 
30 layers of extracellular PG, ~10-20 nm thick, with membrane-attached lipoteichoic acids, 
and wall teichoic acids in the PG layer itself [9]. Gram-positive bacteria can modify the 
glycan chains of the PG layer as methods of evading the host immune system, for example by 
O-acetylation and N-deacetylation, which make the glycan chains poor substrates for 
lysozyme [10]. O-acetylation of the MurNAc residue at the C6 hydroxyl group has also been 
observed in Gram-negative bacteria [11]. Gram-negative bacteria possess a single layer of 
PG, 3-6 nm thick, which lies parallel to the CM surface in a disordered, circumferential 
fashion, between the CM and an OM [12,13]. In E. coli, the pH of this periplasmic space 
changes depending on the pH of the external environment [14]. This is contrary to within the 
cytoplasm which is maintained at pH 7.4-7.8 [14]. The OM of Gram-negative bacteria 
possesses porins and attached lipopolysaccharides (LPS), the O-antigen of which can be 
modified as a method of evading the host immune system [15].  
  
3 
 
  
The PG layer is essential for bacterial viability and exclusive to the prokaryotic domain [5]. 
PG synthesis is therefore an attractive target for the development of antibiotics, for example 
the glycopeptides (e.g. vancomycin) and the β-lactams (e.g. penicillin). However, due to 
wide-spread usage of these PG-targeting antibiotics, bacteria have developed resistance 
mechanisms to almost every known antibiotic. For example, β-lactams, which target the 
proteins responsible for PG synthesis and hydrolysis, cause a discoordination of these 
processes which induces intracellular expression and export of enzymes capable of 
hydrolysing the attacking β-lactam, termed β-lactamases. This process is discussed in more 
detail in section 1.6.   
The increasing prevalence of resistant bacterial strains highlights the urgency to discover 
novel antibiotic targets, with the PG layer remaining one of the most promising sources. 
Characterisation of the proteins involved in PG synthesis and hydrolysis, and the functional or 
spatio-temporal interactions between these proteins, will help to establish these novel targets. 
 
1.2 The peptidoglycan sacculus 
The PG layer is composed of repeating disaccharide subunits forming linear glycan chains 
connected by short peptides. These glycan chains are formed from β1,4 linked N-
acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc) residues [16]. A 
pentapeptide is attached to the lactoyl group of each MurNAc residue. In E. coli this 
pentapeptide is comprised of; L-Ala-D-iGlu-m-Dap(meso-diaminopimelic acid)-D-Ala-D-Ala, 
however the composition of this peptide stem can vary across species and strains [3]. The 
characteristic mesh-like composition of the PG layer arises from the cross-linkage of peptides 
protruding from adjacent glycan chains. The architecture of the PG sacculus has remained 
largely unknown due to its heterogeneous and non-crystalline nature. However, recently it has 
been isolated from the Gram-negative model organism E. coli and visualised by cryo-electron 
microscopy (figure 1.1) and atomic force microscopy (AFM) [12, 17, 18]. In E. coli, the 
glycan chains can be separated by HPLC analysis up to 30 disaccharides in length [19], and it 
is estimated that the average glycan chain length in E. coli is 21 disaccharides [20, 21]. This 
number varies dramatically across species for example in the Gram positives, Bacillus species 
can contain glycan chains that are 50-250 disaccharides in length [22], where S. aureus 
contains, on average, glycan chains that are 16 disaccharides in length [23].  
The mechanisms of PG growth during elongation and division are poorly understood [24]. PG 
synthesis is thought to be facilitated by multi-enzyme complexes of periplasmic and 
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membrane-bound PG synthases and hydrolases. The activity and spatio-temporal localisation 
of these proteins is coordinated from the CM by prokaryotic cytoskeletal elements, and 
associating CM proteins, and from the OM by membrane-anchored lipoproteins. The 
intracellular prokaryotic actin homolog MreB is essential for rod shape in a number of species 
and is thought to control insertion of nascent PG throughout the lateral cell wall [25]. MreB 
forms discrete, dynamic patches which move along the short axis of the cell in a helical and 
circumferential fashion [26]. The current model suggests that MreB and associated proteins 
act to spatio-temporally position and/or regulate the PG synthase/hydrolase complexes along 
the lateral cell wall, supported by the observed helical insertion of lipid II [21,22]. This cell 
wall synthesis machinery specific for elongation of the cell is termed the elongasome and will 
be discussed in more detail in section 1.5.1. 
The polymerisation of the prokaryotic tubulin homologue FtsZ into the Z ring is essential for 
cell division [29]. The Z ring recruits a number of other essential division proteins which in 
turn recruit PG synthases. This complex is termed the divisome and is required for the 
formation of the septum, daughter cell pole synthesis and cleavage [30]. This will be 
discussed in more detail in see section 1.5.2.  
Gram-negative bacteria are also capable of coordinating PG synthesis from the OM. The OM-
anchored lipoproteins, LpoA and LpoB interact with, and are essential for the in vivo activity 
of, the CM-anchored major PG synthases PBP1A and PBP1B, respectively [25,26]. This 
regulation will be discussed in more detail in section 1.3.4. 
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Figure 1.1 The peptidoglycan sacculus [12] 
Electron cryotomography slices of an E. coli sacculus show the perpendicular orientation of the glycan strands to 
the polar axis of the cell. SW; Side wall. GR; granule. W; wrinkle.  
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1.3 Peptidoglycan synthesis in E. coli 
1.3.1 Synthesis of the peptidoglycan precursor lipid II 
Lipid II is the last PG precursor and its synthesis is initiated in the cytoplasm. The sequential 
action of three enzymes, GlmS, GlmM, and the bifunctional GlmU, complete four activities; 
glucosamine-6-phosphate synthase, phosphoglucosamine mutase, glucosamine-1-phosphate 
acetyltransferase, and N-acetylglucosamine-1-phosphate uridyltransferase which yield the 
nucleotide-activated UDP-GlcNAc from fructose-6-phosphate [27-29].  
MurA (formerly MurZ) catalyses the transfer of an enolpyruvate moiety from 
phosphoenolpyruvate (PEP), onto UDP-GlcNAc, to yield UDP-MurNAc-enolpyruvate. This 
is reduced by the NADPH-dependent UDP-MurNAc dehydrogenase MurB, to yield UDP-
MurNAc [35]. The antibiotic fosfomycin targets MurA whose essential activity is the first 
committed step to PG synthesis [31,32].  
The successive activity of four murein (Mur) ligases; MurC, MurD, MurE and MurF, catalyse 
the addition of L-Ala, D-iGlu, m-Dap, and a D-Ala-D-Ala dipeptide, respectively, to the D-
lactoyl moiety of UDP-MurNAc [33,34]. L-Ala is converted to D-Ala by the alanine racemase 
DadX (and/or Alr) [40]. The D-Ala-D-Ala dipeptide is generated by two D-Ala-D-Ala ligases, 
DdlA and DdlB [41]. The glutamate racemase MurI is activated by UDP-MurNAc-L-Ala to 
catalyse the formation of D-iGlu from its L-enantiomer [42]. m-Dap occurs as an intermediate 
of the lysine biosynthetic pathway [43].  
The transferase MraY catalyses the transfer of the phospho-MurNAc pentapeptide moiety 
from UDP-MurNAc-pentapeptide to the membrane acceptor molecule undecaprenol 
phosphate (Upr-P), creating the CM-linked intermediate, lipid I [44]. MurG catalyses the 
transfer of GlcNAc from the nucleotide-activated sugar UDP-GlcNAc to lipid I to form the 
β1,4 linked disaccharide pentapeptide, lipid II (GlcNAc-β1,4-MurNAc-L-Ala-D-iGlu-m-Dap-
D-Ala-D-Ala) [40,33]. See figure 1.2 for a schematic of the formation of lipid II and 
incorporation of lipid II into the pre-existing PG layer.   
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Figure 1.2 Synthesis and hydrolysis of peptidoglycan [46] 
The synthesis of the last PG precursor, lipid II, is initiated and completed in the cytoplasm with the sequential 
activity of MurC, MurD, MurE, and MurF which respectively catalyse the addition of L-Ala, D-iGlu, m-Dap, and 
a D-Ala-D-Ala dipeptide to the D-lactoyl moiety of UDP-MurNAc. The transferase MraY catalyses the transfer of 
the phospho-MurNAc pentapeptide moiety from UDP-MurNAc-pentapeptide to the membrane acceptor 
molecule undecaprenol phosphate (Upr-P), creating the CM-linked intermediate, lipid I. MurG catalyses the 
addition of a GlcNAc residue forming lipid II. Lipid II is ‘flipped’ into the periplasmic space by integral 
membrane proteins FtsW/RodA, to be incorporated into the pre-existing PG layer by a process of 
glycosyltransferase (GTase) reactions and transpeptidation (TPase) reactions. These processes are performed by 
the PG synthases. The PG hydrolases including endopeptidases (EPase), carboxypeptidases (CPase), lytic 
transglycosylases (LT) and amidases have specificity for almost every bond of the PG network and cleavage of 
these bonds allows insertion of nascent material. 
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1.3.2 Growth of the sacculus 
In E. coli, lipid II is flipped from the cytoplasmic side of the CM to the periplasmic side by 
integral CM proteins; either MurJ or FtsW/RodA or both [41,42]. Lipid II undergoes 
processive polymerisation into glycan chains via glycosyltransferase (GTase) reactions. The 
pre-existing donor glycan chain is transferred to the next lipid II molecule, the energy 
required for which is produced by the removal of the Upr-P anchor of the acceptor chain [29-
31]. The pentapeptide side chains between adjacent strands are cross-linked by transpeptidase 
(TPase) reactions between the carboxyl group of the penultimate D-Ala residue of a donor 
strand and the ε-amino group of the m-Dap residue of an acceptor strand. The energy for this 
cross-linkage is generated from the cleavage of the terminal D-Ala residue of the donor strand 
[51]. Referred to as DD-peptide bonds these D-Ala-m-Dap linkages comprise 93% of cross-
links in E. coli. A small percentage of peptides are connected by m-Dap-m-Dap linkages (LD-
peptide bonds) [21]. Glycosyltransferase reactions can occur without subsequent 
transpeptidation, as observed upon application of TPase domain-targeting β-lactams [52]. 
The bifunctional Class A penicillin-binding proteins (PBPs) PBP1A, PBP1B and PBP1C, 
monofunctional TPase Class B PBPs, PBP2 and PBP3 and the monofunctional GTase MtgA, 
carry out these processes for the successful incorporation of nascent PG into the sacculus (see 
section 1.3.3 for more detail) [51]. Enzymes possessing GTase activity are the target of the 
phosphoglycolipid antibiotic moenomycin, which mimics the structure of lipid II and binds to 
the GTase domain of PBPs [53]. β-lactams, such as penicillin, are structurally analogous to 
the terminal D-Ala-D-Ala dipeptide and covalently bind to the TPase active site to block 
activity, hence the nomenclature, penicillin-binding proteins [54]. Modifications to the 
substrates to which these compounds mimic, are a method of acquiring multi-drug resistance 
[55]. 
There are a number of models for dynamic PG growth [51,12,13]. Most agree that PG 
synthases produce glycan chains from the PG precursor lipid II and attach it to the pre-
existing sacculus where PG hydrolases generate the space for incorporation of the nascent 
material. Indeed, if there were only insertion of PG, the cell wall would thicken rather than 
increase in surface area, whereas the cell is capable of doubling in length whilst maintaining a 
constant diameter. Intuitively then, there must be coordination between PG hydrolysis and PG 
synthesis. Höltje’s ‘three-for-one’ model purports that three nascent glycan strands are 
synthesised and docked beneath one pre-existing glycan strand, before PG hydrolases remove 
the docking strand allowing for simultaneous insertion of the nascent material [43,51]. This 
would facilitate safe and coordinated enlargement of the sacculus whilst maintaining rod-
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shape (see figure 1.3). The model suggests the presence of multi-enzyme PG-synthesising 
complexes for the coordination of PG synthesis and hydrolysis. Further, a theory was 
presented for the bactericidal properties of PG synthase-targeting antibiotics. It was proposed 
that the inhibition of the PG synthases, by moenomycin and penicillin for example, does not 
stop the movement of this multi-enzyme complex, leaving the space-making hydrolases free 
to degrade PG without subsequent insertion of newly synthesised PG, and thus cause cell lysis 
[52,53]. A single-layered model for PG in Gram-negative bacteria is currently widely 
accepted. Huang et al (2008) used their ‘elastic’ model to predict that the single layered 
scenario is most likely, in comparison to the scaffold model which purports that the glycan 
chains lie vertically [60]. Similarly, Gan et al, (2008) used electron cryotomography of the E. 
coli sacculus to reveal the perpendicular orientation of the glycan chains to the polar axis of 
the cell (see figure 1.1), which supports the single-layered model rather than the vertical 
glycan strands of the scaffold model [12].  
While much of the basic PG-synthesising apparatus in E. coli, and described in the following 
sections, are conserved throughout Gram-negative and Gram-positive bacteria, the myriad of 
morphologies that exist suggest differing methods of coordinating the processes of PG 
synthesis and hydrolysis [46]. A broad example of this is the absence of an OM in Gram-
positive bacteria, therefore the OM-anchored proteins described in the following sections, 
such as NlpI and LpoA are not present. However, the redundantly essential endopeptidases of 
B. subtilis  CwlO and LytE, are controlled by the CM-bound FtsEX sub complex [61] which 
likely acts to coordinate hydrolase activity with PG synthesis where, in contrast to, and 
presented in this work, a number of EPases in E. coli that are controlled by an OM-anchored 
lipoprotein. As the proteins that these OM-anchored proteins interact and regulate are widely 
conserved throughout walled bacteria, for example PBP1A whose interaction with LpoA is 
essential in vivo for PBP1A activity, it is therefore possible that PBP1A orthologues in other 
species may undergo regulation by different methods. The mechanisms of controlling 
hydrolase activity in E .coli and described in this project may be conserved throughout Gram-
negative bacteria due to the ubiquity of the proteins involved; however other species may 
have adaptations on these methods to tailor the coordination between PG synthesis and 
hydrolysis with their size, growth rate and external environments.  
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Figure 1.3 The ‘three-for-one’ model of peptidoglycan growth [50] 
Proposed by Höltje (1998) the three-for-one model suggests that a multi-enzyme complex of PG synthases 
(TPases; transpeptidases, TG/GTase; transglycosylases) and hydrolases (LT; lytic transglycosylases, EP; 
endopeptidases) act to insert three nascent PG strands (grey strands) using one pre-existing strand as a template. 
The template docking strand is removed by the action of PG hydrolases.  
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1.3.3 Peptidoglycan synthases of E. coli 
Table 1.1 The synthases/regulators of Escherichia coli PG synthesis 
 
1See text for detailed discussions and references     2Figures obtained from [62] 
CM, cytoplasmic membrane; OM, outer membrane; SP, soluble periplasmic 
MOPS, potassium morpholinopropane sulfonate 
MOPS
MOPS 
minimal
PBP1A mrcA 93636 6.1 • CM                        
• Lateral wall   
• Division site
• GTase             
• TPase                 
• Cell wall 
synthesis in 
cell elongation
• PBP2                                   
• LpoA
554 116
PBP1B mrcB 94292 9.1 • CM                         
• Division site 
• Lateral wall
• GTase             
• TPase                 
• Cell wall 
synthesis in 
cell division
• PBP3                         
• LpoB                        
• MltA    
• MltB    
• TolA                                                                                          
• Slt
• FtsN                
• CpoB       
• FtsW      
512 139
PBP1C pbpC 85067 9.5 • CM • GTase             
• TPase                 
• Unknown
• PBP1B                         
• PBP2   
• PBP3                               
• MltA 
• MltB
18 11
PBP2 pbpA/ 
mrdA
70857 8.8 • CM                        
• Lateral wall   
• Division site
• TPase                          
• Essential for 
cell elongation               
• PBP1A         
• MreC
• MltA 
• MltB  
• Slt
324 76
PBP3 ftsI 63877 9.6 • CM                         
• Division site
• TPase                          
• Essential for 
cell division              
• PBP1B                          
• FtsW              
• Slt                                
• ZapA                                                                                                         
• FtsQ
• FtsL       
• FtsK  
• MltB
• Slt     
349 144
MtgA mtgA 27369 10.4 • CM                        
• Division site 
• GTase          
• Unknown   
• PBP3                             
• FtsW                             
• FtsN
47 22
LpoA lpoA 72873 5.3 • OM                        
• Lateral wall
• Regulation  
of PBP1A 
activity
• PBP1A 513 250
LpoB lpoB 22516 6.4 • OM                        
• Division site
• Regulation  
of PBP1B 
activity
• PBP1B 1490 954
CpoB ybgF 25932 8 • SP              
• Division site
• Regulation of 
PBP1B 
activity 
• PBP1B 
• TolA
5262 1511
Copy number 
synthesised per 
generation
2Interaction       
partners
1
Activities/            
Primary role
1 LocalisationpI
MW 
(Da)
GeneProtein 
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1.3.3.1 The bifunctional penicillin-binding proteins 
In E. coli there are three families of enzymes responsible for PG synthesis; the bi-functional 
Class A PBPs (PBP1A, PBP1B and PBP1C), the monofunctional TPase Class B PBPs (PBP2 
and PBP3), and a monofunctional GTase (MtgA) (table 1.1).  
The major PG synthases of E. coli are the bifunctional Class A PBPs; PBP1A (mrcA) and 
PBP1B (mrcB). Cells with single deletions in these genes grow normally, but a double 
deletion is synthetically lethal, indicating these proteins are redundantly essential for cell 
growth [55,56]. Both proteins are CM-anchored via a single transmembrane region, possess a 
small non-catalytic domain and have two enzymatic domains (GTase and TPase) that are 
linked by a short β-rich region [44,56,49]. PBP1A and PBP1B, as well as PBP2 and PBP3, 
were recently shown to be folded and inserted into the CM by the concerted action of the 
membrane protein insertase/foldase YidC, and the Sec translocon [66]. 
The activity of PBP1A can be observed in vitro using radioactively-labelled lipid II [67]. By 
observing the resulting material by reversed-phase HPLC, PBP1A produces glycan chains 
that are, on average, 18.2 disaccharides in length with 26.4% of peptides participating in 
cross-links [67]. There is an initial delay in cross-link formation and PBP1A is unable to 
cross-link pre-formed glycan strands, implying that TPase reactions require ongoing GTase 
activity [67].  
PBP1A/1B bind non-covalently to the peptide stem allowing the active site serine residue of 
the TPase domain to attack the carbonyl carbon atom of the D-Ala-D-Ala dipeptide [59,60]. 
This forms an acyl-enzyme intermediate that concomitantly cleaves the terminal D-Ala 
residue [59,60]. The energy released from this cleavage facilitates the formation of cross-links 
with an adjacent acceptor peptide stem [51].  
Presently, there is no crystal structure for E. coli PBP1A, however, based on homology with 
PBP1A from Acinetobacter baumanii it possesses a small non-catalytic domain located close 
to the TPase domain. This region is termed the Outer-membrane Docking Domain or ODD 
and is the predicted interaction site for the OM-anchored lipoprotein LpoA, an interaction 
essential for in vivo PBP1A function [31]. This interaction, and the role of PBP1A in cell 
elongation, will be discussed in section 1.3.4. PBP1A localises to the lateral cell wall and 
upon deletion causes the formation of cells with a narrower diameter [70]. This, and its 
interaction with PBP2, the Class B PBP essential for cell elongation, will be discussed in 
1.3.3.3.  
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The crystal structure of E. coli PBP1B has been determined in complex with moenomycin 
which binds to the active site of the GTase domain [71]. The annotated GTase domain is 
similar to that found in the bifunctional PBP2 of Staphylococcus aureus and a GTase domain 
from a Class A PBP from Aquifex aeolicus, indicating a high degree of active site 
conservation [63,64]. Unlike the structure of the bifunctional PBP2 from the Gram-positive S. 
aureus, E. coli PBP1B possesses a non-catalytic domain, between the TPase and GTase 
domains, that is structurally homologous (24% sequence identity) to a domain found in the 
UvrB protein, termed the UvrB domain 2 homolog, or UB2H domain [65,62]. Recently this 
domain was characterised as the docking domain for the OM-anchored lipoprotein LpoB, an 
interaction essential for the in vivo function of PBP1B [75]. Like LpoB, the UB2H domain is 
only found in the γ-proteobacteria. PBP1B has been shown to dimerise with a KD of 130 nM 
[76] and it is hypothesised that PBP1A also forms a homodimer. 
As-of-yet there is no data purporting to the primary function of PBP1C (pbpC) which is 
anchored to the CM [77]. In affinity chromatography experiments it specifically retained 
PBP1B, PBP2, PBP3 and the lytic transglycosylase MltA, on sepharose beads, implying it 
exists as part of the multi-enzyme PG-synthesising complex, yet shows no phenotype upon 
deletion [77]. PBP1C polymerises PG and binds moenomycin, but a deletion in pbpC results 
in a loss of only 3% PG synthesis activity compared to 95% in a PBP1B deletion [77]. 
Dispensable for growth and expressed at ~20 copies per cell [62], it is thought unlikely that 
this protein has a major contribution to PG synthesis.   
 
1.3.3.2 Monofunctional peptidoglycan synthases  
The monofunctional PG synthases of E. coli are the Class B PBP TPases, PBP2 (pbpA) and 
PBP3 (ftsI) and the GTase, MtgA (mtgA). The Class B PBPs possess a non-catalytic N-
terminal domain and a C-terminal catalytic TPase domain. The function of the N-terminal 
domain has been hypothesised to facilitate protein-protein interactions, and/or aid in substrate 
binding [43,49].  
PBP2 is essential to bacterial viability and it has been shown, originally by Spratt (1975), if 
the activity of this monofunctional TPase is blocked by the β-lactam mecillinam, cells no 
longer grow as rods but adopt an ovoid morphology before lysis [78]. A GFP-PBP2 protein 
fusion was shown to predominantly localise in dynamic patches throughout the circumference 
of the lateral cell wall [79]. PBP2 is also capable of localising to the division site, albeit 
briefly, before the onset of constriction, but cannot in the presence of aztreonam which binds 
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with high specificity to PBP3 [70,53]. The localisation of PBP2 to the division site therefore 
relies on the activity of PBP3.  
The monofunctional TPase PBP3 is essential for cell division [78]. If the activity of PBP3 is 
blocked by the specific binding of the β-lactam aztreonam, cells form filaments before lysing 
[81]. PBP3 forms a subcomplex with the lipid II flippase FtsW prior to localisation to the 
division site (see section 1.5.2) [82]. The crystal structure of PBP3 from E. coli shows a 
transmembrane helix followed by a bimodular periplasmic region consisting of a C-terminal 
catalytic TPase domain and the non-catalytic N-terminal domain [83]. The TPase domain 
shows structural homology to the corresponding catalytic domains of other published PBP3 
crystal structures, including Acinetobacter baumanii and Pseudomonas aeruginosa [75,76]. 
MtgA is a CM-anchored, non-essential, monofunctional GTase that polymerises lipid II in 
vitro [77,78]. In cells absent of PBP1B, and expressing a temperature sensitive PBP1A, MtgA 
localises to sites of cell division. This localisation is thought to occur to compensate for the 
lack of GTase activity through direct or indirect interactions with PBP3, FtsW and FtsN [86]. 
However, at present, the primary role of MtgA is unknown.  
 
1.3.3.3 Interactions between Class A and Class B peptidoglycan synthases 
As described above, two monofunctional TPases have been characterised as essential for 
growth. PBP1A/1B are redundantly essential for growth, each being able to compensate for 
the lack of the other but a double deletion is synthetically lethal [55,79]. PBP1A is the 
primary Class A PBP during elongation (section 1.5.1) and PBP1B is the primary Class A 
PBP during cell division (section 1.5.2). As the cell is capable of propagating in the presence 
of only one of these PBPs, it suggests that there exist interactions between the components of 
their non-cognate complexes (section 1.5.3).  
Bacterial two-hybrid analysis and affinity chromatography, using immobilised PBP2 
incubated with a membrane fraction from E. coli, showed the specific interaction between 
PBP2 and PBP1A [70]. The continuous GTase activity of PBP1A can be measured in vitro 
using dansylated lipid II in which a fluorescent dansyl moiety is conjugated to the ε-amino 
group of the m-Dap residue. Polymerisation of dansylated lipid II and subsequent digestion 
with a muramidase (e.g. cellosyl) results in muropeptides with less fluorescence than the 
substrate [88]. Hence, GTase activity can be measured as fluorescence against time. Using 
this assay, PBP2, and not PBP3, was shown to stimulate lipid II consumption by PBP1A [70]. 
As PBP2 is essential for cell elongation, and both PBP1A and PBP2 localise to the lateral cell 
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wall, PBP1A and PBP2 are likely the primary PG-synthesising proteins during cell elongation 
and PBP2 is involved in the regulation of PBP1A GTase activity.  
Affinity chromatography using immobilised PBP3, incubated with a membrane extract from 
E. coli, showed the specific retention of PBP1B [89]. The interaction was confirmed in vivo 
and in vitro using co-immunoprecipitation and surface plasmon resonance (SPR) and occurs 
with an estimated KD of 435 nM. Like PBP3, PBP1B primarily localises to the cell division 
site, and this localisation is dependent on the presence, but not activity, of PBP3, implying 
that PBP3 and PBP1B are the primary PG synthases during cell septation [89].  
 
1.3.4 Outer-membrane lipoprotein activators of PBPs 
In E. coli, and presumably other Gram-negative bacteria, the cellular function of PBP1A and 
PBP1B relies on interactions with the OM-anchored lipoproteins, LpoA and LpoB, 
respectively [25,26]. The deletion of one Lpo and its non-cognate PBP is synthetically lethal, 
indicating that cells require either PBP1A and LpoA or PBP1B and LpoB for growth [25,26]. 
LpoA and LpoB are evolutionarily restricted to the γ-proteobacteria and the enterobacteria, 
respectively, while orthologs of PBP1A and PBP1B are expressed throughout walled bacteria 
[69]. LpoA and LpoB have coevolved with their respective PBP docking domains, 
hypothesised to be the ODD of PBP1A and confirmed to be the UB2H domain of PBP1B 
[25,67].  
LpoB is comprised of a long OM-anchored N-terminal flexible region with a maximal length 
of ~145 Å and a small C-terminal globular domain (figure 1.4A) [75]. It is long enough to 
reach from the OM through pores in the PG layer to interact with the UB2H domain of 
PBP1B with an estimated KD of 810 nM. Upon interaction, LpoB stimulates the GTase 
activity of PBP1B ~8 fold and stimulates cross-link formation from 53% to 73% of peptides 
[31]. LpoB stimulates the GTase domain of PBP1B causing a subsequent enhancement of 
TPase activity, indicating these domains are intrinsically connected, or that the TPase domain 
of PBP1B has specificity for polymerised substrate [90].  
PBP1B/LpoB has another role in the coordination of OM constriction with PG synthesis, 
primarily through shared interactions with the Tol/Pal system [91]. The Tol-Pal system is a 
cell envelope-spanning complex of membrane-bound and periplasmic proteins required for 
coordination of membrane growth [92]. CpoB (Coordinator of PG synthesis and OM 
constriction, associated with PBP1B) is encoded by the last gene in the Tol/Pal operon, ybgF, 
and interacts directly with PBP1B and TolA [82,84]. Its localisation to the divisome is reliant 
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on ongoing PG synthesis but not PBP1B. PBP1B, LpoB, TolA and CpoB form a complex in 
which the activity of PBP1B is modulated based on the energy state of the Tol/Pal complex 
[82,85]. These functional interactions provide a mechanism for altering PG synthesis in 
response to OM invagination during daughter cell separation [91]. 
The structural model of LpoA was elucidated as part of this project (see section 3.1.2.2). 
LpoA exists as an elongated, bimodular monomer of ~70 kDa long enough to presumably 
reach through pores in the PG layer from the OM to interact with PBP1A (figure 1.4B) [95]. 
This interaction has not been characterised to the same degree as PBP1B/LpoB, in part due to 
the lack of a crystal structure for E. coli PBP1A [95]. The N-terminal domain (LpoAN) 
consists primarily of tetratrico-peptide repeat (TPR) motifs which are frequently found in 
proteins with known interaction partners [96]. Between the helices of a number of these TPR 
motifs, are conserved amino acids [95]. LpoA stimulates the TPase activity of PBP1A, 
increasing the percentage of peptides in cross-links from 41% to 67% [31]. Conversely to 
LpoB/PBP1B, the stimulation of TPase activity by LpoA causes an increase in GTase 
activity, although this stimulation has not been observed using the same continuous 
fluorescence-based GTase activity assay used to show the stimulation of PBP1B by LpoB or 
PBP1A by PBP2 [81,88]. The catalytically active domains of PBP1A/B are clearly 
functionally linked and are activated in different ways by their cognate lipoprotein interaction 
partners. 
The C-terminal domain of LpoA (LpoAC) is capable of interacting with, and stimulating the 
activity of, PBP1A alone, inferring it is this domain with which LpoA interacts with PBP1A 
[25,62]. The structural model of E. coli LpoAC predicts two unstructured ‘wing’-like domains, 
of presently unknown function, which are not present in the crystal structure of the Gram-
negative organism Haemophilus influenzae, in which LpoA is essential [90,91]. These 
unstructured regions are thought to fold into rigid structures when engaged in protein-protein 
interactions [91,87]. Both LpoAN and CpoB possess TPR-like motifs and cells absent in both 
are synthetically sick inducing OM blebbing and lysis [83,87,85]. However, cells lacking 
PBP1A and CpoB do not have a phenotype, indicating a second role for LpoA, independent 
of PBP1A regulation. Specifically, cpoB-mrcA-lpoA(ΔTPR) cells re-establish the same defects 
as a cpoB-lpoA- strain, implying it is LpoAN that possesses this additional role. Cells lacking 
CpoB and the TPR domain of LpoA are only sick in the absence of PBP1B, and grow 
normally in the presence of active PBP1A. LpoAN and CpoB are therefore thought to be 
redundantly essential for the coordination of PG and OM growth.    
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Figure 1.4 CM-anchored PG synthases are regulated by OM-anchored lipoproteins [67,87] 
A. LpoB (blue) is anchored to the OM and uses its ~145 Å flexible N-terminal region to reach through pores in 
the PG layer to interact with the UB2H domain (yellow) of PBP1B (grey) to stimulate activity. B. LpoA is 
anchored to the OM and is predicted to reach through pores in the PG layer to interact with the ODD of PBP1A 
to stimulate activity. The C-terminal domain of LpoA (orange) is sufficient to stimulate PBP1A activity. The N-
terminal domain of LpoA (dark blue) possesses TPR-like motifs and has an additional CpoB-related function. 
The crystal structure of E. coli PBP1A is not yet known.  
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1.4 Peptidoglycan hydrolysis in E. coli 
1.4.1 The peptidoglycan hydrolases of E. coli 
Current models of PG growth agree that simply synthesising and inserting nascent PG into the 
pre-existing PG layer would not facilitate successful growth of the sacculus. Instead, pre-
existing PG must be cleaved or even removed prior to insertion of nascent PG. This process is 
accomplished by the PG hydrolases which turnover approximately 40-50% of the PG layer 
per generation [101]. In E. coli there are ~30 membrane-bound and soluble, periplasmic PG 
hydrolases, with hydrolytic activity identified for almost every glycosidic/amide bond of the 
sacculus (figure 1.5 and tables 1.2-1.6) [102]. They include the N-acetylmuramyl-L-alanine 
amidases, N-acetylglucosaminidases, lytic transglycosylases, endopeptidases and 
carboxypeptidases [94,95]. Those enzymes relevant to this project will be discussed in detail 
in the following sections.  
The turnover products of PG hydrolysis are recycled for de novo PG synthesis, used for cell 
signalling, and are essential for the induction of β-lactamase production in response to 
antibiotic stress (section 1.6) [96,97]. PG hydrolases are also required for PG remodelling in 
response to extracellular challenges, influencing pathogenicity [102]. 
Single deletions of hydrolase genes show no effect on growth and many of the enzymes have 
multiple activities, therefore if PG hydrolysis is essential there must be a high degree of 
functional redundancy, which complicates the characterisation of specific hydrolases [103]. 
Some have specificities for intact sacculi or soluble muropeptides where others, termed 
autolysins, can be responsible for cell lysis. Relative to the number of PG hydrolases in E. 
coli, there are few known regulators, e.g. EnvC, NlpD and BolA (section 1.4.6). How these 
potentially autolytic enzymes are regulated is an important facet of PG growth and forms the 
basis for much of this project.  
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Figure 1.5 The peptidoglycan hydrolases of E. coli [103] 
E. coli PG hydrolases cleave almost every amide and peptide bond in the PG network. The endopeptidases 
(EPase) cleave the amide bond between DD, LD, and DL-peptides. Carboxypeptidases (CPases) cleave the 
terminal D- or L-amino acids of peptide stems. Amidases (Ami) hydrolyse the bond between the D-lactoyl of 
MurNAc and the N-terminal L-Ala residue. The amidase AmiD is capable of cleaving this bond at an anhydro-
MurNAc sugar. 
 
1.4.2 Endopeptidases of E. coli  
The endopeptidases (EPases) are the PG hydrolases responsible for the cleavage of amide 
cross-links. Those that cleave between D-Ala (position 4) and m-Dap (position 3) residues are 
termed DD-EPases [103]. These include the penicillin sensitive PBP4, PBP7, and AmpH, the 
penicillin-insensitive MepA (murein endopeptidase A), and three novel, redundantly essential, 
EPases Spr, YebA and YdhO, recently renamed to MepS, MepM and MepH, respectively 
[98-102]. MepA also possesses LD-EPase activity, however, monofunctional LD-EPases are 
less common in Gram-negative bacteria than Gram-positive. One such protein has been 
identified in E. coli, which remains uncharacterised, that releases the terminal D-Ala-D-Ala 
dipeptide upon cleavage of (L)-m-Dap-D-Ala cross-linked muropeptides, the opposite activity 
of the MurF ligase [109]. It is also hypothesised to catalyse the formation of (L)-m-Dap-(D)-
m-Dap cross-linkages (LD-TPase activity), in correlation with an LD-TPase from 
Enterococcus faecalis which cleaves the D-Ala-D-Ala dipeptide to form the same bond 
[80,105,82]. See table 1.2 for a list of the EPases of E. coli. 
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Table 1.2 The endopeptidases of E. coli 
1See text for detailed discussions and references     2Figures obtained from [62] 
CM, cytoplasmic membrane; OM, outer membrane; SP, soluble periplasmic 
MOPS, potassium morpholinopropane sulfonate 
MOPS
MOPS 
minimal
PBP4 dacB 51798 8.9 • SP/CM              
• Type 4 Class C 
PBP
• DD-EPase              
• DD-CPase              
• Deletion causes  
reduced β-
lactamase 
induction
― 441 133
PBP7/8 pbpG 34271 9.9 • SP                     
• Type 7 Class C 
PBP
• DD-EPase              
• Septum cleavage           
• Biofilm formation              
• PBP8 formed 
from action of 
OmpT                       
• Stimulates Slt 
activity
• Slt 1005 242
AmpH ampH 41849 9.5 • CM                    
• Type AmpH 
Class C PBP
• DD-EPase              
• DD-CPase
― 460 116
MepA mepA 30098 8.8 • SP                     
• LAS 
Metallopeptidase 
• DD-EPase             
• LD-EPase               
― 625 273
MepS mepS/ 
spr
21039 10 • OM                   
• NlpC/P60 
(CHAP 
superfamily)
• DD-EPase              
• Redundantly 
essential with 
MepM and MepH
― 3931 2535
MepM mepM/ 
yebA
49057 9.5 • M23/LytM 
metallopeptidase
• DD-EPase              
• Metallopeptidase   
• Redundantly 
essential with 
MepS and MepH                 
• Septum cleavage      
• LytM domain
― 341 379
MepH mepH/ 
ydhO
30317 10.5 • NlpC/P60 
(CHAP 
superfamily)
• DD-EPase              
• Redundantly 
essential with 
MepS and MepM
― 265 238
Interaction       
partners
1
Copy number 
synthesised per 
generation
2Protein Gene
MW 
(Da)
pI
Localisation/ 
Protein family
Activities 
/Primary role
1
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1.4.2.1 Penicillin-sensitive endopeptidases 
Like all PG hydrolases, PBP4 (dacB) is non-essential in E. coli, however a single deletion in 
dacB results in the diminished induction of the β-lactamase AmpC [112]. PBP4 shows 
sequence similarity to the Class C family of β-lactamases and belongs to the type 4 family of 
PBPs [113]. It is soluble and periplasmic, although a loose association to the CM has been 
observed [107]. It possesses both DD-EPase and DD-CPase activity on sacculi and soluble 
muropeptides, and is potentially autolytic [99,106]. Like many of the hydrolases there is no 
known regulator of activity. The crystal structure of PBP4 shows a face-to-face-dimer with 
each monomer consisting of an interesting formation of three domains; the catalytic serine 
residue at position 62 is located within domain 1, into which domain 2 is inserted, into which 
domain 3 is inserted (figure 1.6) [115]. This Russian doll-like domain assembly is conserved 
between other type 4 PBPs with known crystal structures; Actinomadura R39 DD-peptidase 
and PBP4a of B. subtilis [108,109]. The active site of E. coli PBP4, and conserved among 
other type 4 PBPs, accommodates its substrate through the presence of a hydrophobic residue 
at the C-terminus of the β3 strand situated in the active site-containing domain 1. In addition, 
a number of residues of domain 2 are utilised to create a pocket to facilitate the binding of the 
terminal H3N
+–CH–COO- group of the m-Dap and its cross-linked amino acid [117]. Domain 
3 is globular with a strong hydrophobic core, constitutes ~40% of the dimer surface, and has a 
hypothesised role in the regulation of substrate entry to the active site [118].  
PBP7 (pbpG) is a soluble monofunctional EPase sharing 15% sequence identity with PBP4 
[119]. It is the second most abundant PBP behind the CPase PBP5 (dacA) and while a 
deletion in pbpG causes no observable phenotype, a double deletion of both proteins  causes 
considerable morphological defects [112-113]. It is reported that PBP7, and its proteolytic 
degradation product PBP8, are exclusively active against intact sacculi [122]. PBP8 is an 
artefact formed during purification as a result of C-terminal degradation of PBP7 by the OM 
protease OmpT [123]. Inactivation or overexpression of PBP7/8 has no effect on sacculi 
composition, but an interaction occurs with the soluble lytic transglycosylase, Slt70, causing 
stimulation of Slt activity, implying cooperativity of different hydrolytic activities [111,115]. 
Although individually non-essential, PBP4 and PBP7 have been implicated as determinants 
for controlling bacterial cell morphology in E. coli [121]. 
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Figure 1.6 Monomeric and dimeric crystal structures of PBP4 [115] 
The monomeric (A) and dimeric (B) crystal structures of PBP4 as determined by [115] reveals three distinct 
domains. The catalytic serine residue at position 62 is situated in domain 1, with domain 3 forming a distinct 
globular region. Domain 3 constitutes ~40% of the dimer surface 
 
1.4.2.2 Penicillin-insensitive endopeptidases 
MepA is a DD-EPase belonging to the LAS metallopeptidase family and contains a Zn2+-
binding catalytic triad (His-113, Asp-120, and His-211) at the active site, thus making it 
susceptible to metal chelators such as EDTA [116,117]. The crystal structure is an elongated 
dimer [127]. MepA is soluble and periplasmic and shows no morphological changes upon 
over-expression or deletion. It possesses both DD-EPase and LD-EPase activity, cleaving 
both D-Ala-m-Dap and m-Dap-m-Dap amide linkages [128]. 
MepS (Spr), MepM (YebA) and MepH (YdhO) DD-EPases of E. coli, and the DL-EPases 
CwlO and LytE of B. subtilis, were the first evidence of redundantly essential hydrolases for 
PG growth in their respective organisms [120,121]. In E. coli, MepS, MepM and MepH 
cleave the D-Ala-m-Dap peptide linkages and, like all other PG EPases, single deletions in 
each are viable. However, cells lacking all three lyse rapidly indicating redundant essentiality 
for PG growth and were shown to be the hydrolases responsible for creating the space 
required for nascent PG insertion in E. coli [129].  
MepS belongs to the NlpC/P60 group of peptidases, and its structure has been determined by 
NMR spectroscopy [131]. It possesses a novel catalytic triad of Cys-His-His within a 
structurally-buried active site. MepH also belongs to this family of peptidases; however, only 
MepH has been shown to be active on intact sacculi [129]. The overexpression of active PBP7 
is sufficient to phenotypically compensate for a deletion in mepS [132], implying that MepS is 
A B
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active on sacculi in vivo. MepS is expressed at >2000 copies per cell during exponential phase 
but is rapidly subjected to proteolytic degradation facilitated by the OM-anchored New 
Lipoprotein I (NlpI) and the tail-specific protease, Prc (described in more detail in section 1.7) 
[108]. 
MepM belongs to the lysostaphin-like metalloprotease (LytM) M23 family of peptidases and 
has a Zn2+-binding active site, and thus is inactivated by metal chelators [124,125]. It 
expresses a LytM domain, commonly found in PG-binding proteins, and proteins implicated 
in daughter cell separation such as the regulators of amidase activity, NlpD and EnvC (section 
1.4.6) [135]. Deletion of mepM in an envC-nlpD- background exacerbates cell division defects 
implying either an indirect role in amidase regulation or a direct role in cell separation [134]. 
However, despite this implicated role in cell separation, MepM has a disseminated peripheral 
localisation [134].  
 
1.4.3 Carboxypeptidases of E. coli 
Carboxypeptidase (CPase) activity results in the removal of the terminal D-Ala residue at 
position 5 of a pentapeptide [136]. Formation of the acyl-enzyme complex on the peptide 
stem, and the attack of the active site serine on the carbonyl moiety of the D-Ala-D-Ala 
dipeptide by the PBP, is the same as the TPase reaction [51]. The deacylation step of CPases 
utilises the proton of a H2O molecule, rather than the amino group of an adjacent peptide 
stem, which is abstracted allowing nucleophilic attack and rupture of the scissile ester bond of 
the terminal dipeptide of the acyl-enzyme complex. The acyclic bond formed from this 
reaction is the same for CPase and TPase reaction and results in the release of the terminal D-
Ala residue [60,128]. CPase activity acts to limit the amount of pentapeptides available for 
TPase reactions to around 1% [21]. Presumably, in the absence of CPase activity, excessive 
TPase reactions occur and the PG insertion process becomes unbalanced, or the percentage of 
inappropriate cross-links increases [21]. See table 1.3 for a list of the CPases of E. coli. 
E. coli possesses six redundant DD-CPases; PBP4, PBP4b, PBP5, PBP6, PBP6b and AmpH 
[136]. As discussed, PBP4 is a bifunctional peptidase possessing both DD-EPase and DD-
CPase activity, however, in vivo, it is thought to primarily act as an EPase [113,98]. PBP4b 
(pbp4b/yfeW) belongs to the AmpH type Class C PBP family and is a CM-bound DD-CPase. 
Cells grow normally upon a single gene deletion, and when combined with all other known 
DD-CPases [138]. It is also expressed at very low levels, indicating its activity is not essential 
for growth [62]. 
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Table 1.3 The carboxypeptidases of Escherichia coli 
1See text for detailed discussions and references     2Figures obtained from [62] 
CM, cytoplasmic membrane; OM, outer membrane; SP, soluble periplasmic; C, Cytoplasm 
MOPS, potassium morpholinopropane sulfonate 
 
 
 
MOPS
MOPS 
minimal
PBP4 dacB 51798 8.9 • SP/CM            
• Type 4 Class C 
PBP
• DD-CPase              
• DD-EPase     
― 441 133
AmpH ampH 41849 9.5 • CM                 
• Type AmpH 
Class C PBP
• DD-CPase           
• DD-EPase 
― 460 116
PBP4b yfeW 47752 7.7 • CM                 
• Type AmpH 
Class C PBP
• DD-CPase               ― 26 15
PBP5 dacA 44444 8.3 • CM                   
• Type 5 Class C 
PBP
• DD-CPase            
• Overproduction 
causes spherical 
cells and lysis                   
• Transcriptionally 
regulated by BolA           
― 4143 1180
PBP6 dacC 44461 7.7 • CM                 
• Type 5 Class C 
PBP
• DD-CPase            
• Transcriptionally 
regulated by BolA                
― 740 876
PBP6b dacD 44346 6.2 • CM                 
• Type 5 Class C 
PBP
• DD-CPase                 ― 29 6
LdcA ldcA 33622 5.7 • C                     
• S66 Peptidase
• LD-CPase                  ― 380 179
DdpX ddpX 21281 4.9 • M15 Peptidase  
• VanY 
superfamily
• D-Ala-D-Ala 
recycling in 
stationary phase
― ― 19
Protein Gene
MW 
(Da)
pI Localisation
Activities 
/Primary role
1
Interaction       
partners
1
Copy number 
synthesised per 
generation
2
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The monofunctional CPase PBP5 (dacA) is the most abundant PBP in E. coli at ~800 copies 
per cell and is most highly expressed during exponential growth [120]. The crystal structure 
shows a bitopic homodimer anchored to the periplasmic face of the CM by a C-terminal 
amphipathic helix, that localises to both the septa and the lateral cell wall [139–141]. The N-
terminal domain of PBP5 facilitates DD-CPase activity, while membrane binding via the C-
terminal domain is essential for in vivo function [133,134]. PBP5 is thought to process newly 
synthesised pentapeptides not used in TPase reactions in order to maintain the overall 
percentage of pentapeptide-containing muropeptides to ~1%, inferring a close relationship 
with the bifunctional PG synthases, although no interactions have yet been observed [132,95]. 
Overexpression of PBP5 leads to the formation of stable spherical cells [144]. While the DD-
CPases of E. coli are individually dispensable for growth, a dacA deletion in combination 
with other hydrolases have significant morphological abnormalities, highlighting the 
importance of this enzyme in the control of cell shape as well as septal hydrolysis, e.g. a 
dacA-dacC- strain forms filaments and a dacA-amiA-amiC- triple mutant induces a twisted 
morphology [135,136]. Deletion of dacB in a dacA- background has severe morphological 
defects exacerbated by a deletion in pbpG. It is thought that the deletion of dacA causes an 
increase in the relative amount of pentapeptide substrate for TPase reactions resulting in 
aberrant cross-linking activity, thus causing morphological changes [143]. 
PBP6 (dacC) is a DD-CPase with 62% sequence homology to PBP5, and is also attached to 
the CM by a C-terminal amphipathic helix [146]. Cells absent of PBP6 possess an unchanged 
pentapeptide content, this is the converse for cells absent in PBP5, implying again that PBP5 
is the major DD-CPase in E. coli. Transcription of both PBP5 and PBP6 is regulated by BolA 
(section 1.4.6) [144].  
The amino acid sequence of PBP6b (dacD) is similar to that of PBP5 and PBP6 and as such 
the protein possesses DD-CPase activity and is anchored to the CM by an amphipathic C-
terminal region [138,139]. However, it is expressed at low levels and is not essential for 
growth [54,138].  
AmpH (ampH) is a PBP and, like PBP4, is a bifunctional peptidase possessing both DD-
EPase and DD-CPase activity on intact sacculi and soluble muropeptides [140,141]. If ampH 
is deleted in a mrcA- or dacA- background, cells undergo significant morphological defects 
including an increased diameter and squared cell poles implying it contributes to regulation of 
normal cell shape [150].  
  
26 
 
  
E. coli possesses three LD-CPases which cleave the terminal D-Ala from L-Ala-D-iGlu-m-
Dap-D-Ala rather than a pentapeptide [104]. Only the cytoplasmic LdcA has been 
characterised in appreciable detail, the other two, identified as active on UDP-MurNAc-
tetrapeptide, being an 86 kDa periplasmic protein and a 12 kDa protein of unknown 
localisation [142,143]. LdcA is primarily involved in PG turnover, processing the internalised 
tetrapeptide products of PG hydrolysis (section 1.6) [153]. The tri-peptide formed from this 
catabolism is a crucial part of the PG recycling system of E. coli, producing substrate for 
MurF and Mpl to synthesise UDP-MurNAc-pentapeptide (figure 1.8) [154]. A deletion in 
ldcA results in increased frequency of lysis during stationary phase through the incorporation 
of UDP-MurNAc-tetrapeptide into the PG layer which can only act as acceptors for cross-
linking [155].  
DdpX is a Zn2+-binding dipeptidase that cleaves the D-Ala-D-Ala dipeptide [110]. During 
stationary phase the primary role of DdpX is the recycling of D-Ala-D-Ala for de novo PG 
synthesis and for subsequent D-Ala oxidation as an energy source during nutrient starvation 
[156]. 
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1.4.4 N-Acetylmuramyl-L-alanine amidases of E. coli 
N-Acetylmuramyl-L-alanine amidases cleave the amide bond between the N-terminal L-Ala of 
the peptide and the D-lactoyl moiety of the MurNAc residue [157]. E. coli possesses five 
known amidases (table 1.4); three soluble, periplasmic amidases AmiA, AmiB and AmiC, the 
OM-tethered lipoprotein AmiD, and the cytoplasmic AmpD.  
 
Table 1.4 The amidases of E. coli  
1See text for detailed discussions and references     2Figures obtained from [62]     3Genetic interaction 
CM, cytoplasmic membrane; OM, outer membrane; SP, soluble periplasmic; C, cytoplasm 
MOPS, potassium morpholinopropane sulfonate 
MOPS
MOPS 
minimal
AmiA amiA 31412 10 • SP                     
• Division site 
(dependent upon 
EnvC)                 
• Amidase 3 
superfamily
• Septum cleavage                       
• Activated by 
EnvC
• EnvC3 676 290
AmiB amiB 47985 9.3 • SP                    
• Division site 
(dependent upon 
EnvC)                  
• Amidase 3 
superfamily
• Septum cleavage                        
• Activated by 
EnvC
• EnvC3 343 173
AmiC amiC 45634 9.6 • SP                    
• Division site 
(dependent upon 
NlpD)                  
• Amidase 3 
superfamily
• Septum cleavage                        
• Activated by 
NlpD
• NlpD 410 68
AmiD amiD 31072 7.1 • OM                    
• Division site      
• Amidase 2 
superfamily
• Cleaves 
MurNAc-L-Ala 
and 1,6-anhydro-
MurN Ac-  L-Ala
― 141 82
AmpD ampD 20536 5.3 • C                     
• Amidase 2 
superfamily
• Cleaves 1,6-
anhydro-MurNAc-   
L-Ala                          
• PG recycling
― 269 202
Protein Gene
MW 
(Da)
pI Localisation
Activities 
/Primary role
1
Interaction       
partners
1
Copy number 
synthesised per 
generation
2
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The activity of AmiA, AmiB and AmiC is crucial for cell septation (section 1.5.2). AmiA and 
AmiB belong to the amidase 3 superfamily and AmiA is a Zn2+-binding peptidase. A single 
deletion in amiA causes the formation of chains, 3-4 cells long, in 5-10% of a population 
[158]. The crystal structure of AmiC shows a novel N-terminal PG-binding AMIN domain 
required for divisome localisation [159].  
 
A single deletion of AmiB causes no obvious phenotype whereas around 20-30% of cells 
lacking AmiC will grow as chains 3-6 cells long [151,152]. The amidases crucial for cell 
septation, AmiA, AmiB and AmiC, require activation by LytM domain-containing 
lipoproteins EnvC and NlpD, which is discussed in more detail in section 1.4.6 [162].  
When deletions in these three amidases are combined with either, all of the lytic 
transglycosylases (Slt, MltA-F), or the EPases (PBP4, PBP7 and MepA) cells can form chains 
of up to 100 cells [152,154].  
AmpD is a cytoplasmically localised amidase with exclusive activity for the amide bond in 
anhydro-MurNAc-L-Ala [164]. It has a crucial role in processing the internalised turnover 
products of PG hydrolysis to supply substrates for de novo PG synthesis and β-lactamase 
induction (see section 1.6 for more details).  
 
 
1.4.5 Lytic transglycosylases of E. coli 
E. coli encodes one soluble lytic transglycosylase (LT), Slt70, or simply Slt and seven 
membrane-bound LTs; MltA, MltB, MltC, MltD, MltE, MltF and MltG (table 1.5) [165]. The 
cleavage of the β1,4 glycosidic bond between the MurNAc and GlcNAc residues forms an 
oxocarbonium ion intermediate, much like lysozyme, but instead of deprotonation by H2O, it 
is the catalytic glutamate residue of the LT that deprotonates the hydroxyl group at C6 of the 
MurNAc sugar. This deprotonation facilitates the nucleophilic attack of C1 of the same 
MurNAc residue resulting in the formation of a 1,6-anhydro ring [166].  
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Table 1.5 The lytic transglycosylases of E. coli 
 
1See text for detailed discussions and references     2Figures obtained from [62] 
CM, cytoplasmic membrane; OM, outer membrane; SP, soluble periplasmic 
MOPS, potassium morpholinopropane sulfonate 
MOPS
MOPS 
minimal
Slt slt 73353 8.8 • SP                   
• LT family 1
• Septum cleavage    
• Inhibited by 
bulgecin A              
• Stimulated by 
PBP7
• PBP1B         
• PBP1C       
• PBP7            
• PBP3
270 204
MltA mltA 40410 9 • OM                  
• LT family 2
• Septum cleavage      
• Overproduction 
causes spherical 
cells and lysis at 
30°C
• PBP1B 
(through 
MipA)            
• PBP1C        
• PBP2          
• PBP3
901 286
MltB mltB 40255 9 • OM                  
• LT family 3
• Septum cleavage      
• Overproduction 
causes spherical 
cells and lysis at 
30°C                       
• Soluble form 
termed Slt 35
• PBP1B          
• PBP1C        
• PBP2          
926 274
MltC mltC 40112 9.4 • OM                  
• LT family 1
• Septum cleavage ― 392 148
MltD mltD 49417 9.9 • OM                  
• LT family 1
• Septum cleavage   
• LysM domain        
• Overproduction 
causes spherical 
cells and lysis 
― 761 644
MltE/ 
EmtA
mltE 22212 9.2 • OM                  
• LT family 1
• Septum cleavage ― 1942 609
MltF yfhD 58302 5.3 • OM                  
• LT family 1b
• Septum cleavage   
• Overproduction 
causes spherical 
cells and lysis 
― 70 22
MltG yceG 38247 9.4 • CM                  
• YceG-like 
superfamily
• Endolytic               
• Glycan chain 
terminase
• PBP1B 312 70
Activities/   
Primary role
1
Interaction       
partners
1
Copy number 
synthesised per 
generation
2Gene
MW 
(Da)
pI LocalisationProtein 
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The recycling of 1,6-anhydroMurNAc-containing muropeptides is crucial for induction of the 
β-lactamase ampC in response to antibiotic stress (section 1.6) [167]. As previously 
mentioned, Slt interacts with and is stimulated by PBP7, but interactions with PBP3, PBP1B 
and PBP1C have also been observed [115,159]. Slt has been implicated as a quality control 
enzyme in PG synthesis, highlighted by the Slt-dependent degradation of nascent PG during 
β-lactam stress, in which TPase activity is abated preventing incorporation into the PG layer 
[169]. 
Recently a novel CM-bound endolytic transglycosylase, MltG, was characterised as a putative 
glycan chain terminase during PG synthesis by PBP1B [170]. The digestion of PG by MltG 
results in muropeptides possessing the anhydro-moiety, characteristic of LT activity, and like 
the other LTs, it is non-essential. MltG interacts with PBP1B, and does not interact with 
PBP1A. It is suggested therefore that the endolytic activity of MltG is linked to processing 
nascent PG synthesised by PBP1B, thereby controlling glycan chain length [170]. 
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1.4.6 Regulators of peptidoglycan hydrolysis in E. coli 
The regulation of PG synthesis has been well documented in recent years, both from the CM 
by cytoskeletal elements and associating proteins, and from the OM by membrane-anchored 
lipoproteins. Relative to the number of PG hydrolases in E. coli, regulators of PG hydrolysis 
are poorly understood and will be discussed here (see table 1.6). 
 
Table 1.6 The regulators of peptidoglycan hydrolysis in E. coli 
1See text for detailed discussions and references     2Figures obtained from [62]     3Genetic interaction 
CM, cytoplasmic membrane; OM, outer membrane; SP, soluble periplasmic 
MOPS, potassium morpholinopropane sulfonate 
 
As alluded to in section 1.4.4 the amidases crucial for daughter cell separation during 
division, AmiA, AmiB and AmiC, are regulated by the LytM domain-containing lipoproteins 
EnvC and NlpD [134].  
AmiA and AmiB are recruited to the site of septation and activated by the lipoprotein EnvC, 
itself recruited by the late division protein FtsN (section 1.5.2). The binding of EnvC to AmiB 
causes a conformational change releasing an α-helix from within the active site, normally 
occluding substrate binding, thus activating the enzyme [171]. EnvC (yibP) is a non-catalytic, 
CM-bound member of the LytM-like metallopeptidases [163,164]. EnvC was firstly shown to 
possess hydrolytic activity, however, this has now been disproven with its apparent activity 
MOPS
MOPS 
minimal
EnvC yibP 46594 9.9 • CM/SP               
• Division site
• Inactive                
• Activation of 
AmiA and AmiB                  
• LytM domain
• AmiA3          
• AmiB3
258 106
NlpD nlpD 40149 9.5 • OM                     
• Division site     
• M23/LytM 
metallopeptidase
• Inactive                
• Activation of 
AmiC                          
• LytM domain
• AmiC 1349 695
BolA bolA 11922 6.2 ― • Control of dacA 
and dacC 
transcription
― 1945 2040
Interaction       
partners
1
Copy number 
synthesised per 
generation
2Localisation
Activities 
/Primary role
1Protein Gene
MW 
(Da)
pI
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coming from its activation of AmiA and AmiB [164,125]. The crystal structure of the C-
terminal LytM domain of EnvC purports a degenerate active site with the absence of a 
catalytic metal ion, highlighting its apparent lack of activity. EnvC also possesses a coiled-
coil domain which is required for localisation to the division site through associations with 
FtsEX (see section 1.5.2) [153,165]. Site-directed mutagenesis identified the following amino 
acids as crucial for correct stimulation of amidase function; V353, R405, K321, V324. These 
amino acids are localised around the non-catalytic ‘active site’ of the LytM domain of EnvC, 
however, direct interactions with AmiA/B have not been identified thus far [162]. 
The activity of AmiC is regulated by the lipoprotein NlpD at the division site [162]. The N-
terminal PG-binding AMIN domain of AmiC is required for divisome localisation. Like 
AmiB, AmiC possesses a helix which occludes the active site. NlpD interacts directly with 
AmiC, with an estimated KD of ~12 µM, to remove the helix and activate the protein [159]. 
  
Like EnvC, NlpD is catalytically inactive and has no effect on its non-cognate amidases. 
Single deletions in EnvC and NlpD lead to morphological changes consistent with deletions 
in their cognate amidases [134]. E. coli encodes one OM-bound amidase, AmiD which does 
not participate in cell division, but also cleaves the amide bond in anhydro-MurNAc-L-Ala 
[175].  
 
The gene bolA is responsible for transcriptionally regulating the DD-CPase genes dacA 
(PBP5) and dacC (PBP6) and is essential for correct cell morphology in exponential growth 
[144]. Overexpression of bolA results in osmotically stable spherical cells and has elevated 
expression during stationary phase and when cells are grown in nutrient-starved media 
[167,135].  
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1.5 Multi-enzyme complexes facilitating PG growth 
Safe and coordinated enlargement of the sacculus is thought to be facilitated by multi-enzyme 
complexes of concomitantly active PG synthases and hydrolases [59]. As alluded to in section 
1.3.2, insertion of new material is controlled from the cytoplasm by prokaryotic cytoskeletal 
elements and from the OM by membrane-anchored lipoproteins (section 1.3.4). These 
membrane-spanning complexes have evolved specificity for elongation and division and are 
termed the elongasome (figure 1.7) and the divisome (figure 1.8), respectively.  
 
1.5.1 The elongasome 
PG synthesis during elongation is controlled by the intracellular prokaryotic actin homologue, 
MreB. MreB is essential for the maintenance of cell shape in most rod-shaped bacteria and 
polymerises into helical filaments or discrete patches in an ATP-dependent manner [168,22]. 
The integral CM proteins, MreC and MreD are encoded by the same operon as MreB and are 
also essential for rod-shape in E. coli [178]. MreC interacts with both MreB and MreD to 
form a CM-bound complex [179]. MreC is a single transmembrane dimeric protein where 
MreD is a polytopic membrane protein, and deletion of either leads to spherical cells and lysis 
[171,172]. In the absence of MreC and MreD, MreB does not form helical filaments, this is 
also true of RodA [179]. 
RodA and FtsW are integral membrane proteins belonging to the SEDS (shape, elongation, 
division, and sporulation) family of proteins. FtsW is the lipid II flippase during cell division 
and RodA is predicted to be the flippase during elongation [48]. RodA interacts with MreB 
and is essential for rod-shape, forming spheroid cells upon deletion [173,174]. As discussed, 
PBP2 is the only PBP essential for cell elongation [78]. Active RodA is required for the 
proper function of PBP2, presumably for delivering nascent PG precursor to PBP1A 
[175,176].  
The bitopic integral CM protein RodZ co-localises with MreB and interacts with both 
monomeric and filamentous forms as shown by co-crystallographic analyses [186]. RodZ 
assists in the association of MreB filaments to the CM to facilitate subsequent interactions 
with MreC and MreD [177,178].  
MreB directly interacts with the penultimate and final enzymes of lipid II synthesis, MraY 
and MurG [188]. The localisation of MurG to the lateral cell wall is dependent on MreBCD 
and indicates that this subcomplex mediates the positioning or control of the PG synthesis 
machinery [169,19]. Supporting this, MreB moves helically and circumferentially throughout 
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the longitudinal axis of the cell and, using fluorescently-labelled vancomycin, the helical 
insertion of nascent PG into the lateral cell wall has been observed [189].  
To date there is no definitive participation, or direct interactions, of PG hydrolases with 
components of the elongasome, perhaps owing to their high degree of functional redundancy 
(see section 1.4). Intuitively, hydrolases must be present to create space for the insertion of 
nascent PG. Three novel, redundantly essential E. coli DD-EPases have been identified and 
are discussed in section 1.4.2.2, although there are no direct interactions with the PG-
synthesising complex [129].  
 
 
Figure 1.7 Schematic representation of the elongasome [24] 
MreB, and the associated membrane proteins MreC, MreD, RodA and RodZ, act to position or control the PG 
synthases PBP1A and PBP2 during cell elongation. RodA is the predicted lipid II flippase during cell elongation 
and presumably delivers the PG precursor to PBP1A/2. RodZ facilitates the localisation of MreB to the CM. As-
of-yet unidentified hydrolases (Hyd) are hypothesised to interact directly with components of the elongasome. 
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1.5.2 The divisome 
Gram-negative bacteria employ a constrictive mode of cell division; invagination of the multi-
layered cell envelope occurs simultaneously with septum formation, synthesis of daughter cell 
poles, and cell cleavage [4]. These processes are initiated by the reversible GTP-dependant 
polymerisation of the cytoplasmic prokaryotic tubulin homologue, FtsZ, into the cytokinetic Z 
ring, and its stabilisation at the mid-cell membrane [23,182,183]. ZipA and the actin-like FtsA 
simultaneously localise to the mid-cell through interactions with the conserved C-terminal tail 
of FtsZ [192–194]. ZipA and FtsA act to stabilise the Z ring and anchor it to the CM through 
the C-terminal amphipathic helix of membrane-bound FtsA protofilaments [187,188]. ZapA, 
ZapB, ZapC, and ZapD are also present at this stage but are not essential for division, as well 
as FtsEX whose association to the septum depends on FtsZ and ZipA [4].  
FtsEX is an CM-bound subcomplex essential for the recruitment of EnvC which is required 
for the activation of the amidases AmiA/B (section 1.4.6) [154,166]. EnvC is recruited to the 
divisome through the periplasmic loop of FtsX, the transmembrane component of the 
complex [197]. The ATP hydrolysis facilitated by the cytoplasmically localised FtsE, allows 
EnvC to bind and activate AmiB (section 1.4.6) [171]. FtsE has been shown to interact with 
FtsZ and it is thought that FtsEX facilitates the coordination of amidase activity with the 
constriction of the Z ring [189,190]. During division, the septum formed by the PG-
synthesising proteins of the divisome is initially shared between daughter cells. The activity 
of these periplasmic amidases and AmiC cleave the peptide stem from glycan strands at the 
newly formed septum and is a crucial step in daughter cell separation [149,167,191].  
The hierarchical recruitment of the ‘late’ division proteins FtsK, FtsQ, FtsL, FtsB, FtsW, 
PBP3, PBP1B/LpoB and FtsN initiates formation of the septum [4]. PBP1B/LpoB are not 
essential as their function can substituted by PBP1A/LpoA [200]. FtsK is required for 
recruitment of the subcomplex FtsQLB which assembles prior to association to the divisome, 
of which, FtsQ is responsible for the recruitment of the predicted lipid II flippase during cell 
division, FtsW [193,194]. FtsW forms a complex with the monofunctional TPase PBP3 
independent of the rest of the divisome [41,74,195]  
PBP3 is the only PBP essential for cell division and interacts with and recruits the major PG 
synthase, PBP1B, and the last division protein recruited to the division site, FtsN [78]. FtsN 
interacts with a number of divisome proteins, yet its primary function is unknown [204]. 
However, FtsN has been shown to interact and stimulate the activity of PBP1B [205]. FtsN 
possesses a SPOR PG-binding domain which is not essential for function, and recruits the 
lipoprotein NlpD, which in turn activates the amidase AmiC (section 1.4.6) [198,199]. FtsN is 
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also responsible for recruiting, but not activating, AmiB [207]. Presumably, MraY and MurG 
are also present at the divisome to facilitate delivery of nascent lipid II precursor to the PG 
synthesis machinery, via FtsW. Indeed, although MurG is observed to form loci throughout 
the lateral cell wall, during division it localises at mid-cell [188].  
The divisome has a secondary responsibility in coordinating OM invagination with septal PG 
growth and constriction, facilitated by the recruitment of the Tol/Pal system to the division 
site by FtsN [92]. The Tol/Pal complex traverses the CM and OM via various components; 
the CM-bound subcomplex, consisting of the integral membrane proteins TolQ, TolR and 
TolA; the periplasmic TolB, and the OM lipoprotein Pal, which is non-covalently bound to 
PG [208]. The last gene of the Tol/Pal operon encodes the protein CpoB. CpoB was 
discovered to be the functional link between the Tol/Pal system and the divisome and is 
discussed in section 1.3.4.   
 
 
Figure 1.8 Schematic representation of the divisome [24] 
The cytoplasmic prokaryotic tubulin homologue FtsZ polymerises in a GTP-dependant manner into the Z ring at 
the mid-cell membrane. ZipA and FtsA are essential for stabilisation and tethering the Z ring to the CM. 
Accessory proteins, ZapA-D are non-essential stabilisation proteins. FtsW is the lipid II flippase during cell 
division. FtsW interacts with PBP3 and presumably delivers nascent lipid II to the PG-synthesising core 
complex, PBP1B/3 and LpoB. FtsEX recruits EnvC which recruits and activates the amidases AmiA and AmiB. 
FtsN recruits NlpD to the division site for activation of AmiC. The Tol-Pal complex is recruited to the divisome 
by FtsN. The Tol/Pal system is functionally linked to the divisome via shared interactions with CpoB to 
coordinate OM constriction with PG synthesis.  
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1.5.3 Colocalisation of the elongasome and the divisome 
The switch from PG growth during elongation, to the circumferential invagination at the mid-
cell, remains elusive. However, there are number of interactions between the elongasome and 
the divisome, which suggest the complexes may co-localise and possess secondary functions 
[71,201,202]. 
A penicillin insensitive pre-septal PG synthesis phase between elongation and the onset of 
constriction was observed and termed PBP3 independent PG synthesis, or PIPS [211]. It has 
been suggested that it is PBP2 that is responsible for this pre-septal phase of PG growth 
facilitated by the Z ring which recruits the elongasome to the division site through a direct and 
essential interaction between FtsZ and MreB [30, 209, 212]. The identification of the transient 
localisation of MreBCD and PBP2 at the division site indicates that it is the elongasome that 
facilitates this pre-septal PG synthesis, coordinated by FtsZ [213]. It is thought that as the 
elongasome reaches the future site of septal synthesis, the PG-synthesising complex becomes 
uncoupled from MreB and is captured by the Z ring, and that it is this that redirects PG 
synthesis from lateral cell wall PG insertion to septal growth [204,205].  
After this redirection, the rest of the divisome is formed and daughter cell separation can 
begin. FtsZ, independent of Z ring formation, has been shown to oscillate in a helical fashion 
throughout the lateral cell wall [215]. Divisome disassembly presumably releases FtsZ, and 
the associated PG-synthesising complex, to redistribute the PG synthesis machinery for lateral 
cell wall growth [215].  
Localisation of PBP2 has been seen to overlap with that of PBP3 [79]. Direct interactions 
between the two, and of PBP2 with FtsQ, FtsN and FtsW have been observed at the division 
site [210]. MreB and PBP2 localise to the division site simultaneously with FtsZ, but 
disseminate by ~60% of division, implying they are not involved with the latter stages of 
divisome assembly or the synthesis of daughter cell poles [71,24]. 
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1.6 Peptidoglycan recycling and β-lactamase induction 
Around 50% of PG in E. coli is turned over per generation, with 6-8% lost to the culture 
supernatant, hence, a large percentage of the released material is reutilised [101]. PG 
recycling is a non-essential process, however, the turnover products of PG hydrolysis are 
internalised and reutilised for de novo PG synthesis and intracellular communication 
regarding the state of the PG layer, for example the induction of β-lactamase in response to 
antibiotic stress (figure 1.9) [207,208]. 
AmpG was the first link between PG turnover and β-lactamase induction in response to 
antibiotic stress [186]. A deletion in ampG prevents β-lactamase induction and results in the 
release of muropeptides into the medium [106]. AmpD is also essential for PG recycling and a 
deletion in ampD leads to the increased expression of AmpC, and the cytoplasmic 
accumulation of 1,6-anhydro-N-acetylmuramyl-L-Ala-D-iGlu-m-Dap (anhydro-MurNAc-tri-
peptide) [218]. β-lactamase induction does not occur in ampG-ampD- strains [219]. These data 
indicate that the major CM permease in Gram-negative organisms, for the internalisation of 
PG turnover products, is AmpG and that AmpD is a cytoplasmic amidase with specificity for 
anhydro-containing muropeptides.  
AmpG has specificity for anhydro-containing muropeptides (GlcNAc-β1,4-MurNAc-
anhydro), formed by the action of LTs [106]. The internalisation of periplasmic anhydro-
MurNAc-containing muropeptides by AmpG is thought to be dependent on PMF, as shown by 
susceptibility to the PMF inhibitor CCCP (carbonyl cyanide m-chlorophenyl hydrazine) 
[220].  
Once internalised, anhydro-muropeptides are the substrate for the cytosolic N-acetyl-
glucosamidase NagZ, which hydrolyses the β1,4-glycosidic bond removing the GlcNAc 
residue [221]. The products of this reaction become the substrate for the anhydro-muropeptide 
specific amidase AmpD which removes the peptide stem from the D-lactoyl moiety of the 
MurNAc residue. This activity produces anhydro-MurNAc tetrapeptides which are processed 
by the LD-CPase LdcA, an activity which is essential during stationary phase (section 1.4.3).  
AmpD can act directly on internalised anhydro-MurNAc-containing muropeptides to produce 
GlcNAc-β1,4-MurNAc-anhydro. This is the substrate for a cascade of enzymes that produce 
the precursor for PG synthesis, UDP-MurNAc-pentapeptide (figure 1.9) [164].  
Under normal conditions UDP-MurNAc-pentapeptide binds to the transcriptional regulator of 
the β-lactamase gene ampC, termed ampR, to repress its activity and thus prevent the 
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expression and export of AmpC [222]. Under antibiotic stress, the activity of PG hydrolases 
becomes unregulated resulting in a cytoplasmic accumulation of anhydro-containing 
muropeptides which act to displace UDP-MurNAc pentapeptide from ampR, leading to de-
repression and induction of AmpC β-lactamase production [159,215]. E. coli does not possess 
an inducible ampR/ampC operon, therefore studies are generally carried out in cells 
transformed with a plasmid containing the operon from Enterobacter cloacae [224].  
A minor percentage of PG turnover products are internalised by other CM integral membrane 
proteins including the oligopeptide permease (Opp) [225]. The Opp is composed of OppA, 
OppB, OppC, OppD and OppF, and its permease activity is modulated by the tripeptide 
binding capacity of MppA (murein peptide permease A) [218,219].  
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Figure 1.9 Peptidoglycan recycling and β-lactamase induction  
The majority of the PG turnover products of EPase, CPase, amidase and LT digestion are internalised by the 
membrane permease AmpG. Anhydro-MurNAc-containing muropeptides, from LT digestion, are processed by 
NagZ, which removes the GlcNAc residue. The products are catabolised by the cytoplasmic amidase AmpD, 
which removes the peptide chain to be reutilised for de novo PG synthesis. AmpD can also process the anhydro-
containing muropeptides after internalisation to produce GlcNAc-MurNAcanhydro. The processive action of NagZ, 
the kinase AnmK, the etherase MurQ and NagA, which deacetylates GlcNAc-6-phosphate, yields glucosamine-
6-phosphate which can be utilised by the de novo PG synthesis pathway. Under normal circumstances, UDP-
MurNAc-pentapeptide binds to the regulator of ampC expression, ampR, to repress expression. β-lactam stress 
results in the cytoplasmic accumulation of anhydro-containing muropeptides which displaces UDP-MurNAc-
pentapeptide from ampR, leading to ampC expression, which is externalised to hydrolyse the antibiotic. 
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1.7 New lipoprotein I (NlpI) 
NlpI is an OM-anchored lipoprotein with a currently unknown cellular function. Deletion of 
nlpI causes filamentation at elevated temperatures (42°C) and low osmolarity, whereas the 
overexpression of NlpI results in the formation of prolate spheroids [228]. NlpI has therefore 
been predicted to be involved in cell division. In concordance with this, NlpI interacts with 
two heat shock proteins, IpbA/B which are thought to be involved in nucleoid separation and 
correct localisation of the Z ring, with overexpression of NlpI leading to the disturbance of 
FtsZ [229].  
Deletion of NlpI also leads to a hypervesiculation phenotype dependent on the activity of two 
EPases, PBP4 in stationary phase and MepS in exponential phase [230]. The nlpI- phenotype 
is suppressed by a deletion of mepS [230]. Complementation with a plasmid containing WT 
MepS, but not with that of an active site mutant, indicates it is the unregulated activity of 
MepS which causes the nlpI- phenotype. NlpI is therefore hypothesised to regulate EPase 
activity. In the absence of NlpI, it is thought that unregulated PG hydrolysis decouples 
Braun’s lipoprotein (Lpp) from the PG layer which covalently connects the OM and the PG 
layer. Increased amounts of free Lpp (Lpp not bound to the PG layer) correlates with OM 
vesiculation [222,223]. Periplasm-containing OM vesicles are primarily utilised in host-
pathogen interactions and biofilm formation [232].  
Recently, NlpI has been shown to facilitate the proteolytic degradation of MepS, identifying a 
key role in the control of EPase activity and PG hydrolysis [108]. NlpI and MepS interact 
with the tail-specific protease Prc, but only MepS is subject to degradation, where 12 C-
terminal amino acids of NlpI are removed [108]. In the absence of NlpI, the half-life of MepS 
increases from ~2 min to ~45 min.  
The crystal structure of NlpI has been determined and shows the formation of a homodimer 
(see figure 1.10) [233]. Each monomer is 33 kDa with both OM-binding N-termini close 
together. Each monomer consists of 14 α-helices forming 4 canonical TPR-like domains; 
helices 2 and 4 (TPR1), 4 and 5 (TPR2), 6 and 7 (TPR3) and 12 and 13 (TPR4). However, 
unlike canonical TPR-containing proteins, the superhelical structure of NlpI folds back in on 
itself, with the C-terminus inserted into the N-terminus, forming a characteristic globularity. 
Within this fold, long-range contacts occur between the first helix of each helix-turn-helix 
(‘A’ helix) further strengthening this globularity. There is a putative binding cleft formed 
from the curvature of the helices on each monomer which would be available for protein-
protein interactions [233]. 
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Figure 1.10 Crystal structure of NlpI [233] 
A. Crystal structure of the monomer of NlpI. NlpI is composed of 14 α-helices forming 4 TPR-like motifs made 
of helices 2 and 4 (TPR1), 4 and 5 (TPR2), 6 and 7 (TPR3) and 12 and 13 (TPR4). The C-terminus is folded 
back inside the N-terminus forming an overall globular structure with ‘A’ helices forming long-range contacts 
with the C-terminal fold. B. Crystal structure of the dimer of NlpI. The dimer interface consists of the N-terminal 
regions, and helices 1, 2, 3, 11, 12, 13 and 14.  
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1.8 Aims 
E. coli possesses around 30 PG hydrolases and many have potentially autolytic activity. 
While the understanding of how PG synthesis is regulated has developed in recent years, the 
processes by which PG hydrolysis is regulated remains poorly understood. Intuitively, these 
two processes are functionally linked in multi-enzyme complexes, however, few direct 
interactions have been observed, particularly during cell elongation. The aims of this project 
were to; 
1. Determine the structural model of the OM-anchored lipoprotein regulator of PG 
synthesis during elongation, LpoA. 
2.  Characterise the interaction of LpoA and PBP1A. 
3. Search for novel interactions partners of LpoA. 
4. Identify direct connections between PG synthesis and PG hydrolysis. 
5. Structurally and functionally characterise the PG hydrolases PBP4 and MepA.  
6. Determine the primary function of the predicted PG hydrolase regulator, NlpI, in vitro 
and in vivo. 
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2 Methods 
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2.1 Microbial methods 
2.1.1 Bacterial growth and storage 
E. coli cells were cultivated as liquid culture in Luria Bertani (LB) media (10 g/L Tryptone, 
10 g/L NaCl, 5 g/L yeast, pH 7.5), with growth monitored at regular intervals by 
spectrophotometry (578 nm), or on LB-agar plates (10 g/L Tryptone, 10 g/L NaCl, 5 g/L 
yeast, 1.5% agar, pH 7.5). When cultivating cells for the purification of proteins destined for 
nuclear magnetic resonance (NMR) spectroscopy analysis, M9 media was used, (5.29 g/L 
Na2HPO4, 3 g/L KH2PO4, 0.5 g/L NaCl, and 1 g/L [
15N]-NH4Cl, 1 mM MgSO4, 0.1 mM 
CaCl2, 2 mM Thiamine, 0.3% [
13C]-glucose, pH 6.8-7.2) with more detail described in section 
2.3.2. Orbital shaking and incubation at 25, 30 or 37°C was used to promote growth. For short 
term storage, bacteria were grown on LB-agar plates and stored at 4°C. For long term storage, 
cells were grown to an OD578 of 0.5-0.6 and stored at -80°C with 10% glycerol. 
 
2.1.2 Production of competent E. coli cells 
An o/n culture was used to inoculate 50 ml of LB and cells were grown to exponential phase 
at 37°C before harvesting by centrifugation (4500 × g, 4°C, 15 min). Pelleted cells were 
resuspended in 15 ml of ice cold TFB1 solution (100 mM RbCl, 50 mM MnCl2, 10 mM 
CaCl2, 15% glycerol, pH 5.8, adjusted with acetic acid) and were incubated for 90 min on ice. 
Cells were harvested again by centrifugation and resuspended in 2 ml of ice cold TFB2 
solution (10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15% glycerol, pH 6.8, adjusted with 
KOH). Cells were resuspended and aliquoted on -70°C ethanol ice. Competent cells were 
frozen at -80°C, if not used immediately. 
 
2.1.3 Isolation of plasmid DNA from E. coli cells 
Plasmids were isolated from bacterial cells using either PeqGOLD Mini or Midi-prep plasmid 
extraction kits (PeqLAB), as per manufacturer’s instructions. The concentration of isolated 
plasmids was estimated using Nanodrop ND1000 V3.7.1 software.  
 
2.1.4 Transformation of plasmid DNA into competent E. coli cells 
Aliquots containing 100 μl of competent E. coli cells were thawed on ice and 1-10 μl of 
purified plasmid were added. After a 10 min incubation on ice, cells were heat-shocked at 
42°C for 1 min and placed back on ice for 15 min. Cells were incubated with 900 μl of LB for 
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1 h at 37°C before 100 μl and 900 μl of the cell suspension were plated on LB agar plates, 
containing any appropriate antibiotic, and incubated o/n at 37°C. For the overexpression and 
purification of proteins, BL21(DE3) competent cells, expressing the T7 promotor, were used. 
DH5α competent cells were used for long term storage and future plasmid isolation.     
 
2.1.5 Excision of kanamycin resistance cassette using pCP20 
The plasmid pCP20 was used to create antibiotic marker-less strains [226,227]. It encodes an 
Flp recombinase which acts to ‘flip out’ kanamycin resistance cassettes flanked by FRT 
(flippase recognition target) regions. It contains ampicillin and chloramphenicol resistance 
cassettes and is thermo-sensitive. This protocol was used prior to addition of other plasmids 
containing a kanamycin resistance cassette, or creating multiple deletions via P1 phage 
transduction. 
The pCP20 plasmid was transformed as described in section 2.1.4 but, due to the 
thermosensitive nature of the plasmid, cells were incubated at 30°C instead of 37°C. 
Transformed cells were plated on either ampicillin or chloramphenicol plates o/n at 30°C to 
remove the kanamycin resistance cassette. A colony was picked and re-streaked on LB-agar 
without antibiotic, and incubated at 42°C to remove the pCP20 plasmid. A colony was picked 
and re-streaked on kanamycin, ampicillin/chloramphenicol and standard LB plates as a screen 
to check for the successful removal of kanamycin resistance, and of the pCP20 plasmid. 
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2.2 Protein methods 
2.2.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
For the observation of the yield and purity of proteins, as well as in vitro/in vivo interaction 
assays, proteins were separated according to their molecular weight using SDS-PAGE. 
Samples were mixed 2:1 with SDS-loading buffer (4 ml 1 M Tris/HCl, 5.1 ml 75% glycerol, 
0.6 g SDS, 0.4 ml 0.1% bromphenol blue) and were boiled for 10 min with 10% β-
mercaptoethanol to reduce disulphide linkages. Samples were briefly centrifuged to remove 
condensation and loaded onto polymerised acrylamide gels (12 or 15% acrylamide w/v) (see 
table 2.1). Electrophoresis was carried out at 100 V for 1-2 h in a BioRad gel tank system 
containing the appropriate volume of TGS running buffer (20 mM Tris, 192 mM glycine, 
0.1% SDS). Gels were stained with Coomassie staining solution (1 g/L Coomassie brilliant 
blue R250, 50% methanol, 40% H2O, 10% acetic acid) and destained in destaining solution 
(30% methanol, 60% H2O, 10% acetic acid), until a clear background was obtained. In some 
cases a zinc staining kit (Biorad) or a silver staining kit (Sigma) were used as per 
manufacturer’s instructions. Gels were scanned between two plastic sheets using an Epson 
perfection V350 scanner and cropped and annotated using Microsoft Paint/Picture manager 
and Microsoft PowerPoint. 
 
Table 2.1 SDS-PAGE gel recipe for six gels  
  Volume (ml) 
Components 12% separation gel 15% separation gel Stacking  gel 
H2O 7.2 4.2 4.9 
Buffer 7.5 1   7.5 1   2.5 2 
Acrylamide3 12 15 1.5 
10% SDS 0.3 0.3 0.1 
2% TEMED 1.5 1.5 0.5 
1.4% APS 1.5 1.5 0.5 
 1 1.5 M Tris/HCl, pH 8.8  
2 0.5 M Tris/HCl, pH 6.8  
3 Rotiphorese (Roth, Germany) 
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2.2.2 Western blotting procedure 
For a list of the antibodies used in this project and their working dilutions see table 5.1. 
Western blot 
Proteins were separated by SDS-PAGE (section 2.2.1) before being transferred to a 
nitrocellulose membrane using a BioRad wet-blot system, as per manufacturer’s instructions, 
for 1 h at a constant current of 350 mA in Western blot buffer (20 mM Tris, 192 mM glycine, 
0.1% SDS, 10% methanol).  
Immunodetection 
Nitrocellulose membranes were removed and incubated o/n at 4°C, with gentle agitation, in 
10 ml TBS (Tris-buffered saline) blocking buffer (10 mM Tris/HCl, 0.09% NaCl, 0.5% 
casein, pH 7.5). An optimised concentration of primary antibody was incubated with the 
nitrocellulose membrane in 10 ml TBS for 90 min at RT with gentle agitation. The membrane 
was washed with three cycles of 10 ml TBST (TBS + 0.1% Tween-20) for 5 min each. The 
membrane was incubated with a secondary antibody, usually goat α-rabbit-HRP, in 10 ml of 
TBS for 90 min at RT with gentle agitation. 
Enhanced chemiluminescence visualisation  
The membrane was washed as before in three cycles of TBST for 5 min each before 
visualisation using an enhanced chemiluminescence (ECL) kit (GE healthcare) as per 
manufacturer’s instructions. An ImageQuant LAS4000mini biomolecular imager (GE 
Healthcare) was used to visualise blots and the accompanying software was used to process 
the images. 
 
2.2.3 Estimation of protein concentration 
The concentrations of purified proteins and cell lysates were estimated using bovine serum 
albumin (BSA) standards in a PierceTM BCA protein assay kit (Thermo scientific), as per 
manufacturer’s instructions (see figure 2.1). Most often however, the concentration of purified 
protein samples, absent in Triton X-100, was estimated using a NanoDrop spectrophotometer 
and accompanying ND1000 V3.7.1 software which calculates the concentration of the sample 
based on the absorbance of the protein at 280 nm using the extinction coefficient and 
molecular weight of the sample.  
 
  
49 
 
  
 
Figure 2.1 Example BSA standard curve 
Bovine serum albumin (BSA) standards plotted as concentration against absorbance, read at 550 nM.  
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2.3 Protein purifications 
A list of all plasmids for the overproduction of proteins is given in table 5.2.  
2.3.1 Protein overproduction and cell fractionation 
The procedure for soluble protein overproduction was the same for each protein purified, 
unless stated in the specific protein purification section. E. coli BL21(DE3) cells harbouring 
specific overexpression plasmids were grown o/n at 37°C with an appropriate antibiotic. O/n 
cultures were diluted 1:50 in 3 L of LB media and grown at 37°C with orbital shaking to an 
OD578 of 0.5-0.6. Protein overexpression was induced with the addition of 1 mM IPTG and 
incubation for a further three hours at 30°C. Cells were kept for 10 min on ice before 
harvesting by centrifugation (7500 × g, 4°C, 15 min) (Beckman Coulter – F500 rotor). 
Pelleted cells were resuspended in 40 ml of ice cold resuspension buffer (25 mM Tris/HCl, 10 
mM MgCl2, 300 mM NaCl, 10% glycerol, pH 7.5). A small amount of DNase, 1/1000 
protease inhibitor cocktail (Sigma) and 100 μM phenylmethylsulfonylfluoride (PMSF) were 
added prior to sonication (3 × 20 s at 10, 20, 30, 40, 50, 60% power, 30 s rest between each 
setting) and ultracentrifugation (140000 × g, 4°C, 15 min) to remove the membrane fraction. 
For the purification of membrane proteins the supernatant was discarded, and the membrane-
containing pellet solubilised by stirring o/n with extraction buffer (25 mM Tris/HCl, 10 mM 
MgCl2, 1 M NaCl, 2% Triton X-100, 20% glycerol, pH 7.5). Purification steps continue as 
described in each specific protocol section. 
 
2.3.2 Protein overproduction for NMR spectroscopy  
In the case of protein purification for nuclear magnetic resonance (NMR) spectroscopy 
analysis, proteins were labelled with [13C] and [15N]. M9 minimal media was used (5.29 g/L 
Na2HPO4, 3 g/L KH2PO4, 0.5 g/L NaCl, and 1 g/L [
15N]-NH4Cl, 1 mM MgSO4, 0.1 mM 
CaCl2, 2 mM Thiamine, 0.3% [
13C]-glucose, pH 6.8-7.2) in which [
13C] and [15N] isotopes 
were the only carbon and nitrogen sources, respectively. Standard LB day cultures were made 
with the appropriate overexpression strain diluted 1/70 and grown at 37ºC for 8 h. Of this day 
culture, 1 ml was used to inoculate 100 ml of M9 media and grown o/n at 37ºC with orbital 
shaking. Cells were harvested by centrifugation (7500 × g, 4°C, 15 min), resuspended in 1 ml 
of fresh M9 media and used to inoculate the remaining 900 ml of M9 media in which cells 
were grown to an OD578 of 0.5-0.6. Subsequent purification steps are protein specific and the 
same for unlabelled protein purification. 
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2.3.3 Immobilised metal ion affinity chromatography (IMAC) 
This is the first purification step for proteins with an oligo-histidine tag (His-tag) either from 
isolated cell lysate or a solubilised membrane fraction. All His-tags are N-terminal unless 
stated. Specific protein buffer conditions can be found under the relevant sections, however 
the most common buffer conditions are given here as an example. Isolated supernatant was 
applied to a 5 ml HisTrap HP column (GE healthcare) using an ÄKTA Prime+ (GE 
Healthcare) by 50 ml Superloop, pre-equilibrated with buffer 1 (25 mM Tris/HCl, 10 mM 
MgCl2, 300 mM NaCl, 20 mM imidazole, 10% glycerol, pH 7.5) at 1 ml/min collecting 10 ml 
fractions. The column was washed with 5 column volumes of buffer 1 at 2 ml/min before the 
step-wise elution of bound proteins with buffer 2 (25 mM Tris/HCl, 300 mM NaCl, 400 mM 
imidazole, 10% glycerol, pH 7.5) at 2 ml/min collecting 4 ml fractions. Flow-through, wash, 
and elution fractions were analysed by SDS-PAGE and those containing the best yield and 
purity were either stored at -80°C with 10% glycerol, if purification was sufficient, or 
dialysed against the appropriate buffer for a second step of purification, usually IEX. If a 
native form of the protein was required, samples were incubated with 1 unit/ml of thrombin 
(Novagen) prior to dialysis and IEX to remove the cleaved His-Tag. 
 
2.3.4 Ion exchange chromatography (IEX) 
If IEX is the first step of purification, harvested cellular pellets were resuspended in a low/no 
NaCl buffer, if not, samples were dialysed against 2 × 2 L of IEX buffer 1 (50 mM Tris/HCl, 
pH 8.0), o/n and 1 hr in the morning. A 5 ml HiTrap SP HP or Q HP (depending on the charge 
of the protein) (GE healthcare) ion exchange column was prepared with 5 column volumes of 
dH2O and 5 column volumes of IEX buffer 2 (50 mM Tris/HCl, 1 M NaCl, pH 8.0) before 
equilibration with IEX buffer 1. Protein was applied via 50 ml Superloop using an ÄKTA 
Prime+ at 1 ml/min collecting 10 ml fractions. The loaded column was washed with 15% IEX 
buffer 2 for 3 × 10 ml fractions at 2 ml/min. Proteins were eluted with a salt gradient of 15-
100% IEX buffer 2 for 100 ml collecting 4 ml fractions. Fractions (flow-through, washes, and 
elutions) were analysed by SDS-PAGE and those containing the best yield and purity were 
either stored at -80°C with 10% glycerol, if purification was sufficient, or dialysed against the 
appropriate buffer for another method of purification. 
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2.3.5 Hydroxyapatite chromatography  
Hydroxyapatite purification utilises positively charged calcium ions and negatively charged 
phosphate groups to separate proteins by metal affinity and cation exchange respectively 
[236]. Prior to purification, samples were dialysed o/n against buffer 1 (10 mM KPO4, 300 
mM NaCl, pH 6.8). A 5 ml hydroxyapatite column (BioRad Bioscale Mini CHT II 40 μm 5 
ml cartridge) was washed with 5 column volumes of dH2O and equilibrated with buffer 1 
before application of the protein sample by 50 ml Superloop at 1 ml/min. The column was 
washed for 3 × 10 ml fractions with buffer 1 before elution of bound proteins using a gradient 
of 0-100% buffer 2 (500 mM KPO4, 300 mM NaCl, pH 6.8) over 50 ml at 1 ml/min collecting 
4 ml fractions. Fractions (flow-through, washes, and elutions) were analysed by SDS-PAGE 
and the fractions containing the best yield and purity were either stored at -80°C with 10% 
glycerol, if purification was sufficient, or dialysed against the appropriate buffer for another 
step of purification. 
 
2.3.6 Size exclusion chromatography 
Size exclusion chromatography (SEC) was usually the last step of protein purification. 
Samples were concentrated to 4-5 ml using a Vivaspin 6 column (Sartorius Stedim biotech) 
and applied to a HiLoad 16/60 Superdex 200 column prewashed with dH2O and equilibrated 
with SEC running buffer (25 mM HEPES/NaOH, 300 mM NaCl, 10 mM MgCl2, 10% 
glycerol, pH 7.5). Protein samples were loaded onto the column at 1 ml/min collecting 4 ml 
fractions. Peak UV fractions were analysed by SDS-PAGE and those of highest yield and 
purity were pooled, aliquoted and stored at -80°C. 
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2.4 Specific protein purification protocols 
2.4.1 Purification of LpoA versions 
The protocol is as described in [31]. His-LpoA from E. coli and H. influenzae (LpoAH.i), as 
well as the truncated E. coli versions (N-terminal domain, LpoAN and C-terminal domain, 
LpoAC), were grown and protein overexpression induced as described in section 2.3.1, with 
the exception of using 500 mM NaCl. Sonication and ultracentrifugation of the lysate was 
followed by IMAC (section 2.3.3) using buffer 1 (25 mM Tris/HCl, 10 mM MgCl2, 500 mM 
NaCl, 20 mM imidazole, 10% glycerol, pH 7.5) and buffer 2 (25 mM Tris/HCl, 500 mM 
NaCl, 400 mM Imidazole, 10% glycerol, pH 7.5). LpoA, LpoAH.i and LpoA
C required IEX 
using a HiTrap Q HP column as a second purification step (section 2.3.4), whereas LpoAN 
required only SEC (section 2.3.6), using 25 mM HEPES/NaOH, 500 mM NaCl, 10% 
glycerol, pH 7.5 as running buffer. After IEX, LpoA, LpoAH.i and LpoA
C were also purified 
by SEC. Fractions with the highest yield and purity were pooled, concentrated and dialysed 
against storage buffer before being frozen at -80°C. See figure 2.2 for the SDS-PAGE gels of 
the purified LpoA versions. 
 
Figure 2.2 SDS-PAGE analysis of purified LpoA versions 
Analysis of protein yield and purity of E. coli His-LpoA (72 kDa) (A), His-LpoAN (28 kDa) (B), His-LpoAC (55 
kDa) (C) and full length His-LpoA from H. influenzae (55 kDa) (D). Proteins were separated by 12% SDS-
PAGE and visualised by Coomassie staining. 
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2.4.2 Purification of PBP1A from E. coli and H. influenzae 
This protocol is as described in [67]. E. coli BL21(DE3) cells carrying the plasmid pTK1A-
His-PBP1A or pET28-His-PBP1A from H. influenzae were grown in 4 L of LB supplemented 
with 50 µg/ml kanamycin to an OD578 of 0.3 at 30°C. Overexpression was induced with 0.05 
mM IPTG for a further 90 min at 30°C before harvesting the cells by centrifugation (7500 × 
g, 4°C, 15 min). Cells were resuspended in 30 ml of buffer 1 (25 mM Tris/HCl, 10 mM 
MgCl2, 100 mM NaCl, pH 7.5) before sonication and ultracentrifugation (140000 × g, 4°C, 60 
min). The resulting pellet was resuspended in 20 ml of salt buffer (25 mM Tris/HCl, 10 mM 
MgCl2, 1 M NaCl, 20% glycerol, pH 7.5) and homogenised. The cells were ultracentrifuged 
again and the pellet resuspended in 20 ml of extraction buffer (25 mM Tris/HCl, 10 mM 
MgCl2, 1 M NaCl, 2% Triton X-100, 20% glycerol, pH 7.5) before o/n incubation at 4°C with 
stirring.  
The solubilised membrane-containing supernatant was obtained by ultracentrifugation 
(140000 × g, 4°C, 60 min) and applied to 2 ml of Ni2+-Nitrilotriacetic acid (NTA) Superflow 
beads (Qiagen), prewashed with dH2O and equilibrated with buffer A (25 mM Tris/HCl, 10 
mM MgCl2, 1 M NaCl, 5 mM imidazole, 20% glycerol, pH 7.5), for 2 h at 4°C with gentle 
mixing. Beads were obtained using a gravity column and were washed with 50 ml of buffer 
A. Elution of bound proteins was carried out with 10 × 1 ml of buffer B (25 mM Tris/HCl, 10 
mM MgCl2, 1 M NaCl, 400 mM imidazole, 20% glycerol, pH 7.5).  
The protein buffer was gradually changed by o/n dialysis against dialysis buffer 1 (25 mM 
Tris/HCl, 10 mM MgCl2, 1 M NaCl, 10% glycerol, pH 7.5), followed by 90 min against 
dialysis buffer 2 (10 mM NaAcetate, 10 mM MgCl2, 500 mM NaCl, 10% glycerol, pH 4.8) 
and finally 90 min against dialysis buffer 3 (10 mM NaAcetate, 10 mM MgCl2, 200 mM 
NaCl, 10% glycerol, pH 4.8). The protein sample was diluted 1:1 with dilution buffer (10 mM 
NaAcetate, 10 mM MgCl2, pH 4.8) and applied to a prewashed and equilibrated 5 ml HiTrap 
SP HP column in IEX buffer 1 (10 mM NaAcetate, 10 mM MgCl2, 100 mM NaCl, 0.1% 
Triton X-100, 10% glycerol, pH 4.8). The column was washed with 50 ml of IEX buffer 1 
before eluting bound proteins using a 0-100% salt gradient with IEX buffer 2 (10 mM 
NaAcetate, 10 mM MgCl2, 1 M NaCl, 0.1% Triton X-100, pH 4.8). After analysis by SDS-
PAGE, fractions containing the highest yield and purity were dialysed o/n against storage 
buffer (25 mM HEPES/NaOH, 10 mM MgCl2, 300 mM NaCl, 0.1% Triton X-100, pH 7.5) 
before being aliquoted and stored at -80ºC. See figure 2.3A/B for the SDS-PAGE gels of 
purified PBP1A versions. 
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2.4.3 Purification of the outer-membrane PBP1A docking domain (ODD)  
This protocol was developed and optimised by Adeline Derouaux from the Vollmer lab. 
BL21(DE3) cells harbouring the plasmid pQE30-His-ODD were grown in 1 L of LB 
supplemented with 50 µg/ml of kanamycin to an OD578 of 0.6 at 37°C and left for a further 2 
h (no IPTG induction required). Cells were pelleted by centrifugation (7500 × g, 15 min, 4°C) 
and resuspended in 12 ml of buffer 1 (25 mM Tris/HCl, 20 mM imidazole, 200 mM NaCl, 
10% glycerol, pH 7.5) before sonication and ultracentrifugation (140000 × g, 1 h, 4°C). The 
resulting supernatant was applied to 2 ml of washed and equilibrated Ni2+-NTA bead resin 
and incubated o/n at 4°C with mixing. The beads were washed with 40 ml of buffer 1 before 
elution of bound proteins with elution buffer (25 mM Tris/HCl, 400 mM imidazole, 200 mM 
NaCl, 10% glycerol, pH 7.5) collecting 10 × 1 ml fractions. Peak fractions were pooled and 
applied to a HiLoad 16/60 Superdex 200 column for SEC in 25 mM HEPES/NaOH, 100 mM 
NaCl, 10% glycerol, pH 7.5 (section 2.3.6). Peak fractions were collected and analysed by 
SDS-PAGE before being concentrated, aliquoted and stored at -80°C. See figure 2.3C for the 
SDS-PAGE gel of purified His-ODD. 
 
Figure 2.3 SDS-PAGE of PBP1A from E. coli and H. influenzae and the ODD from E. coli  
Analysis of protein purity and yield of thrombin-cleaved His-PBP1A from E. coli (A) and H. influenzae (B) both 
at ~93 kDa and His-ODD from E. coli PBP1A (13 kDa) (C). Proteins were separated by 12% (A and B) or 15% 
(C) SDS-PAGE and visualised by Coomassie staining. 
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2.4.4 Purification of PBP4 versions 
 
PBP4 and PBP4 S62A purification 
This protocol is as described in [115]. Protocol for growth of cells is as stated in section 2.3.1. 
BL21(DE3) pET21-PBP4 or BL21(DE3) pET21-PBP4(S62A) were grown with 100 µg/ml 
ampicillin, and protein overexpression was induced with 1 mM IPTG for 8 hours at 20°C 
before harvesting cells by centrifugation. Cell pellets were resuspended in 40 ml of pre-cooled 
buffer 1 (50 mM Tris/HCl, 30 mM NaCl, pH 6.8). After sonication and ultracentrifugation, 
native PBP4 versions were purified using a 5 ml HiTrap SP HP IEX column (section 2.3.4) 
before hydroxyapatite purification (section 2.3.5) and SEC using 25 mM HEPES/NaOH, 300 
mM NaCl, 10% Glycerol, pH 6.8 as a running buffer (section 2.3.6). Fractions of the highest 
yield and purity were concentrated, aliquoted and stored at -80°C. See figure 2.4A/B for the 
SDS-PAGE gel of purified PBP4 and PBP4(S62A). 
 
His-PBP4 delta domain 3 (PBP4ΔD3)  
BL21(DE3) pET28a-His-PBP4 Δ173-247 (domain 3) cells were cultivated and protein 
overexpression induced as described in section 2.3.1 in LB supplemented with 50 µg/ml 
kanamycin. After harvesting, sonication and ultracentrifugation, the protein was purified via 
IMAC, IEX and SEC by the standard protocols described in sections 2.3.3, 2.3.4 and 2.3.6, 
with a final storage buffer consisting of 25 mM HEPES/NaOH, 300 mM NaCl, 10% glycerol, 
pH 7.5. Purified protein samples were pooled, concentrated and stored at -80°C. This 
construct encodes a non-cleavable His-Tag. See figure 2.4C for the SDS-PAGE gel of 
purified His-PBP4ΔD3. 
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Figure 2.4 SDS-PAGE analysis of purified PBP4 versions 
Analysis of final protein purity and yield of PBP4 (51 kDa) (A), PBP4(S62A) (51 kDa) (B) and His-PBP4ΔD3 
(42 kDa) (C). Proteins were separated by 12% SDS-PAGE and visualised by Coomassie staining. 
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2.4.5 Purification of PBP7 versions 
 
PBP7 and PBP7 S67A purification 
BL21(DE3) pET28a-His-PBP7 or BL21(DE3) pET28a-His-PBP7(S67A) cells were grown 
and protein overexpression induced as described in section 2.3.1 in LB supplemented with 50 
µg/ml kanamycin. Purification was carried out by IMAC using buffer 1 (25 mM 
HEPES/NaOH, 500 mM NaCl, 20 mM imidazole, 10% glycerol, pH 7.5) and buffer 2 (25 
mM HEPES/NaOH, 300 mM NaCl, 400 mM imidazole, 10% glycerol, pH 7.5) (section 2.3.3) 
and SEC using (25 mM HEPES/NaOH, 500 mM NaCl, 10% glycerol, pH 7.5) (section 2.3.6). 
Purified protein was analysed by SDS-PAGE, concentrated, aliquoted and stored at -80°C. 
See figure 2.5A/B for the SDS-PAGE gels of purified PBP7 and PBP7(S67A). 
 
Figure 2.5 SDS-PAGE analysis of purified PBP7 versions  
Analysis of final protein purity and yield of His-PBP7 (33 kDa) (A) and His-PBP7(S67A) (32 kDa) (B). Proteins 
were separated by 12% SDS-PAGE and visualised by Coomassie staining. 
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2.4.6 Purification of MepS versions  
 
MepS and MepS C68A purification 
This protocol was optimised as part of this project. BL21(DE3) pET21b-His-MepS or 
BL21(DE3) pET21b-MepS(C68A) cells were grown in 4 L of LB supplemented with 50 
µg/ml kanamycin at 37°C to an OD578 of 0.5-0.6 before the induction of protein 
overexpression with 1 mM IPTG for 90 min at 37°C. Purification was carried out by IMAC 
and SEC as described in 2.3.3 and 2.3.6 using 25 mM HEPES/NaOH, 300 mM NaCl, 10% 
glycerol, pH 7.5 as SEC running buffer. Purified protein was analysed by SDS-PAGE 
concentrated, aliquoted, and stored at -80°C. See figure 2.6A/B for the SDS-PAGE gels of 
purified MepS and MepS(C68A). 
 
Figure 2.6 SDS-PAGE analysis of purified MepS versions  
Analysis of final protein purity and yield of His-MepS (21 kDa) (A) and His-MepS(C68A) (21 kDa) (B). 
Proteins were separated by 12% SDS-PAGE and visualised by Coomassie staining. 
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2.4.7 Purification of MepM  
This protocol was optimised as part of this project. BL21(DE3) pET21b-His-MepM cells 
were grown in 3 L of LB at 37°C in LB supplemented with 50 µg/ml kanamycin to an OD578 
of 0.5-0.6 before the induction of protein overexpression with 50 μM IPTG for 2 h at 25°C. 
Purification was carried out by IMAC and SEC as described in 2.3.3 and 2.3.6 using 25 mM 
HEPES/NaOH, 300 mM NaCl, 10% glycerol, pH 7.5 as SEC running buffer. After analysis 
by SDS-PAGE, fractions with the highest purity and yield were concentrated, aliquoted and 
stored at -80°C. See figure 2.7 for the SDS-PAGE gel of purified MepM. 
 
 
Figure 2.7 SDS-PAGE analysis of purified MepM  
Analysis of final protein purity and yield of His-MepM (49 kDa). Protein was separated by 12% SDS-PAGE and 
visualised by Coomassie staining. 
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2.4.8 Purification of MepA  
This protocol belongs to the Vollmer group. MC1061 pJFK-MepA cells lacking the soluble 
lytic transglycosylase, Slt, were grown o/n with 0.8% glucose and 50 μg/ml kanamycin and 
inoculated 1:200 into 5 L of LB supplemented with 12% sucrose and 50 μg/ml kanamycin to 
an OD578 of 0.6 at 37°C. Overproduction of native MepA was induced with 1 mM IPTG for a 
further 1 h at 37°C. After 10 min on ice and harvesting by centrifugation, cells were 
resuspended in 50 ml buffer 1 (10 mM Tris/Maleate, 10 mM MgCl2, pH 6.5) and lysed by 
sonication. The soluble fraction was obtained by ultracentrifugation and IEX was carried out 
using a 5 ml HiTrap SP HP column in buffer A (10 mM Tris/Maleate, 10 mM MgCl2, pH 5.2) 
and washed for 50 ml before the elution of bound proteins using a 100 ml salt gradient of 0-
100% buffer B (10 mM Tris/Maleate, 10 mM MgCl2, 1 M NaCl, pH 5.2) at 2 ml/min 
collecting 4 ml fractions. Appropriate fractions were pooled and concentrated for SEC in 25 
mM HEPES/NaOH, 300 mM NaCl, 10% glycerol, pH 7.5. Fractions with the highest yield 
and purity were pooled, concentrated and stored at -80°C. See figure 2.8 for the SDS-PAGE 
gel of purified native MepA. 
 
 
Figure 2.8 SDS-PAGE analysis of purified MepA 
Analysis of protein purity and yield of native MepA (31 kDa). Protein was separated by 12% SDS-PAGE and 
visualised by Coomassie staining. 
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2.4.9 Purification of NlpI(sol)/NlpIΔC11(sol)  
This protocol is as described in [233]. BL21(DE3) pET28-His-NlpI or BL21(DE3) pET28-
His-NlpIΔC11 were grown in LB supplemented with 50 µg/ml kanamycin, and 
overproduction induced, as described in section 2.3.1. Cells were pelleted by centrifugation 
(7500 × g, 15 min, 4°C) and resuspended in 40 ml of buffer 1 (25 mM Tris/HCl, 200 mM 
NaCl, pH 7.5) before sonication and ultracentrifugation. His-NlpI or His-NlpIΔC11 were 
purified using IMAC using buffer 1 as running buffer and buffer 1 with 400 mM imidazole 
for the step-wise elution of bound proteins. The resulting purification was excellent, and only 
SEC was necessary as a second purification method, in 25 mM HEPES/NaOH, 200 mM 
NaCl, 10% glycerol, pH 7.5. IEX was carried out if a thrombin cleavage step was required 
after IMAC. Purified proteins were pooled, concentrated and stored at -80°C. See figure 2.9 
for the SDS-PAGE gel of purified His-NlpI and His-NlpIΔC11. 
 
 
Figure 2.9 SDS-PAGE analysis of purified His-NlpI and His-NlpIΔC11 
Analysis of protein purity and yield of His-NlpI(sol) (33 kDa) and His-NlpIΔC11 (32 kDa). Proteins were 
separated by 12% SDS-PAGE and visualised by Coomassie staining. 
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2.4.10 Purification of EnvC  
E. coli BL21(DE3) cells harbouring the plasmid pET28-His-EnvC, were cultivated in LB 
supplemented with 50 µg/ml kanamycin, and protein overexpression induced as described in 
section 2.3.1. Cells were harvested by centrifugation, resuspended in buffer 1 (25 mM 
HEPES/NaOH, 300 mM NaCl, pH 7.5), sonicated and ultracentrifuged to obtain the soluble 
fraction. His-EnvC was purified by IMAC and SEC as described in section 2.3.3 and 2.3.6 
using buffer 1 as SEC running buffer. Fractions with the highest yield and purity were pooled, 
concentrated and stored at -80°C in 10% glycerol. See figure 2.10 for the SDS-PAGE gel of 
purified His-EnvC. 
 
 
Figure 2.10 SDS-PAGE analysis of purified His-EnvC  
Analysis of protein purity and yield of His-EnvC (43 kDa). Protein was separated by 12% SDS-PAGE and 
visualised by Coomassie staining. 
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2.5 Advanced protein methods 
2.5.1 Interaction assays 
2.5.1.1 Preparation of E. coli periplasmic extract for affinity chromatography 
This protocol was adapted from [237]. O/n cultures of MC1061 cells were used to inoculate 2 
L of LB which were grown, with orbital shaking at 37°C, until an OD578 of 0.5-0.6 was 
reached. Cells were harvested by centrifugation (7500 × g, 4°C, 15 min) and resuspended in 
16 ml of 100 mM Tris/HCl, pH 8.0. Cells were centrifuged again and resuspended in 8 ml of 
200 mM Tris/HCl, pH 8.0. Another 8 ml of 200 mM Tris/HCl, pH 8.0 was added, this time 
containing 1 M sucrose, 1 mM EDTA and 1 ml of 1 mg/ ml lysozyme. Cells were incubated 
with 17.6 ml of H2O and DNase for 30-60 min at RT until cells became 90% spheroplasts as 
observed by light microscopy (see figure 2.11). Cells were centrifuged (12000 × g, 4°C, 30 
min) and the periplasm-containing supernatant dialysed in equal volumes against high salt 
buffer (10 mM Tris/Maleate, 10 mM MgCl2, 400 mM NaCl, 10% glycerol, pH 7.2) and low 
salt buffer (10 mM Tris/Maleate, 10 mM MgCl2, 150 mM NaCl, 10% glycerol, pH 7.2). 
 
 
Figure 2.11 Light microscopy image of spheroplasts during periplasmic extraction 
Cells after an osmotic shock became spheroplasts. 
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2.5.1.2 Preparation of E. coli membrane extract for affinity chromatography 
This protocol was adapted from [237]. O/n cultures of MC1061 cells were grown in 2 L of LB 
at 37ºC with orbital shaking to an OD578 of 0.5-0.6 before harvesting by centrifugation (7500 
× g, 4°C, 15 min). Cells were resuspended in 20 ml of 10 mM Tris/maleate, pH 7.2 with the 
addition of 1/1000 PIC, 100 µM PMSF and DNase. Cells were disrupted by sonication and 
were ultracentrifuged (140000 × g, 4°C, 1 h). The supernatant was discarded and the 
membrane-containing pellet was resuspended in 20 ml of 10 mM Tris/maleate, 1 mM EDTA, 
1 M NaCl, 2% Triton X-100, pH 6.8 and incubated at 4°C o/n with agitation. Solubilised 
membrane extract was isolated by ultracentrifugation (140000 × g, 4°C, 1 h) and the 
supernatant dialysed in equal volumes against high salt buffer (10 mM Tris/Maleate, 10 mM 
MgCl2, 400 mM NaCl, 10% glycerol, pH 7.2) and low salt buffer (10 mM Tris/Maleate, 10 
mM MgCl2, 150 mM NaCl, 10% glycerol, pH 7.2). 
 
2.5.1.3 Affinity chromatography 
This protocol was adapted from [237]. For the immobilisation of purified protein, 0.8 g of 
desiccated CNBr-activated sepharose beads (GE Healthcare) were re-hydrated with 200 ml of 
1 mM HCl before the addition of 8-10 mg of purified protein in 10 ml of coupling buffer (100 
mM NaHCO3, 10 mM MgCl2, 500 mM NaCl, 0.1% Triton X-100, pH 8.3) o/n with agitation. 
A control column was used in parallel, absent of protein. The beads were washed with 25 ml 
of coupling buffer and any remaining active groups were blocked with high Tris blocking 
buffer (200 mM Tris/HCl, 10 mM MgCl2, 500 mM NaCl, 0.1% Triton X-100, pH 8.0) o/n 
with agitation at 4°C. The beads were washed with three cyclic alterations of blocking buffer 
and acetate buffer (100 mM NaAcetate, 10 mM MgCl2, 500 mM NaCl, 0.1% Triton X-100, 
pH 4.8) before washing with 10 ml of binding buffer (10 mM Tris/HCl, 10 mM MgCl2, 50 
mM NaCl, 0.1% Triton X-100, pH 7.2). Depending on the desired experiment, 10 ml of the 
low salt isolated membrane or periplasmic extracts from section 2.5.1.1 and 2.5.1.2 
respectively, were applied to the beads o/n with agitation at 4°C. Alternatively, a 1:1 mixture 
of the extracts was also used.  
After incubation, the whole sample was applied to a gravity column and the flow-through was 
collected. The isolated beads were washed with 50 ml of binding buffer before the elution of 
weakly bound proteins using 20 ml of low salt elution buffer 1 (10 mM Tris/HCl, 10 mM 
MgCl2, 150 mM NaCl, 0.1% Triton X-100, pH 7.2) plus a final elution step with low salt 
elution buffer 2 (10 mM Tris/HCl, 10 mM MgCl2, 1 M NaCl, 0.1% Triton X-100, pH 7.2).  
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The columns were washed with 10 ml of high salt binding buffer (10 mM Tris/HCl, 10 mM 
MgCl2, 400 mM NaCl, 0.1% Triton X-100, pH 7.2) before 10 ml of high salt 
membrane/periplasmic/mixture extract was applied and incubated o/n with agitation at 4°C. 
As before, the flow-through was collected and the beads washed with binding buffer and 
bound proteins eluted with high salt elution buffer 3 (10 mM Tris/HCl, 10 mM MgCl2, 2 M 
NaCl, 0.1% Triton X-100, pH 7.2). 
Samples from each fraction (flow-through, washes, elution 1, elution 2 and elution 3) were 
resolved by SDS-PAGE and proteins transferred to a nitrocellulose membrane by Western 
blotting, using purified antibodies for primary immunodetection. 
 
2.5.1.4 Proteomics-based identification of interacting proteins 
Equal volumes of membrane and periplasmic fractions (low salt or high salt) were combined 
1:1 with dialysis buffer (10 mM Tris/Maleate, 10 mM MgCl2, 100 mM NaCl, pH 7.2) and 
dialysed o/n against 3 L of the same dialysis buffer. The protein of choice was diluted to 2 
mg/ml in coupling buffer (50 mM NaH2PO4, 500 mM NaCl, pH 8.0) and was dialysed o/n 
against the same buffer.  
To a 2 ml reaction tube, 300 μl of Affigel (BioRad) bead suspension was added and washed 
with ice cold H2O, and equilibrated with coupling buffer before the addition of 500 μl of 
dialysed protein. The samples were incubated o/n at 4°C with gentle agitation. In parallel, 
coupling buffer was applied to washed Affigel beads absent of protein, as a negative control. 
After incubation, the beads were obtained by centrifugation (4000 × g, 4 min, 4ºC) and were 
firstly washed with blocking buffer (200 mM Tris/maleate, 500 mM NaCl, pH 8.0) before 
incubation with blocking buffer for 3 h at 4°C with agitation.  
Beads were isolated by centrifugation as before and washed with elution buffer (10 mM 
Tris/maleate, 500 mM NaCl, 0.2% N-lauroylsarcosine), to remove any non-specifically bound 
contaminants, and equilibrated with binding buffer (10 mM Tris/maleate, 10 mM MgCl2, 100 
mM NaCl, 1% Triton X-100, pH 7.2). To the protein-loaded beads, 1.5 ml of the dialysed 
membrane/periplasmic fraction was added and incubated o/n at 4°C with agitation. Samples 
were centrifuged and the supernatant collected before transferring the beads to clean tubes and 
washing with binding buffer and low triton wash buffer (10 mM Tris/Maleate, 10 mM MgCl2, 
100 mM NaCl, pH 7.2). The beads were again transferred to spin-dry columns (Generon 
Proteus Clarification Mini Spin Column) and any retained proteins were eluted with 250 µl of 
elution buffer. Eluted proteins were precipitated with 750 µl of ethanol and stored at -20°C 
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o/n. For the identification of novel interaction partners, samples were centrifuged (14000 × g, 
20 min, 4°C) and the supernatant removed and left to air-dry. Once complete, the samples 
were sent for mass spectroscopy analysis by Dr. Joe Gray at the Pinnacle Institute, Newcastle 
University. 
 
2.5.1.5 In vitro cross-linking and pull-down experiments 
The hexahistidine tag, used for the purification of many of the proteins in this project, binds to 
Ni2+-NTA bead resin (Qiagen) and proteins lacking this tag are not retained. We utilise these 
properties for the rapid identification of in vitro interactions. The retention of one native 
protein of interest in the presence of another possessing a hexahistidine tag by Ni2+ beads, 
whilst not being retained alone, is indicative of an interaction.  
Equimolar concentrations (2 µM unless stated) of purified proteins of interest were incubated 
in 200 µl of binding buffer (10 mM HEPES/NaOH, 10 mM MgCl2, 150 mM NaCl, 0.05% 
Triton X-100, pH 7.5) for 10 min on ice. Proteins of interest (one tagged, one native) were 
cross-linked with 1.08 µl of 30% formaldehyde (final concentration 0.2% by volume). After 
incubating the samples at 37ºC for 15 min, any excessive cross-linking was blocked with 100 
mM Tris/HCl, pH 7.5. In each experiment, the individual His-tagged and native proteins were 
treated the same as the mixture. An aliquot was taken prior to incubation with Ni2+-NTA 
beads as an applied sample for subsequent SDS-PAGE analysis.   
Ni2+-NTA beads were prepared by washing 100 µl bead suspension, per sample, with 2 × 1.5 
ml of H2O and equilibration with 2 × 1.5 ml of binding buffer. Protein samples were applied 
to equilibrated beads with 1.3 ml of binding buffer and incubated o/n with agitation at 4°C. 
Samples were centrifuged (4000 × g, 4 min,  4°C) and the beads washed 6 × 1 ml with wash 
buffer (10 mM HEPES/NaOH, 10 mM MgCl2, 150 mM NaCl, 50 mM imidazole, 0.05% 
Triton X-100, pH 7.5). Beads were resuspended in 250 µl of wash buffer and transferred to 
spin-dry columns and centrifuged (4000 × g, 5 min, RT). The isolated beads were transferred 
to clean reaction tubes and bound proteins eluted, and cross-linking reversed, by the addition 
of 50 µl of SDS-PAGE loading buffer and boiling for 10 min. Samples were centrifuged 
(10000 × g, 5 min, RT) and resolved by SDS-PAGE alongside the respective applied samples 
(table 2.2). 
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His-protein + Native protein His-protein Native protein 
Applied Elution Applied Elution Applied Elution 
Table 2.2 Example SDS-PAGE scheme of an in vitro Ni2+-bead pull-down experiment 
An aliquot was taken prior to incubation with Ni2+-NTA beads (Applied). A sample was taken after thorough 
washing, reversing of cross-linkage and elution. A mixture of a His-tagged protein and a native protein are 
compared to the individual proteins. 
 
2.5.1.6 Surface plasmon resonance (SPR) 
The protocol is as described in, and adapted from [237] and carried out using a ProteOn 
XPR36 system (Biorad). Running buffer consisted of 10 mM Tris/maleate, 150 mM NaCl, 
0.05% Triton X-100, pH 7.5.  
All immobilised proteins, excluding PBP1A, were immobilised directly to a GLC general 
amine coupling SPR sensorchip, after activation of the chip using N-Hydroxysuccinimide 
(NHS) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) coupling, 
as per manufacturer’s instructions. An empty control lane was activated and applied with 
running buffer absent of protein. After activation and immobilisation, the chip surface was 
washed with high salt regeneration buffer (10 mM Tris/maleate, 1 M NaCl, 0.05% Triton X-
100, pH 7.5) and any remaining unsaturated amino groups blocked with the application of 
ethanolamine. The surface was washed again with regeneration buffer and equilibrated with 
running buffer. Up to 6 analytes could be applied to the surface at 75-100 μl/min for 3-5 min 
at 25°C.  
For the creation of a PBP1A surface, 10 mg/ml of ampicillin in 0.1 mM sodium acetate, pH 
4.6 was firstly immobilised by general amine coupling as per manufacturer’s instructions, 
before the application of 75 µg/ml PBP1A at 30 µl/min for 5 min, at 35ºC. As before, a 
control lane was activated in parallel in which ampicillin was immobilised but no protein was 
applied. After the immobilisation of PBP1A, the surface was washed with regeneration buffer, 
before any free ampicillin was hydrolysed with the application of 1 µM of the β-lactamase 
Vim4 (Pseudomonas aeruginosa, Adeline Derouaux, Vollmer group). Prior to application of 
the analyte, the surface was washed with regeneration buffer and equilibrated with running 
buffer.  
The associated ProteOn software was used to calculate the equilibration response (Req) values 
which were plotted against analyte concentration. Scratchard analysis by non-linear regression 
was used to estimate the dissociation constant (KD) of an interaction. 
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2.5.1.7 Microscale thermophoresis (MST) 
Microscale thermophoresis (MST) is a technique by which biomolecular interactions can be 
observed in solution and without the need for immobilisation, thereby providing a ‘close-to 
native’ environment. MST refers to the movement of molecules along a microscopic 
temperature gradient; a movement which is sensitive to minute changes in the solvation state 
of a protein, as well as its charge and size, changes that occur upon an interaction with another 
protein. By titrating a serially-diluted unlabelled ligand with a fluorescently-tagged protein of 
constant concentration, these changes can be tracked and dissociation constants estimated 
from any resulting equilibration/cooperative binding events [238]. Movement of the 
fluorescently-tagged protein can occur along the temperature gradient, or against the 
temperature gradient. It is not yet known which protein properties are attributable to this 
effect, but binding events may occur from a low FNorm to a high FNorm or vice versa. In 
both instances KD estimation can be undertaken. 
The protocol was carried out as per manufacturer’s instructions and as described in [238] 
using a Monolith NT.115TM series MST machine (Nanotemper). 
One protein of interest was fluorescently-labelled, as per manufacturer’s instructions, using 
either amine reactive dye (NT-647 N-hydroxysuccinimide [NHS]) or cysteine reactive dye 
(NT-647 malaimide). The choice of dye can depend upon, for example, the participation of 
cysteines in structurally integral disulphide bonds or perhaps the lack of surface exposed 
lysines for amine-based labelling. Both methods are suitable for use and neither gives better 
or worse results, however, cysteine labelling can be better for estimating interaction sites due 
the amino acid specificity of labelling. Optimisation of an appropriate concentration of 
fluorescently-labelled protein (200-1500 fluorescence units) was carried out by adjusting the 
LED power and capillary coating (standard, hydrophobic, hydrophilic, or premium) before 
starting the experiment. The unlabelled ligand was two-fold serially diluted 16 times in MST 
running buffer (25 mM HEPES/NaOH, 150 mM NaCl, 0.05% Triton X-100, pH 7.5) before 
the addition of an optimised constant concentration of fluorescently-labelled protein, taking 
into account the resulting dilution effect of combining labelled and unlabelled proteins. Prior 
to every experiment a ‘cap scan’ was completed to measure the fluorescence of each sample 
and determine the exact position of each capillary. The resulting temperature jump and 
subsequent thermophoresis data were used to trace unlabelled ligand concentration against 
normalised fluorescence trace (FNorm). The dissociation constant (KD) can be estimated 
using the accompanying Nanotemper Analysis software. Figure 2.12 depicts how the machine 
works and a typical MST timetrace. 
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SDS-Denaturation (SD) test 
Occasionally, during the pre-experiment cap-scan, it was clear that the binding of the 
unlabelled ligand caused a concentration-dependent fluorescence change, either fluorescence 
quenching or enhancement. If this change resulted in a binding curve it was possible to use 
the raw fluorescence data to estimate the apparent KD. In these cases, an SDS-Denaturation 
(SD) test was completed to rule out fluorescence changes due to protein aggregation. Once the 
initial samples have been run and the cap-scan completed, the samples containing the three 
highest and three lowest concentrations of unlabelled ligand were centrifuged (10000 × g, 5 
min). The supernatant was collected and 10 μl was mixed 1:1 with 4% SDS and 40 mM DTT 
before boiling for 10 min. Samples were briefly centrifuged before analysing the fluorescence 
again by cap-scan. If the fluorescence across all six samples was now uniform, the initial 
change in fluorescence was due to a ligand binding event close to where the fluorophore was 
situated and the apparent KD could be calculated using the raw fluorescence values (see figure 
2.13). In these instances the y-axis will be labelled ‘fluorescence’ instead of the usual 
‘FNorm’ and the capillary scan of the SD-test will be shown in the corresponding raw data 
figure in the appendix. If the change in fluorescence was still evident, the fluorescently-
labelled protein may be aggregating. To solve this problem the samples were centrifuged 
again to remove large aggregates, the capillary coating changed, or 0.05% BSA or Tween 20 
was added.  
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Figure 2.12 Principles of Microscale Thermophoresis (MST) 
A. Adapted from [238]. An infrared (IR) laser (wavelength 1470 nm) is used to create a localised temperature 
gradient. The laser is coupled into the path of fluorescent excitation and emission using an IR dichroic mirror. 
Each capillary contains a fluorescently-labelled protein of constant concentration and a serially diluted 
unlabelled ligand. The thermophoretic movement of the fluorescently-labelled protein is measured. Interactions 
between proteins of interest lead to changes in solvation state, size and charge of the fluorescent protein which 
change its thermophoretic movement. B. A typical MST timetrace. The IR laser causes an initial temperature 
jump (T-Jump) before thermophoretic movement is observed away, or towards the site of excitation. Turning off 
of the IR laser leads to a rapid inverse temperature jump (Inv.T-jump) before the back diffusion of molecules. 
Serial dilution of an unlabelled ligand allows observation of concentration dependent changes on the 
thermophoretic movement of the fluorescently-labelled proteins. The accompanying software is used to estimate 
the dissociation constant of an interaction. 
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Figure 2.13 Ligand dependent fluorescence quenching/enhancement  
A. Example of a pre-experiment cap-scan showing ligand concentration-dependent fluorescence enhancement 
(cap 1 – cap 16 = High concentration – low concentration). B. Cap-scan of the three highest and lowest ligand 
concentration samples after performing an SDS-denaturation (SD) test. Fluorescence is the same for each sample 
indicating the fluorescence enhancement was due to a ligand binding event and an apparent KD can be calculated 
from the raw fluorescence data. 
 
2.5.1.8 In vivo co-immunoprecipitation assay 
Method is described in, and adapted from [205]. An o/n culture of E. coli BW25113 cells and 
an appropriate mutant strain was used to inoculate 150 ml of Lennox LB (Fisher Scientific) 
and was cultivated to an OD578 of 0.5-0.6 at 37°C before harvesting by centrifugation (4500 × 
g, 4°C, 25 min). Cells were resuspended in 6 ml of CL buffer 1 (50 mM NaH2PO4, 20% 
sucrose, pH 7.4). The amine reactive cross-linker, DTSSP (3,3'-dithiobis 
(sulfosuccinimidylpropionate) (ThermoFisher), was freshly dissolved (20 mg/ml in dH2O) 
and added to the isolated cell suspension and incubated at 4°C with agitation for 1 h. Cross-
linked cells were then harvested by centrifugation (4500 × g, 4°C, 25 min) and resuspended in 
6 ml CL buffer 2 (100 mM Tris/HCl, 10 mM MgCl2, 1 M NaCl, pH 7.5). DNase, PIC and 
PMSF were added prior to sonication at low levels before ultracentrifugation of the lysate 
(140000 × g, 4°C, 1 h). The membrane pellet was resuspended in 2.5 ml of CL buffer 3 (25 
mM Tris/HCl, 10 mM MgCl2, 1 M NaCl, 1% Triton X-100, 20% glycerol, pH 7.5) and the 
solubilised membrane extracted o/n with stirring at 4°C.  
1 2 3 14 15 16
High concentration Low concentration
A
B
Capillary
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Samples were ultracentrifuged (140000 × g, 4°C, 1 h) to remove debris, before removing 2 × 
1.2 ml of each supernatant to be subsequently diluted with 0.6 ml of CL buffer 4 (75 mM 
Tris/HCl, 10 mM MgCl2, 1 M, NaCl, pH 7.5). One sample was incubated with an optimised 
concentration of specific antibody with the other used as a negative control. Both samples 
were incubated at 4°C with agitation for 5 h. For the isolation of antibodies, and thus cross-
linked interaction partners, 100 µl of protein G-coupled agarose bead resin (Roche) were 
washed (2 × CL buffer 4, 2 × CL wash buffer [2:1 CL buffer 3 and CL buffer 4]) and added to 
each sample, and incubated o/n at 4°C with agitation.  
Samples were centrifuged and the supernatant retained before washing the beads 10 × 1 ml 
with CL wash buffer. After the final wash, beads were resuspended in 250 µl CL wash buffer 
and transferred to 2 ml spin dry columns and centrifuged to isolate the beads. These were then 
resuspended in 50 µl of fresh SDS-loading buffer and boiled to elute bound proteins, and 
reverse cross-linkage, and were collected by centrifugation (10000 × g, RT, 5 min). 
Supernatant and elution samples were resolved by SDS-PAGE and transferred to a 
nitrocellulose membrane by Western blotting to detect for specific interaction partners using 
purified antibodies (see section 2.2.2). The secondary antibody used here is Trueblot Anti-
Rabbit IgG-HRP specific for native antibodies. See table 2.3 for an example SDS-PAGE 
scheme for a typical in vivo co-immunoprecipitation experiment. 
 
WT strain Mutant strain 
Supernatant Elution Supernatant Elution 
IP C IP C IP C IP C 
 
Table 2.3 Example SDS-PAGE scheme for an in vivo co-immunoprecipitation experiment 
Supernatant samples after incubation with protein G-coupled agarose beads were compared to samples of 
washed and eluted beads. IP; immunoprecipitated. C; control (no-antibodies). 
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2.5.2 Activity assays 
2.5.2.1 Fluorescent-bocillin binding assay 
This assay utilises a fluorescent form of a β-lactam, bocillin (Molecular Probes, Inc., Eugene), 
which binds to the serine residue at the active site of PBPs for detection after resolving by 
SDS-PAGE. A typical sample consists of 10 μg/ml of purified PBP, 20 ng of FL-bocillin, in a 
final volume of 50 μl with 10 mM HEPES/NaOH, 10 mM MgCl2, pH 7.5. A negative control 
sample was pre-incubated for 10 min with 10 ng of penicillin G to block the active site of the 
PBP. Samples were incubated for 10 min at 37°C before all samples were boiled for 30 min 
with 30 μl of SDS-PAGE loading buffer and resolved by SDS-PAGE. Fluorescence was 
observed using a Typhoon Fluoroimager (Excitation laser; 488 nm, emission filter; 520 BP20, 
PMT voltage; 400-800). Figure 2.14 depicts PBP1A from E. coli as an example. 
 
Figure 2.14 Fluorescent-bocillin binding assay using PBP1A 
Fluorescent-bocillin binding assay to demonstrate the correct folding of the active site of PBP1A after 
purification. Coomassie-stained 12% SDS-PAGE gel (Left) and protein after visualising bocillin fluorescence 
using a Typhoon Fluoroimager (Excitation laser; 488 nm, emission filter; 520 BP20, PMT voltage; 400-800) 
(Right). Pre-incubation with penicillin G prevents the binding of bocillin to the protein as a negative control. 
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2.5.2.2 Muropeptide/sacculi-based endopeptidase activity assays 
Muropeptides of the appropriate strain were isolated by o/n cellosyl digestion of 100 µl of 
intact sacculi at 37°C with 10 µg of cellosyl and 20 mM NaPO4, pH 4.8, before boiling for 10 
min, centrifugation (10000 × g, 10 min, RT) and retention of the supernatant [21]. 
Alternatively, isolated high molecular weight sacculi, of the appropriate strain, obtained as 
described in section 2.7.1, were used. Hydrolases were incubated at optimised concentrations 
in 100 µl of EPase buffer (10 mM HEPES/NaOH, 10 mM MgCl2, 150 mM NaCl, and 0.05% 
Triton X-100, pH 7.5). To begin the reaction, 10 µl of isolated muropeptides/sacculi were 
added. Muropeptide-containing samples were incubated for 30 min-18 h at 37°C with shaking 
and those containing intact sacculi were incubated for 2-18 h. In some muropeptide-based 
assays, a 50 µl sample was taken at 5 min and the remaining sample left for a further 25 min. 
To stop the reaction, samples were boiled for 10 min prior to centrifugation (10000 × g, RT, 
10 min). In some cases 20 mM EDTA was required to fully abate the reaction. After stopping 
the reaction, samples incubated with intact sacculi were subjected to an o/n cellosyl digestion 
at 37°C with shaking in 10 µg of cellosyl and 20 mM NaPO4, pH 4.8, before boiling for 10 
min, centrifugation (10000 × g, 10 min, RT) and retention of the supernatant. The released 
muropeptide-containing supernatants were reduced and analysed by reversed-phase HPLC as 
described in section 2.5.2.5. EPase activity was expressed as the relative amounts of Tetra 
monomers and TetraTetra dimers. An example of EPase digestion chromatograms are shown 
in figure 2.15. The chemical structure of detected muropeptides can be found in figure 2.17. 
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Figure 2.15 Chromatograms of a sacculi-based endopeptidase activity assay 
Example of an intact WT sacculi (MC1061) EPase assay, incubated with and without EPase. The released 
muropeptides were reduced with sodium borohydride and separated by reversed-phase HPLC using an Agilent 
Technologies series 1200 HPLC system with a Prontosil 120-3-C18-AQ 3 μm (Bischoff) reversed-phase column 
and detected by UV. The chemical structure of detected muropeptides can be found in figure 2.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4
0
0
4
0
0
0 10 20 30 40 50 60 70
MC1061
No enzyme
MC1061
+ EPase
Tetra
Tetra
TetraTetra
TetraTetra
Retention time (min)
A
b
s
o
rb
a
n
c
e
 a
t 
2
0
5
 n
m
 (
m
A
U
)
  
77 
 
  
2.5.2.3 Spectrophotometric D-Alanine release assay 
This protocol is adapted from [118] and was carried out in collaboration with Dr. David 
Roper, Warwick University before optimisation at Newcastle University by Katharina Peters. 
The carboxypeptidase (CPase) activity of PG hydrolases results in the release of the terminal 
D-Ala residue from the pentapeptide stem of PG precursors. Using UDP-MurNAc 
pentapeptide as a substrate, and in this case PBP4, it was possible to spectrophotometrically 
measure the release of D-Ala. 
Each reaction sample consisted of 200 μl of CPase buffer (50 mM HEPES/NaOH, 10 mM 
MgCl2, pH 7.6), 3 units of D-amino acid oxidase (Sigma), 6 units of horseradish peroxidase 
(HRP) (Sigma), Amplex Red (Sigma), and an optimised concentration of protein.  
All constituents of the reaction were added and mixed directly in a quartz cuvette (Hellma, 10 
mM light path, 15 mM centre), before the addition, and brief mixing by pipette, of purified 
UDP-MurNAc pentapeptide (BACWAN, Warwick University) to begin the reaction. The 
released D-Ala residues from the CPase activity of PBP4 are oxidatively deaminated by the 
action of D-amino acid oxidase to produce pyruvate and hydrogen peroxide (H2O2). The 
released H2O2 is reduced to H2O by HRP using Amplex Red as an electron donor. Oxidised 
Amplex Red produces resorufin which has an intense pink colour and the production of which 
was measured spectrophotometrically using a Cary 100 Bio UV-visible spectrophotometer 
(wavelength 555 nM) (See figure 2.16 for a schematic of the reaction). The change in 
absorption over 10 min was measured and analysed using the complementing software.  
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Figure 2.16 Schematic diagram of the spectrophotometric carboxypeptidase activity assay 
The CPase activity of PBP4 cleaves the terminal D-Ala residue from UDP-MurNAc pentapeptide substrate, 
which is deaminated by D-amino acid oxidase. The released H2O2 is reduced by HRP using Amplex red as an 
electron donor. Oxidation of Amplex red generates the pink compound resorufin which can be measured at 555 
nM using a spectrophotometer. 
 
2.5.2.4 In vitro transpeptidase activity assay 
This protocol is adapted from [67]. Radioactively-labelled lipid II ([14C]-Dap) was dried in 
glass reaction tubes using a speed-vac (ScanVac) whilst preparing reaction solutions. 
Standard reactions consisted of 100 µl total volume containing 10 mM HEPES/NaOH, 10 
mM MgCl2, 150 mM NaCl, 0.025-0.1% Triton X-100 (NaCl and Triton concentrations are 
inclusive of that brought with the addition of proteins and resuspended [14C]-Dap Lipid II). 
For a single reaction, 15 µM [14C]-Dap Lipid II (resuspended in 5 µl of 0.2% Triton X-100) 
was added to the reaction solution for 1 h at 37°C. Samples were boiled for 10 min before the 
addition of cellosyl buffer (20 mM NaPO4, pH 4.8) and 10 µg of purified cellosyl and were 
incubated at 37°C for 90 min. Samples were again boiled for 15 min, centrifuged (14000 × g, 
RT, 10 min) and supernatants transferred to clean tubes with holes pierced in the lids for 
standard borohydride reduction for reversed-phase HPLC analysis (see section 2.5.2.5). Using 
the associated Laura software, muropeptides corresponding to monomeric and cross-linked 
muropeptides were integrated and TPase activity calculated as a percentage of muropeptides 
in cross-links.  
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2.5.2.5 HPLC analysis 
 
Reduction of released muropeptides  
Released muropeptide-containing supernatants, obtained as described in section 2.5.2.2 and 
section 2.5.2.4, were transferred to new tubes with holes pierced in the lids and were reduced 
using an equal volume of sodium borohydride buffer (boric acid adjusted to pH 9.0 with 
phosphoric acid) and a small spatula of solid sodium borohydride prior to centrifugation 
(3000 × g, RT, 30 min) as described in [21]. The pH of the samples was reduced to 4.5-5 
using 85% phosphoric acid and were analysed by reversed-phase HPLC (see below).  
 
Reversed-phase HPLC analysis of muropeptides 
Protocol is as described in [21]. HPLC analysis of reduced muropeptides (see above) was 
performed using an Agilent Technologies series 1200 HPLC system with a Prontosil 120-3-
C18-AQ 3 μm (Bischoff) reversed-phase column. A 180 min linear gradient of 100% solvent 
A (50 mM sodium phosphate, pH 4.31 + 0.0002% NaN3) to 100% solvent B (75 mM sodium 
phosphate, pH 4.95 + 15% methanol) was used to separate muropeptides at 55°C. Often a 
shorter run of 90 min was used. Unlabelled muropeptides were detected using a UV-detector 
at 205 nm, where [14C]-labelled muropeptides were detected with an online scintillation 
counter (LabLogic). Specific values (mAU or counts per min) of each muropeptide peak were 
recorded and analysed using the accompanying Laura software v4.1.7.70 (LabLogic Systems 
Ltd). The structures of detected muropeptides are depicted in figure 2.17. 
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Figure 2.17 Chemical structure of muropeptides detected by HPLC  
Chemical structure of muropeptides detected by HPLC analysis from in vitro TPase reactions and EPase 
reactions. 1; Penta phosphate, the unreacted substrate of a TPase reaction. 2; Tetra. 3; Penta. 4; TetraTetra. 5; 
TetraPenta. 6; TetraTetraTetra. 7; TetraTetraPenta. MurNAc(r); reduced N-acetylmuramic acid residue. P; 
Phosphate.   
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2.6 Cellular methods 
2.6.1 β-lactamase induction assay 
E. coli does not have an inducible operon for the production of the β-lactamase AmpC, 
therefore for the observation of AmpC induction in E. coli, this protocol requires that all 
strains carry the pJP1 plasmid harbouring the ampR/ampC operon from Enterobacter cloacae 
[224]. This plasmid carries a kanamycin resistant marker, therefore any prior kanamycin 
resistance cassette must be excised using the pCP20 plasmid (see section 2.1.5) before 
transformation of pJP1.  
 
Preparation of the induced and uninduced lysates 
Protocol is adapted from [224] and [239]. O/n cultures of appropriate strains were used to 
inoculate 20 ml of pre-warmed LB and cells were grown to an OD578 of 0.5-0.6. Two 
universal tubes containing 5 ml LB each, per strain, were pre-warmed to 37ºC. To one tube 2 
μg/ml imipenem (N-formimidoyl thienamycin) was added. A negative control was used in 
which no antibiotic was added. To each sample, 5 ml of exponentially growing cells was 
added for 30 min at 37°C, diluting the concentration of imipenem to 1 µg/ml. Samples were 
placed on ice for 5 mins before harvesting by centrifugation (4500 × g, 20 min, 4°C). Cell 
pellets were resuspended in 10 ml of 50 mM sodium phosphate buffer, pH 7.0 and centrifuged 
again. The pellets were resuspended in 1 ml of the same sodium phosphate buffer. To lyse 
cells, 50 µl of lysis buffer (400 mM Tris/HCl, 8 mM EDTA, 200 µg/ml lysozyme, pH 8.0) 
was added to 50 µl of resuspended cells. The remaining 950 µl of resuspended cells were 
frozen at -20°C. Lysis was induced by the addition of 100 µl of H2O and a 5 min incubation at 
RT. Cellular debris was removed by centrifugation (14000 × g, 15 min, RT) and the 
supernatant was collected and placed on ice. The protein concentration of the lysate was 
determined using a Pierce™ BCA Protein Assay Kit (Thermo Scientific) (See section 2.2.3). 
 
Measuring β-lactamase activity using Nitrocefin 
The chromogenic β-lactam nitrocefin was used to measure β-lactamase activity [240]. The 
hydrolysis of nitrocefin causes a colour change of yellow to pink which can be measured 
using a spectrophotometer. Each sample consisted of; 
- 50 μl sample lysate 
- 50 μl 1 mM nitrocefin 
- 900 μl 50 mM sodium phosphate buffer, pH 7.0 
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Sample lysate was added directly to a standard cuvette and the reaction was started at the last 
second with the addition of nitrocefin and sample buffer. Absorbance was read at 492 nm for 
10 min, with a reading taken every 30 s. The purified form of the β-lactamase Vim4 was used 
as a positive control at a concentration of 10 μM. The rate of nitrocefin hydrolysed per min 
per mg of protein was calculated and β-lactamase induction was expressed as the fold 
difference over the control, containing no imipenem. 
 
2.6.2 Antibody purification from immunised rabbit serum 
Antibodies were purified from isolated antisera from rabbits immunised with the specific 
antigen of interest (Eurogentec, Belgium) using affinity chromatography with immobilised 
purified antigen to purify the antibody. 
The coupling of antigen to CNBr-activated sepharose beads was carried out as described in 
section 2.5.1.3 with the purified protein of choice.  
The antigen-immobilised beads were washed with one column volume of elution buffer 1 
(100 mM glycine/HCl, 0.1% Triton X-100, pH 2) to avoid contamination by loosely-bound 
protein during the antibody elution step, followed by equilibration with 30 ml buffer 1 (10 
mM Tris/HCl, 10 mM MgCl2, 1 M NaCl,  0.1% Triton X-100, pH 7.2). Rabbit serum (10 ml) 
was diluted with 35 ml of diluent (10 mM Tris/HCl, 0.1% Triton X-100, pH 7.4) and 
centrifuged to remove unwanted debris (4500 × g, 4°C, 10 min). The supernatant was applied 
to the antigen-bound sepharose beads and incubated o/n at 4°C with gentle agitation. Beads 
were collected with a gravity column allowing the rest of the solution to flow through. The 
beads were washed with 20 ml of buffer 1 and 20 ml of buffer 2 (10 mM Tris/HCl, 10 mM 
MgCl2, 150 mM NaCl, 0.1% Triton X-100, pH 7.2). The antibodies were eluted using 10 × 1 
ml elution buffer 1 and collected in 2 ml reaction tubes containing 200 μl of elution buffer 2 
(2 M Tris/HCl, pH 8.0), to neutralise the pH, and 300 μl of 100% glycerol for storage at -
80°C. Samples were mixed by inversion and 20 μl of each was resolved by SDS-PAGE 
analysis. Coomassie-staining was carried out to observe heavy and light chains of the purified 
antibodies. Fractions possessing the highest concentrations of antibody were combined, 
aliquoted and stored at -80 °C.  
 
 
 
  
83 
 
  
Antibody test 
BW25113 WT cells, and a mutant strain lacking the specific antigen, were grown to an OD578 
of 0.5-0.6 at 37°C with shaking. A 1 ml sample of exponentially growing cells was harvested 
by centrifugation (4500 × g, RT, 10 min) and resuspended in 100 μl TBS and 100 μl of SDS-
loading buffer before boiling for 10 mins. Samples were analysed by SDS-PAGE and 
transferred to a nitrocellulose membrane by Western blotting, using the newly purified 
antibody for primary immunodetection (section 2.2.2). 
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2.7 Cell wall methods 
2.7.1 Isolation of peptidoglycan from E. coli 
This protocol was adapted from [21]. O/n cultures of the appropriate strain were used to 
inoculate 2 L of LB and cells were grown with orbital shaking at 37ºC until an OD578 of 0.5-
0.6 was reached. Cells were harvested by centrifugation (4500 × g, 4°C, 20 min) and 
resuspended in 25 ml of ice cold dH2O. The cell suspension was added drop-wise by Pasteur 
pipette to an equal volume of boiling 8% SDS solution and the sample was boiled for a 
further 30 min. The sample was left to cool to RT before collecting the sacculi by 
centrifugation (140000 × g, 1 h, RT). The pellet was resuspended in 25 ml of dH2O and 
centrifuged as before to remove the SDS. This takes 6-8 repetitions, testing for presence of 
SDS using the Hayashi test (section 2.7.2). After the successful removal of SDS, the sacculi 
pellet was resuspended in 2.2 ml of 10 mM Tris/HCl, 10 mM NaCl, pH 7.0, 250 μl of 3.2 M 
imidazole pH 7.0 and 37.5 μl of 10 mg/ml amylase (for the removal of any residual high 
molecular weight glycogen). After incubation for 2 hours at 37°C, 50 μl of 10 mg/ml Pronase 
E (pre-activated at 60°C for 2 h) was added to remove covently-bound lipoproteins and was 
incubated for 1 h at 60°C. The addition of 2.5 ml of 4% SDS solution and boiling for 15 min 
was used to stop the reaction. Samples were left to cool to RT and the SDS washing step, as 
described before, was repeated using a benchtop ultracentrifuge (OptimaTM TLX, Beckman 
Coulter) (420000 × g , RT, 60 min). Once free of SDS, the isolated sacculi were resuspended 
in 1.2 ml of dH2O containing 0.02% NaN3 and stored at 4°C. 
 
2.7.2 Hayashi Test for the detection of Sodium dodecyl sulphate 
The Hayashi test was performed to check for the absence of SDS during pellet washing steps 
and is as described in [241]. After centrifugation, 335 µl of the supernatant was added to 170 
μl of 0.7 M sodium phosphate, pH 7.2, 7 μl of 0.5% methylene blue and 1 ml of chloroform. 
After vigorous vortexing, two phases were observed. If SDS was present it formed a water-
insoluble blue complex in the lower phase. When the sample was free of SDS, the lower 
phase was clear/pink. 
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2.7.3 Peptidoglycan binding assay 
The protocol was modified from [206] and [31]. A 100 µl sample of ~1 mg/ml purified PG 
suspension was pelleted by centrifugation (10000 × g, 10 min, RT) and resuspended in 100 µl 
of PG binding buffer (10 mM Tris/Maleate, 10 mM MgCl2, 50 mM NaCl, pH 7.5). To the 
resuspended PG solution, 10 µg of the protein of interest was added and incubated on ice for 
30 min. A negative control was used in parallel containing no PG. Samples were centrifuged 
(10000 × g, 10 min, RT) and the supernatant collected (sample S). The pelleted material was 
washed with 200 µl of PG binding buffer, centrifuged and the supernatant collected as before 
(sample W). The pelleted PG was resuspended in 100 µl of 2% SDS solution and stirred for 1 
h. Samples were centrifuged again and the supernatant collected (sample P). Each sample (S, 
W and P) was analysed by SDS-PAGE in comparison to samples absent of PG. Protein 
retention in the P sample, in the presence of PG, is indicative of PG binding. See table 2.4 for 
an example SDS-PAGE scheme for a typical experiment. 
 
+ Peptidoglycan  No Peptidoglycan 
S W P M S W P 
 
Table 2.4 Example SDS-PAGE scheme for a typical peptidoglycan binding assay  
Example layout of samples from a PG binding assay. S; Supernatant. W; Wash. P; Pellet. Samples containing PG 
were directly compared to those absent of PG. M; Marker. 
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3 Results 
 
 
 
 
 
 
 
 
 
 
  
87 
 
  
3.1 Structural characterisation of LpoA and its interaction with PBP1A  
3.1.1 Introduction 
PBP1A is the major PG synthase during cell elongation and relies on an interaction with the 
OM-anchored lipoprotein LpoA for in vivo function [25,26]. Typas et al., (2010) used a 
proteomics-based search for novel PBP1A interaction partners, using immobilised PBP1A 
incubated with membrane/periplasmic fractions from E. coli, to identify LpoA. This was 
confirmed in vivo by co-immunoprecipitation and, independently, by Paradis-Bleau et al., 
(2010), who used a synthetic lethal screen to identify the same cognate relationship.  
In this section we develop on the in vitro characterisation of the interaction between PBP1A 
and LpoA to estimate a KD value and attempt to identify putative interaction sites. We also 
present here the structural model of LpoA using NMR spectroscopy of LpoAN in 
collaboration with the group of Jean-Pierre Simorre at the Institute de Biologie Structurale 
(IBS) Grenoble, France. Combined with other techniques, we published the structural model 
of full length LpoA in 2014 [95]. The structural model identified ‘wing’-like domains, not 
present in LpoA from H. influenzae, in which LpoA in essential [98]. We go on to directly 
compare and contrast E. coli LpoA/B and PBP1A/B with LpoA and PBP1A/B from H. 
influenzae. 
 
3.1.2 Characterisation of the interaction between LpoA and PBP1A 
3.1.2.1 LpoA interacts with PBP1A in vitro 
In order to further characterise the known interaction between LpoA and PBP1A, and to 
estimate the dissociation constant (KD), we employed two in vitro techniques not previously 
performed for this interaction, surface plasmon resonance (SPR) and microscale 
thermophoresis (MST).  
PBP1A (75 µg) was immobilised to an SPR sensorchip surface using immobilised ampicillin 
(section 2.5.1.6). LpoA was applied at various concentrations (0, 0.25, 0.5, 1, 2 and 4 µM) in 
standard running buffer (10 mM Tris/Maleate, 150 mM NaCl, 0.05% Triton X-100, pH 7.5) at 
75 µl/min for 4 min. A control surface was activated without immobilisation of PBP1A. The 
concentration-dependent increase in response units (RU) observed upon application of LpoA 
to the PBP1A-immobilised lane, in comparison to the control lane, was indicative of an 
interaction (figure 3.1A). Unfortunately, the curves generated were not applicable for KD 
value estimation as no equilibrium steady state was reached. We therefore applied MST. 
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PBP1A was fluorescently-labelled at amine residues and used at a concentration of 41.5 nM 
(section 2.5.1.7) (fluorescently-labelled proteins will be herein referred to with the prefix, FL, 
e.g. FL-PBP1A). Unlabelled LpoA was two-fold serially diluted from 30 µM to 0.916 nM and 
titrated with the constant concentration of FL-PBP1A. The MST binding curve is shown in 
figure 3.1B and generated an estimated KD of 852 ± 146 nM, using the accompanying 
Nanotemper MST software.  
 
 
Figure 3.1 LpoA and PBP1A interact directly in vitro 
A. SPR sensorgrams (response units against time) of LpoA injected at 75 μl/min for 4 min over a sensorchip 
surface containing PBP1A, immobilised by amine-coupled ampicillin, or an activated control lane containing no 
protein. B. MST of FL-PBP1A (at amine residues) titrated with unlabelled, serially diluted LpoA from a 
concentration of 30 µM – 0.916 nM. The estimated KD generated was 852 ± 146 nM. MST conditions were 80% 
LED power and 20% MST power. The values are the mean ± standard deviations of three independent 
experiments. The raw MST data are shown in figure 5.1.  
 
 
 
 
880
885
890
895
900
905
910
915
0.1 1 10 100 1000 10000 100000
200
400
B
890
90
910
F
N
o
rm
 [
1
/1
0
0
0
]
880
10-1 101 103 105
LpoA concentration (nM)
0
Time (min)
5 2015
R
e
s
p
o
n
s
e
 (
R
U
)
0
500
10 0
Time (min)
5 2015
4 μM
2 μM
1 μM
0.5 μM
0.25 μM
0 μM
10
A PBP1A surface Control surface
KD = 852  146 nM
300
100
  
89 
 
  
3.1.2.2 LpoA is elongated with a TPR-rich N-terminal domain 
We sought to determine the structure of LpoA in order to identify regions crucial for the 
interaction with PBP1A and use the optimised in vitro methods from 3.1.2.1 to further 
characterise the interaction between LpoA and PBP1A. Multiple attempts have been made to 
obtain the crystal structure of PBP1A, work which is currently ongoing, and, during the 
course of this project, we also attempted to determine the crystal structure of LpoA, but have 
been unsuccessful thus far. We therefore focussed efforts on structure determination by 
nuclear magnetic resonance (NMR) spectroscopy. Full length LpoA is too large for NMR 
analysis, therefore LpoAN (residues 28-256), was purified to homogeneity with [15N] and 
[13C] labelling as described in section 2.3.2. The double labelled protein was purified at 
Newcastle University and was sent for NMR spectroscopy by Nicholas Jean in the lab of 
Jean-Pierre Simorre, IBS, Grenoble who carried out the structural determination experiments 
presented in this section.   
To determine if the protein was suitable for structural determination at the conditions required 
for NMR spectroscopy, the double labelled LpoAN was subjected to 1H-15N heteronuclear 
single quantum coherence (1H-15N-HSQC) at a range of temperatures (5°C–50°C) and pH 
(4.5–7.5), to test if unfolding would occur. Structural determination by NMR spectroscopy 
was then carried out at 50°C and pH 4.5, and chemical shifts assigned to reveal the structure 
shown in figure 3.2A.  
LpoAN contains 12 α-helices forming a number of tetratrico-peptide repeat (TPR) motifs, 
organised individually into super-helical structures, as observed with canonical TPR-
containing proteins. These domains are commonly found in proteins with known interaction 
partners. The elongated spherical shape of LpoAN is ~30 Å in width and ~70 Å in length, with 
a number of highly conserved residues within the grooves formed between helices H7-H8 and 
H3 and H5 [95].  
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Figure 3.2 LpoAN consists of TPR-like motifs and full length LpoA has an elongated shape 
Figures adapted from [95]. A. Structural model of LpoAN based on the NMR spectra of [13C][15N]-LpoAN which 
consists of 12 α-helices adopting TPR-like folding. B. Structural model of full length LpoA, based on the NMR 
structure of LpoAN, the crystal structural model of LpoAC from H. influenzae [100], and AUC and SAXS of the 
full length E. coli protein. The radius of gyration (RG) measured by SAXS was 4.22 nm which best fitted an 
elongated shape.   
 
The large size of full length LpoA (~72 kDa) means it is not possible to carry out structure 
determination by NMR spectroscopy. However, 1H-15N band-selective excitation short-
transient transverse optimised spectroscopy (1H-15N-BEST-TROSY) NMR spectra of the full 
length protein was compared to that of LpoAN, in which none of the signals from the LpoAN 
spectra were found. As LpoAN was concluded to be well ordered, these data imply tumbling 
of the protein due to unstructured regions within LpoAC. As such, the detected 1H, 13C, and 
15N resonances from the full length double-labelled LpoA spectra were analysed by 
HNCACB and BEST-TROSY-(H)N(COCA)NH experiments. We identified two regions 
forming unstructured ‘wing’-like domains absent from the crystal structure of H. influenzae 
LpoAC [100]. These two regions corresponded to 30 assigned residues between N285 and 
P351 and 16 assigned residues between S493 and N531 (figure 3.3A) generated using 
IUPRED for the prediction of intrinsically unstructured proteins (figure 3.3B). Sequence 
alignment of LpoAC from E. coli and H. influenzae showed that these unstructured regions are 
only present in E. coli LpoA (figure 3.3C). 
RG = 3.55 nm RG = 4.39 nm RG = 3.02 nm  
Globular L-shape Extended
N
C
A
B
N-ter
C-ter
RG = 3.55 nm RG = 4.39 nm RG = 3.02 nm  
Globular L-shape Extended
N
C
Globular
R = 3.02 n
L-shape
R  3. 5 
Exte
= 4.3  
  
91 
 
  
 
Figure 3.3 E. coli LpoAC possesses unstructured regions not present in H. influenzae LpoAC 
Figure adapted from [95]. A. Crystal structure of H. influenzae LpoAC superimposed with unstructured regions 
(N285-P351 and S493-N531) from E. coli in blue. B. IUPRED analysis of LpoAC from E. coli predicts which 
residues comprise the two unstructured regions. C. Sequence alignment of H. influenzae and E. coli LpoA 
showing unstructured regions in LpoAC from E. coli are absent in H. influenzae. 
  
 
The structural model of full length E. coli LpoA was created using Phyre [242]. The crystal 
structure of H. influenzae LpoAC was used as a template, superimposed with the identified 
unstructured regions from E. coli LpoA NMR analysis. This was combined with analytical 
ultracentrifugation (AUC) and small angle X-ray scattering (SAXS) of full length E. coli 
LpoA. AUC of full length LpoA predicted an elongated monomer with low flexibility 
between the two domains [95]. SAXS was applied to generate the experimental radius of 
gyration (RG) of full length LpoA compared to three theoretical structural models; globular, 
L-shaped and extended (figure 3.2B). Experimental distance distribution function curves 
obtained from the SAXS data of the three models, and of the experimental run, were 
calculated. The experimental RG determined by SAXS was 4.33 nm, which best matched that 
of the extended model (figure 3.2B). 
 
Finally, using the calculated length of LpoA, and the estimated measurements of the bacterial 
cell envelope, we were able to model the structure of LpoA in the cell. We show an extended 
structure, long enough to reach through pores in the PG network to interact with the non-
catalytic ODD domain of PBP1A (figure 3.4). 
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Figure 3.4  Predicted mechanism of interaction of LpoA and PBP1A 
Based on the elongated structural model, we propose that LpoA, anchored to the OM via LpoAN, reaches 
through pores in the PG layer to interact with PBP1A via the non-catalytic ODD domain, to stimulate activity. 
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3.1.2.3 E. coli LpoAC possesses ‘wing’-like domains not required for interaction with 
PBP1A  
Two unstructured regions in LpoAC were identified which prevented structural determination 
of this domain, and which were not present in the H. influenzae equivalent. As LpoAC is 
responsible for the interaction with PBP1A and is sufficient to stimulate TPase activity in E. 
coli [70], it is possible that these unstructured regions are PBP1A interaction sites. Having 
identified the amino acids comprising these ‘wing’-like domains (wing 1; N285–P351 and 
wing 2; S493–N531) Andrew Gray from the group of Carol Gross at the University of 
California, San Francisco, constructed chromosomal mutations in these proteins. These strains 
only express LpoA lacking wing 1, wing 2, both wings, or lacking the C-terminal domain or 
the TPR domain, and for the WT protein. Purification plasmids for these proteins proved 
unsuccessful, which we hypothesise was due to increased instability upon overexpression.  
Using the chromosomal mutants we were able to carry out multiple in vivo co-
immunoprecipitation assays, in which 10 µl of anti-LpoA antibodies were used to 
immunoprecipitate DTSSP cross-linked membrane extracts from cells expressing the various 
truncated LpoA versions (section 2.5.1.8). Protein G-coupled agarose beads were used to 
obtain anti-LpoA antibodies and conjugated LpoA with any cross-linked interaction partners. 
After thorough washing of the beads, elution of bound proteins, and separation by 12% SDS-
PAGE, proteins were transferred to a nitrocellulose membrane by Western blot. 
Immunodetection with anti-PBP1A antibodies was used to test for interaction in the absence 
of these domains (table 5.1 for working dilutions of antibodies).   
The interaction between LpoA and PBP1A does not rely on the ‘wing’-like domains of LpoA, 
with single and double wing deletions still allowing for interaction (figure 3.5A). However, 
the fainter bands in the truncated LpoA strains in comparison to WT indicate a weaker 
interaction or reduced protein amounts. Western blot analysis revealed there was no change in 
the cellular amounts of LpoA versions in comparison to WT LpoA (Alex Egan, Vollmer 
group, unpublished). The deletion of both the C-terminal domain and TPR domain of LpoA 
prevents the interaction with PBP1A. If the wing-like domains of LpoA are not present to 
facilitate the interaction with PBP1A, we hypothesised that they could be responsible for 
preventing inappropriate interactions with other proteins, for example PBP1B. The 
experiment was repeated with the same immunoprecipitation with α-LpoA antibodies, but 
using anti-PBP1B antibodies for immunodetection. We observe no interaction upon single 
and double deletions of the ‘wing’ domains (figure 3.5B).  
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Figure 3.5 In vivo co-immunoprecipitation of LpoA variants with PBP1A and PBP1B 
A. WT cells, and cells expressing the truncated forms of LpoA, were cross-linked with DTSSP and the 
membrane fraction immunoprecipitated with anti-LpoA antibodies. After incubation with protein G-coupled 
agarose beads and centrifugation, the supernatant was collected. The beads were washed and bound proteins 
eluted. The cross-linkage was reversed prior to SDS-PAGE, Western blotting and immunodetection with anti-
PBP1A antibodies. B. Same as above but immunodetection was carried out using anti-PBP1B antibodies. +, with 
antibody; - without antibody. 
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3.1.3 Comparison of E. coli and H. influenzae LpoA 
In an attempt to characterise these unstructured domains, which are not present in LpoA from 
H. influenzae, we directly compared the PBPs and Lpos from H. influenzae and E. coli. 
Intriguingly, H. influenzae possesses both PBP1A and PBP1B, but does not express LpoB, 
and LpoA is essential. PBP1A, PBP1B, and LpoA from both organisms and LpoB from E. 
coli were purified to homogeneity (sections 2.4.1 and 2.4.2) and compared using the 
established in vitro PBP activity assays.   
Both purified PBP1A versions were analysed by 12% SDS-PAGE analysis after undergoing 
identical purification protocols (figure 2.3A/B). In the interest of keeping the proteins as 
similar as possible, the proteins were purified simultaneously and were not incubated with 
thrombin to remove the His-tag.  
Figure 3.6 shows the complementing FL-bocillin binding assay gel visualised using a 
Typhoon Fluoroimager (section 2.5.2.1). In each case, 10 µg of protein was either directly 
subjected to FL-bocillin or after pre-incubation with penicillin G, to block the active site. We 
show that both versions of PBP1A were purified successfully and have folded active sites. H. 
influenzae LpoA was purified in tandem with that of E. coli LpoA, as show in figure 2.2. 
PBP1B from both organisms, and LpoB from E. coli, were purified to homogeneity by Alex 
Egan from the Vollmer group (not shown). Both PBP1B versions were similarly successful 
upon examination by FL-bocillin binding assay.  
 
 
Figure 3.6 Purified PBP1A from E. coli and H. influenzae have correctly folded active sites 
PBP1A from E. coli and H. influenzae were purified to homogeneity and subjected to a FL-bocillin binding 
assay in which 10 µg of each protein were incubated either directly with 20 ng of FL-bocillin (-), or after pre-
incubation with 10 ng of penicillin G (+). Fluorescence was observed using a Typhoon Fluoroimager (Excitation 
laser; 488 nm, emission filter; 520 BP20, PMT voltage; 400-800). 
E. coli H. influenzae
+ -
E. coli H. influenzae
Penicillin G + - + - + -
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In vitro TPase activity assays were performed to test the effect of the three Lpo proteins on 
PBP activity (section 2.5.2.4). Each PBP was incubated with 15 µM [14C]-Dap Lipid II at a 
concentration of 0.4 mg/ml in the presence or absence of each Lpo, cognate or otherwise, at a 
concentration of 1.2 mg/ml. After a 1 h incubation at 37°C, samples were subjected to cellosyl 
digestion, reduction with sodium borohydride and analysis by reversed-phase HPLC using the 
associating Scintillation counter (section 2.5.2.5). Integration of peaks corresponding to 
monomeric peptides and those in cross-links was completed and plotted, and is shown in 
figure 3.7. 
E. coli PBP1A and PBP1B alone produced PG with ~30% and ~50% of peptides in cross-
links, respectively, as published [31]. Similarly, the stimulation of cross-linking in the 
presence of their cognate Lpo was also as published; in the presence of LpoA, the percentage 
of peptides in cross-links produced by PBP1A was stimulated by 15.9% and PBP1B in the 
presence of LpoB was stimulated by 13.1% [31]. We also confirmed that there was no effect 
on activity of non-cognate E. coli Lpo proteins on E. coli PBPs. Likewise, there was no effect 
of H. influenzae LpoA on PBP1A or PBP1B activity from E. coli.  
The in vitro PG-synthesising activity of H. influenzae PBP1A has been shown previously 
[243]. However, it has not been quantified to the same degree or by the same method 
described in this work. Here we showed that the degree of cross-linkage of PBP1A alone was 
already as high as that of E. coli PBP1A in the presence of its cognate Lpo. The presence of 
either LpoA version had no effect on the amount of peptides in cross-links produced by H. 
influenzae PBP1A, nor did LpoB, with the percentage of peptides in cross-links remaining 
around 50%. 
Despite confirmation of a correctly folded active site using a FL-bocillin binding assay, 
PBP1B from H. influenzae was extremely poor at forming cross-links, either alone or in the 
presence of any Lpo protein.   
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Figure 3.7 In vitro transpeptidase assay comparing Class A PBPs from E. coli and H. influenzae 
PBP1A and PBP1B from E. coli and H. influenzae were incubated with radioactively-labelled lipid II at 0.4 
mg/ml with 1.2 mg/ml of LpoA from E. coli and H. influenzae and LpoB from E. coli for 1 h before boiling and 
cellosyl digestion. Samples were reduced with sodium borohydride and analysed by reversed-phase HPLC. After 
integration, the percentage of muropeptides in cross-links was calculated and plotted. The values are the mean ± 
standard deviations of three independent experiments. See figure 5.2 for the corresponding HPLC 
chromatograms.      
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3.1.4 Conclusions and discussion 
 
Interaction between LpoA and PBP1A 
In this section we have further characterised LpoA and PBP1A by confirming the interaction 
identified by [31] and [32] using alternative in vitro methods. Using SPR we showed the 
interaction between immobilised PBP1A and LpoA applied as an analyte. KD determination 
was not possible from the curves generated by SPR, we therefore performed MST. PBP1A 
was fluorescently-labelled at amine residues and used at a constant concentration of 41.5 nM. 
Two-fold serially diluted unlabelled LpoA was titrated from a concentration of 30 µM to 
0.916 nM. MST measurements were taken and a KD of 842 ± 146 nM was estimated using the 
accompanying software. This KD closely correlates with that of PBP1B and LpoB which has a 
KD of 810 ± 80 nM [75]. It is likely that within the cell the affinity for this interaction may 
change with the environmental conditions and with phases of bacterial growth. Changes in the 
PG layer during growth may allow LpoA to interact with different affinity, or perhaps more 
frequency, and exert different stimulation to coordinate the growth of the PG layer with that 
of the rest of the cell. 
 
Structural model of LpoA 
NMR spectroscopy of LpoAN determined a monomeric domain of ~30 Å in width and ~70 Å 
in length consisting of TPR-like motifs, formed by 12 α-helices. Between helices H7 and H8 
and H3 and H5 are conserved amino acid residues. The presence of TPR-like motifs and 
conserved residues within LpoAN suggest as-of-yet unidentified LpoA interaction partners, 
the search for which will be presented in the next section.   
NMR spectra of the full length version showed unstructured regions not present in that of 
LpoAN. Using IUPRED we identified these unstructured regions within LpoAC and, using 
sequence alignment, found that these unstructured regions were not present in H. influenzae 
LpoA. To obtain a model of E. coli LpoAC the amino acids corresponding to these 
unstructured regions were superimposed onto the published crystal structure of LpoAC from 
H. influenzae. This was combined with SAXS and AUC data for the full length E. coli protein 
and the NMR structure of LpoAN. In doing so we present a structural model for full length E. 
coli LpoA which was published in 2014 [95]. The model predicts an elongated, bimodular, 
monomeric protein, anchored to the OM via LpoAN, long enough to presumably reach 
through pores in the PG layer to interact with the ODD of PBP1A, via LpoAC.  
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Identification of ‘wing’-like domains in LpoAC 
We initially hypothesised that the ‘wing’-like domains identified within LpoAC were putative 
PBP1A interaction sites. However, using in vivo co-immunoprecipitation assays, we show 
that this is not the case, nor are they present to prevent the interaction between LpoA and 
PBP1B. Due to the inability to purify the truncated versions of LpoA, lacking each wing 
individually or both, we cannot exclude the possibility that these domains have a role in 
modulating the interaction with PBP1A, for example the strengthening of interaction. It is 
also possible that these domains are crucial for interactions with novel LpoA binding partners. 
In future, we plan to continue the optimisation of purification of these truncated versions, and 
will further investigate this interaction using the in vitro methods described here. 
Deletion of the C-terminal region of LpoA prevents the interaction with PBP1A, consistent 
with work from our lab showing that LpoAC is the domain required for interaction and 
stimulation of PBP1A activity [70]. The deletion of the TPR domain (LpoAN) also prevents 
an interaction and we hypothesise that without this region the protein may be too short to 
reach through the PG layer to interact with the ODD of PBP1A.  
We have yet to show the direct interaction of the ODD domain and LpoA. However, a recent 
paper showed, by NMR spectroscopy, the interaction between LpoB and the UB2H domain of 
PBP1B [75]. Unfortunately, due to the size of LpoA it would not be possible to use full length 
LpoA to show this interaction by NMR spectroscopy. Instead, we plan to use LpoAC to show 
the direct interaction with the ODD domain. We hypothesise that upon binding of LpoAC with 
the ODD domain, the unstructured ‘wing’-like regions may become rigid to facilitate 
interaction. If this were true we would be able to analyse this interaction by NMR 
spectroscopy. This could identify the amino acids responsible for the interaction, which we 
would subsequently mutate and analyse the effects in vitro and in vivo. 
 
Comparison of E. coli and H. influenzae PBPs and Lpos  
LpoAC from H. influenzae does not possess the ‘wing’-like domains observed in the E. coli 
protein [95]. We therefore sought to compare the interactions and activities of both sets of 
PBPs and Lpos to elucidate the function of the ‘wing’-like domains of E. coli LpoA, and 
investigate why LpoA is essential in H. influenzae. All four PBPs were purified in parallel for 
a direct comparison, as were the two LpoA versions and LpoB from E. coli.  
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We showed that both PBP1A versions have correctly folded active sites, using an FL-bocillin 
binding assay. The same was performed for the PBP1B versions by Alex Egan from the 
Vollmer group (not shown).  
We showed that H. influenzae LpoA does not stimulate its cognate PBP1A and that there is 
no effect of activity of either LpoA on non-cognate PBP1A proteins. PBP1A from H. 
influenzae synthesises PG with the same percentage of muropeptides in cross-links as E. coli 
PBP1A in the presence of its cognate LpoA. It is therefore probable that PBP1A from H. 
influenzae does not require stimulation by LpoA. 
H. influenzae, in comparison to E. coli, is small and slow growing with an average cell length 
of 0.3 µm compared to 2 µm for E. coli. It is therefore possible that the stimulation observed 
in E. coli by LpoA is not required in H. influenzae and cells exist with basal levels of PBP 
activity. This may also explain the lack of activity observed for PBP1B from H. influenzae 
which had almost no TPase activity. The unstimulated activity of one PBP may be all that is 
required for successful growth. 
Why then is LpoA essential in H. influenzae? It is possible, that although there is no effect on 
PBP activity, LpoA is still able to interact with PBP1A, or with PBP1B, and exert an effect 
different to that of E. coli LpoA. In H. influenzae, rather than regulating PBP activity, which 
might not be required due the small size and growth rate of the organism, the primary role 
may be to coordinate membrane growth during proliferation. Without LpoA, and with no 
LpoB to compensate, growth may be uncoordinated leading to cell death. In E. coli, a 
secondary CpoB-related function of LpoA has been identified for the coupling of the Tol-Pal 
system to PG synthesis for the coordination of OM growth [91]. We speculate that this 
secondary function of E. coli LpoA may be the primary function of H. influenzae LpoA, 
however, more work is required to test these hypotheses. 
 
Final word 
The data in this section characterised the interaction between LpoA and PBP1A in vitro and in 
vivo. The structural model of full length LpoA was presented which we used to identify 
unstructured regions in LpoAC that are not interaction sites for PBP1A, and are not present in 
the equivalent from H. influenzae, which we use as a direct comparison of Lpo and PBP 
activities from different organisms, and hypothesise different primary functions for LpoA in 
each. We also identified TPR-like domains and conserved residues within LpoAN which we 
hypothesise may facilitate novel interactions, the search for which is described in section 3.2.  
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3.2 Coordination of peptidoglycan synthases and hydrolases in cell elongation 
3.2.1 Introduction 
The structural model of LpoAN showed a number of TPR-like motifs, between the helices of 
which are a number of conserved amino acids (figure 3.2A) [95]. As LpoAC is sufficient for 
the interaction and the stimulation of PBP1A [70], we hypothesised that the TPR motifs and 
conserved residues of LpoAN could facilitate novel LpoA interactions (figure 3.8). 
This section describes the search for these putative interactions and the identification of the 
PG hydrolase PBP4 as an interaction partner of LpoA. We showed that LpoA interacts with a 
PG synthase and a PG hydrolase and continued by identifying and characterising interactions 
between proteins involved in PG synthesis and hydrolysis, providing significant evidence to 
the hypothesised multi-enzyme complexes for PG growth.  
 
Figure 3.8 The TPR motifs of LpoAN may facilitate novel interactions 
The C-terminal domain of LpoA interacts with PBP1A, yet the NMR structure of the N-terminal domain shows a 
number of TPR motifs which could facilitate interactions with unknown partners.  
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3.2.2 Identification of PBP4 as an interaction partner of LpoA 
3.2.2.1 Proteomics-based search for novel LpoAN interactions partners  
Purified LpoAN (10 mg) was immobilised to sepharose beads with a sample taken before and 
after bead incubation to ensure the successful coupling of an appropriate quantity of protein 
(figure 3.9A) (section 2.5.1.4). After washing and equilibration, the protein-loaded column 
was incubated with a combined membrane and periplasmic fraction from a ΔlpoA E. coli 
strain (obtained as described in sections 2.5.1.1 and 2.5.1.2). After incubation and thorough 
washing, bound proteins were eluted and samples were air-dried before analysis by mass 
spectrometry (MS) performed by Joe Gray at the Pinnacle Institute, Newcastle University. A 
control column was used in which no protein coupling took place. The resulting liquid 
chromatography-mass spectrometry (LC/MS) data yielded a large number of peptide 
fragments that were not present in the control MS report (table 3.1). After analysis using the 
online pBLAST software (National Centre for Biotechnology Information), one 27 amino 
acid peptide fragment was found to match the PG hydrolase PBP4, more specifically, an 
amino acid sequence found within the active site-containing domain 1 (figure 3.9B).  
 
Figure 3.9 Proteomics-based search for LpoAN binding partners finds PBP4 
A. Before and after samples of coupling LpoAN (10 mg) to sepharose beads. Proteins were separated by 12% 
SDS-PAGE and visualised by Coomassie staining. After incubation with a combined E. coli 
membrane/periplasmic fraction, any bound proteins were eluted, dried and sent for MS analysis. B. Section of 
resulting MS report showing a large number of peptide fragments. A 27 amino acid fragment is highlighted 
which, after analysis using the online pBLAST software, corresponded to the PG hydrolase PBP4, and was not 
present in the control column report.  
kDa
26
34
43
55
72
95
130
170
M Before After
A
B
  
103 
 
  
Table 3.1 List of proteins retained by LpoAN  
 
1Proteins corresponding to peptide fragments retained by LpoAN not present in the control in no particular order. 
PBP4 DD-Epase/DD-CPase
FtsK Cell division protein
YdeV Sugar Kinase
PheS Phenylalanine tRNA synthase
YhfA GTP-binding protein
MglB Methyl-Galactose substrate binding protein
YbjY Macrolide transporter subunit
SapB Peptide transport permease
IntZ Prophage integrase
AppA Periplasmic phosphatase
RpoB RNA polymerase B subunit
HrpA RNA helicase
YfhC Deaminase
PldB Lysophospholipase
YaeS Undecaprenol pyrophosphatase synthase
AdhE Alcohol dehydrogenase
YgiM Predicted signal transduction protein
YebS Inner membrane protein
DsdX D-serine transport
NfrB ATP-binding inner membrane transport protein
YegH Inner membrane protein
YgeK DNA-binding transcriptional regulator
YheS ABC transporter ATP-binding protein
YhjG Predicted outer membrane biogenesis
AcpD NAD-azoreductase
GyrB DNA gyrase subunit B
WcaJ UDP-glucose lipid carrier transferase
FabF 3-oxoacyl-ACP synthase
UraA Uracil permease
Ssb ss-DNA binding protein
RluA rRNA/tRNA pseudouridine synthase
YhaK Pirin-related protein
MenF Isochorismate synthase 
YebS Inner membrane protein
FadH 2,4-dienoyl CoA reductase
PhnN Carbon-phosphorous lyase complex
YlcF Prophage tail fiber assemly
YciW Oxidoreductase
EvgS Sensor kinase
YcdU Predicted inner membrane protein
YcgF FAD-binding phosphodiesterase
YhfT Predicted inner membrane protein
YfbQ Aminotransferase
YjiR DNA-binding transcriptional regulator
Protein corresponding to 
peptide fragment
1 Function/Predicted function
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3.2.2.2 LpoA interacts directly with PBP4 in vivo and in vitro 
The MS report contained a large list of peptide fragments, mostly from ubiquitous proteins 
unrelated to PG. We therefore sought to test for a specific interaction between LpoA and 
PBP4 in vitro and in vivo. Native PBP4 was purified to homogeneity (section 2.4.5) and SPR 
was carried out in which full length LpoA (4 µg/ml) was immobilised to the SPR sensorchip 
surface by general amine coupling (section 2.5.1.6). PBP4 was injected at varying 
concentrations (0, 0.25, 0.5, 1, 2 and 4 µM) at 75 μl/min over the LpoA surface and a control 
surface to which no LpoA had been immobilised. The concentration-dependent increase in 
response units (RU) against time over the LpoA surface was indicative of an interaction in 
comparison to the control surface (figure 3.10A). Unfortunately, the SPR binding curves did 
not yield an equilibrium binding phase suitable for accurate KD determination. Instead, a 
‘biphasic’ interaction was observed (see discussion for more details). We therefore applied 
MST to confirm the interaction by a second in vitro method and estimate the dissociation 
constant. 
LpoA was fluorescently-labelled at cysteine residues as per manufacturer’s instructions 
(section 2.5.1.7). A concentration of 166 nM was optimised and unlabelled PBP4 was two-
fold serially diluted from a concentration of 30 μM to 0.916 nM and titrated with the constant 
concentration of FL-LpoA. During the pre-experiment capillary scan, there was a clear 
concentration-dependent fluorescence enhancement (figure 3.10B). An SDS-denaturation 
(SD) test was performed as described in section 2.5.1.7 (figure 5.3). Samples were re-
analysed and all samples contained a uniform fluorescence value, indicating that the 
fluorescence change observed was induced by the binding of unlabelled protein. The raw 
fluorescence data were plotted against PBP4 concentration and an apparent KD of 315 ± 37.7 
nM was estimated using the accompanying software.  
We sought to test the interaction in vivo using co-immunoprecipitation (section 2.5.1.8). WT 
cells (BW25113) and cells lacking PBP4 (BW25113ΔdacB) were cross-linked with DTSSP 
and their membrane fractions obtained as described in 2.5.1.8. The cross-linked membrane 
fractions were immunoprecipitated with 15 µl of anti-PBP4 antibodies, with subsequent 
immunodetection using anti-LpoA antibodies (table 5.1 for working dilutions of antibodies). 
The visualised nitrocellulose membranes are shown in figure 3.10C. LpoA can be observed in 
anti-PBP4 immunoprecipitated samples, indicative of an interaction. The interaction was not 
observed in samples with no immunoprecipitation, or in cells lacking PBP4.  
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Figure 3.10 LpoA interacts directly with PBP4 in vitro and in vivo 
A. SPR sensorgrams (response units against time) of PBP4 injected (5 min, 75 μl/min) over a sensorchip surface 
containing LpoA (4 µg/ml) immobilised by general amine coupling, or an activated control surface containing no 
protein. Contrary to manufacturer’s instructions, the pH for the immobilisation of LpoA was not altered and kept 
at pH 7.5. B. MST of FL-LpoA (at cysteine residues) at a concentration of 166 nM and serially diluted PBP4 
from 30 μM to 0.916 nM (20% MST power, 100% LED power). An apparent KD of 315 ± 37.7 nM was 
estimated using the raw fluorescence values. The values are the mean ± standard deviations of three independent 
experiments. Raw MST data and SD test are shown in figure 5.3. C. In vivo co-immunoprecipitation of PBP4 
and LpoA. Anti-PBP4 antibodies were used to immunoprecipitate DTSSP-cross-linked membrane fractions from 
WT and ΔdacB cells. Samples were incubated with protein G-coupled beads to obtain PBP4 antibodies and any 
cross-linked interaction partners. Detection with anti-LpoA antibodies shows the presence of LpoA after elution 
from protein G-coupled beads in WT immunoprecipitated samples. 
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3.2.2.3 Dissecting the LpoA-PBP4 interaction 
The crystal structure of PBP4 (figure 1.4) shows a structure with three domains [115]. The 
active site-containing domain 1 has domain 2 inserted into it, and domain 2 itself has domain 
3 inserted. It is suggested, that due to the globular nature and hydrophobic core of domain 3, 
that it may be removed without losing structural integrity to the rest of the protein. With this 
in mind, our collaborators at EMBL, Heidelberg constructed a purification plasmid for PBP4 
lacking domain 3, herein referred to as PBP4ΔD3. PBP4ΔD3 was used here to dissect the 
interaction with LpoA in order to infer interaction sites. PBP4ΔD3 was purified to 
homogeneity (section 2.4.4), and used in MST (section 2.5.1.7). 
PBP4ΔD3 was two-fold serially diluted from 10 µM to 0.31 nM and titrated with 166 nM of 
the same FL-LpoA as full length PBP4. The interaction observed did not cause a 
concentration-dependent fluorescence change and yielded an equilibrium MST binding curve 
(figure 3.11B). Using the accompanying software, a KD of 153 ± 31 nM was estimated, an 
affinity within the same range as the interaction with full length PBP4 (shown again in figure 
3.11A). 
We sought to dissect this interaction further by purifying LpoAN and LpoAC (section 2.4.1) 
and testing for interaction with full length PBP4 and PBP4ΔD3 by MST.  
Purified LpoAC was fluorescently-labelled at cysteine residues and used at a concentration of 
125 nM. MST was performed with two-fold serially diluted unlabelled PBP4 from 30 µM to 
0.916 nM. The resulting MST binding curve is shown in figure 3.11C. The apparent KD was 
estimated to be 226 ± 15 nM. Purified PBP4ΔD3 was serially diluted from 10 µM to 0.31 nM 
and used to observe the interaction with FL-LpoAC. The interaction between these truncated 
versions occurred with an estimated KD of 315 ± 21 nM (figure 3.11D).  
LpoAN was fluorescently-labelled at amine residues, used at a standard concentration of 62.5 
nM, and was tested for interaction with full length unlabelled PBP4. The resulting binding 
curve generated an apparent KD of 954 ± 52 nM, significantly weaker than observed for the 
other LpoA versions (figure 3.11E). Interestingly, when testing the interaction between LpoA-
N and PBP4ΔD3 the apparent KD generated was 17 ± 4 nM, one the strongest interactions 
observed by MST in this work (figure 3.11F).  
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Figure 3.11 Microscale thermophoresis of LpoA and PBP4 versions 
MST was carried out using serially diluted PBP4 from a concentration of 30 µM – 0.916 nM or PBP4ΔD3 from 
10 µM – 0.31 nM with cysteine-labelled full length LpoA at 166 nM (A and B) (40% MST power, 100% LED 
power), cysteine-labelled LpoAC at 125 nM (C and D) (20% MST power, 80% LED power) and amine-labelled 
LpoAN at 62.5 nM (E and F) (40% MST power, 20% LED power). The annotated KD of each interaction was 
estimated using the accompanying software. The values are the mean ± standard deviations of at least two 
independent experiments. Raw MST data are shown in figures 5.3-5.8.  
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3.2.2.4 LpoA moderately inhibits PBP4 activity 
LpoA is a regulator of PG synthesis during cell elongation [25,26]. We hypothesised that 
LpoA may also regulate PG hydrolysis, thus providing a direct link between the two 
processes. 
PBP4 possesses both DD-endopeptidase (DD-EPase) and DD-carboxypeptidase (DD-CPase) 
activity. We therefore performed assays to measure both activities of PBP4, alone and in the 
presence of LpoA, to investigate any potential regulatory function of the interaction. 
To investigate the CPase activity of PBP4, I visited the laboratory of Dr. David Roper at the 
University of Warwick who developed a spectrophotometric D-alanine (D-Ala) release assay 
for measuring DD-CPase activity [118]. The assay measures the release of the terminal D-Ala 
residue from the PG precursor UDP-MurNAc-pentapeptide using a coupled enzymatic 
reaction (section 2.5.2.3).  
The concentration of PBP4 was optimised to 17.3 nM in CPase assay buffer (50 mM 
HEPES/NaOH, 10 mM MgCl2, pH 7.6) where it would be possible to observe any stimulation 
or inhibition of activity. Figure 3.12A shows absorbance over time of PBP4 alone (light grey) 
and in the presence of 5 µM LpoA (dark grey). LpoA moderately inhibited the CPase activity 
of PBP4. 
A HPLC-based muropeptide digestion assay was performed to measure PBP4 EPase activity 
in the presence of LpoA (section 2.5.2.2). Isolated muropeptides from WT (MC1061) sacculi 
were incubated with PBP4 (1 μM) in the presence or absence of LpoA (2 μM). After a 30 min 
incubation at 37°C with shaking, the samples were boiled, centrifuged and the digested 
muropeptides reduced for analysis by reversed-phase HPLC (section 2.5.2.5). The 
chromatograms were integrated and the percentage of TetraTetra-containing muropeptides 
consumed was calculated (structure of muropeptides found in figure 2.17). Figure 3.12B 
shows that LpoA moderately inhibited the EPase activity of PBP4 after a 30 min incubation.  
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Figure 3.12 LpoA moderately inhibits the activity of PBP4 
A. Spectrophotometric-based D-alanine release assay showing PBP4 with and without LpoA. The release of the 
terminal D-Ala residue from UDP-MurNAc-pentapeptide by the action of PBP4, and subsequent deamination of 
the residue by D-amino acid oxidase, results in the formation of H2O2. H2O2 is reduced to H2O by HRP using 
Amplex Red (Molecular Probes) as an electron donor. Oxidised Amplex Red produces an intense pink colour 
which is measured using a spectrophotometer (555 nm). The values are the mean ± SD of three independent 
experiments. B. HPLC-based muropeptide digestion assay. PBP4 was incubated with isolated MC1061 
muropeptides at a concentration of 1 μM for 30 min at 37°C with shaking, alone or in the presence of 2 μM 
LpoA. The reaction was stopped with boiling and, after centrifugation to remove any debris, the samples were 
reduced with sodium borohydride for HPLC analysis. The percentage of TetraTetra dimer-containing 
muropeptides digested was calculated. The values are the mean ± standard deviations of three independent 
experiments. A p value of 0.05 for the 30 min samples was calculated using Microsoft Excel showing this data to 
be statistically significant. 
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3.2.3 PBP1A interacts with PBP4  
3.2.3.1 PBP1A interacts directly with PBP4 in vitro and in vivo 
Having shown that LpoA interacts with PBP4 and PBP1A, we hypothesised that there may 
also be a direct interaction between the two PBPs. Using SPR, 75 µg of PBP1A was 
immobilised via amine-coupled ampicillin, and PBP4 was applied at varying concentrations 
(0, 0.25, 0.5, 1, 2 and 4 µM) (section 2.5.1.6). A control lane containing no immobilised 
protein was used in parallel. The positive binding curve generated is shown in figure 3.13A, 
which showed no dissociation phase, preventing the estimation of a KD value. As there is no 
binding event observed for the control lane, we hypothesise that the unusual binding curve is 
due to a strong interaction which prevented dissociation of the analyte after washing.  
To estimate a KD, MST was performed using FL-PBP1A (at amine residues) at a constant 
concentration of 41.5 nM (section 2.5.1.7). FL-PBP1A was mixed with two-fold serially 
diluted unlabelled PBP4 from 30 μM to 0.916 nM. MST measurements yielded a binding 
curve suitable for the estimation of an apparent KD of 66.8 ± 9.1 nM (figure 3.13B).  
A co-immunoprecipitation assay was performed to test for an in vivo interaction (section 
2.5.1.8). Anti-PBP4 antibodies (15 µl) were used to immunoprecipitate DTSSP-cross-linked 
membrane fractions from WT (BW25113) cells and cells lacking PBP4 (BW25113ΔdacB). 
Anti-PBP1A antibodies were used for immunodetection after extraction of PBP4 and any 
cross-linked interaction partners using protein G-coupled beads. Figure 3.13C shows that in 
the presence of anti-PBP4 antibody, and only in WT, PBP1A interacts with PBP4 in vivo. 
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Figure 3.13 PBP1A interacts with PBP4 in vitro and in vivo 
A. SPR sensorgrams (response units against time) of PBP4 injected (5 min, 75 μl/min) over a sensorchip surface 
containing PBP1A immobilised by ampicillin coupling, or an activated control surface containing no protein. B. 
MST of FL-PBP1A (at amine residues) at a concentration of 41.5 nM and serially diluted PBP4 from 30 μM to 
0.916 nM (20% MST power, 80% LED power). An apparent KD of 66.8 ± 9.1 nM was estimated using 
accompanying software. The values are the mean ± standard deviations of three independent experiments. Raw 
MST data are shown in figure 5.9. C. In vivo co-immunoprecipitation of PBP4 and PBP1A. Anti-PBP4 
antibodies were used to immunoprecipitate DTSSP-cross-linked membrane fractions from WT and ΔdacB cells 
prior to incubation with protein G-coupled beads to obtain PBP4 antibodies and any cross-linked interaction 
partners. Detection with anti-PBP1A antibodies shows the presence of PBP1A after elution from protein G-
coupled beads in immunoprecipitated WT cells. 
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3.2.4 PBP7 interacts with PBP1A, LpoA and PBP4  
3.2.4.1 PBP7 interacts directly with PBP1A, LpoA and PBP4 in vitro  
We have now confirmed the in vitro and in vivo interactions of PBP4 with two components of 
the elongation machinery; LpoA and PBP1A. We hypothesised that there may be a larger 
synthase/hydrolase complex in which these proteins belong. PBP7 is also a member of the 
Class C family of PBPs, and is a monofunctional EPase. PBP7 was purified to homogeneity 
by Hamish Yau from the Vollmer group (section 2.4.5) and was tested for interactions with 
PBP1A, LpoA and PBP4.  
MST was performed with FL-PBP7 (at amine residues) which was used at an optimised 
constant concentration of 62.5 nM (section 2.5.1.7). Two-fold serially diluted LpoA was 
titrated with FL-PBP7 from a concentration of 10 μM to 0.31 nM (figure 3.14A). The pre-
experiment capillary scan yielded a concentration-dependent fluorescence enhancement, and 
was confirmed as due to ligand binding by an SD test (figure 5.10). The raw fluorescence 
values were plotted against unlabelled ligand concentration and used to generate a binding 
curve. The accompanying software was used to estimate a KD of 217 ± 92.5 nM.  
FL-PBP1A (at amine residues) was used at a concentration of 41.5 nM. Two-fold serially 
diluted PBP7 was titrated with FL-PBP1A from a concentration of 30 µM to 0.916 nM. The 
MST binding curve generated was used to estimate a KD of 78.5 ± 8.24 nM using the 
accompanying software, similar to that of PBP4 and PBP1A (figure 3.14B).  
We show here that PBP7 interacts with both LpoA and PBP1A with similar affinity as PBP4. 
We therefore hypothesised that there may be a direct interaction between the two hydrolases. 
Using FL-PBP7, at the same concentration of 62.5 nM, titrated with two-fold serially diluted 
PBP4 from a concentration of 30 µM to 0.916 nM, we observed an interaction (figure 3.14C). 
The pre-experiment capillary scan showed a concentration-dependent fluorescence 
enhancement, and was confirmed as due to ligand binding by an SD test (figure 5.12). The 
raw fluorescence values were used to generate an estimated KD of 332 ± 85.8 nM.  
An in vitro Ni2+ bead pull-down assay was used to confirm the interaction between PBP7 and 
PBP4 using His-PBP7 and native PBP4 (section 2.5.1.5). We could show that PBP4 is only 
retained in the presence of His-PBP7 (figure 3.14D). 
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Figure 3.14 PBP7 interacts with PBP1A, LpoA and PBP4 in vitro 
A. Purified PBP7 was labelled for MST at amine residues and used at a concentration of 62.5 nM. LpoA was 
serially diluted from 10 μM – 0.31 nM and MST measured at 20% LED power and 40% MST power. A 
concentration-dependent fluorescence change was observed and analysed by SD test. An estimated KD of 217 ± 
92.5 nM was determined using accompanying software. The values are the mean ± standard deviations of three 
independent experiments. Raw MST data are shown in figure 5.10. B. PBP1A was labelled at amine residues and 
used at a concentration of 41.5 nM. PBP7 was serially diluted from 30 μM and MST measured at 80% LED 
power and 20% MST power. An estimated KD of 78.5 ± 8.24 nM was determined using accompanying software. 
Raw MST data are shown in figure 5.11. The values are the mean ± standard deviations of two independent 
experiments C. FL-PBP7 was titrated with serially diluted PBP4 from a concentration of 30μM – 0.916 nM. 
MST measurements were taken at 40% LED power and 40% MST power. A KD of 332 ± 85.8 nM was estimated 
using accompanying software. The values are the mean ± standard deviations of three independent experiments. 
Raw MST data are shown in figure 5.12. D. In vitro Ni2+ bead pull-down assay using 2 µM His-PBP7 and native 
PBP4. Proteins were cross-linked with formaldehyde and an applied (A) sample taken prior to incubation with 
Ni2+ beads. After thorough washing, proteins were eluted (E), and cross-linking reversed, by boiling with SDS-
loading buffer. Proteins were separated by 12% SDS-PAGE and visualised by Coomassie staining. 
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3.2.4.2 PBP7 - Non-interacting proteins or contradictory interactions  
In addition to the positive PBP7 interactions observed so far, we present a number of proteins 
which do not interact with PBP7. Figure 3.15A/B shows the MST measurements of the 
negative interactions of PBP7 with MepS and MepM, respectively. In each case PBP7 was 
used as a serially diluted and titrated unlabelled ligand. FL-MepS (at amine residues) was used 
at a concentration of 62.5 nM to show no interaction when titrated with PBP7 serially diluted 
from 20 µM to 1.22 nM (figure 3.15A). Likewise, when unlabelled PBP7 was serially diluted 
from 50 µM to 1.526 nM and titrated with FL-MepM (at amine residues), at a concentration of 
125 nM, there was no interaction (figure 3.15B). We tested the interaction between PBP7 and 
MepS by a second in vitro method using a Ni2+ bead pull-down assay using 2 µM of His-
MepS and native PBP7. No retention of PBP7 was observed (figure 3.15C). However, when 
attempting to confirm the interaction between PBP1A and PBP7 by a Ni2+ bead pull-down 
assay, using His-PBP7 and thrombin-cleaved PBP1A, we observed no retention of PBP1A, 
contradicting the MST data (figure 3.15D).  
 
Figure 3.15 PBP7 does not interact with MepS and MepM, or PBP1A by Ni2+ bead pull-down assay 
A. FL-MepS (at amine residues) was used at a concentration of 62.5 nM, and was titrated with two-fold serially 
diluted PBP7 from 20 µM – 1.22 nM for MST. Conditions were 40% MST power and 20% LED power. Raw 
MST data are shown in figure 5.13. B. FL-MepM (at amine residues) at a concentration of 125 nM was titrated 
with two-fold serially diluted PBP7 from 50 µM – 1.526 nM and tested for interaction by MST. Conditions were 
40% MST power and 20% LED power. Raw MST data are shown in figure 5.14. C. In vitro Ni2+ bead pull-down 
assay using His-MepS and thrombin-cleaved PBP7. Proteins were cross-linked with formaldehyde and an applied 
(A) sample taken prior to incubation with Ni2+ beads. After thorough washing proteins were eluted (E) and cross-
linking reversed by boiling with SDS buffer. Proteins were separated by 12% SDS-PAGE and visualised by 
Coomassie staining. D. Same as above using His-PBP7 and thrombin-cleaved PBP1A. 
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3.2.5 Interactions of MepS and MepM 
3.2.5.1 Novel MepS interaction partners 
Continuing the investigation of the interactions between the PG hydrolases, we tested the 
interaction of MepS and MepM using MST (section 2.5.1.7). MepM was fluorescently-
labelled (at amine residues) and optimised to a working concentration of 125 nM. Unlabelled 
MepS was two-fold serially diluted from 30 µM to 0.916 nM and titrated with FL-MepM. We 
observed a repeatable binding curve that yielded an estimated KD of 1175 ± 390 nM using the 
accompanying software (figure 3.16A). 
We have identified direct associations between the PG hydrolases and the PG synthases, and 
it is known that MepS is redundantly essential for cell growth (section 1.4.2.2). We therefore 
tested for an interaction between MepS and PBP1A by MST. FL-PBP1A (at amine residues) 
was used at a concentration of 41.5 nM and was titrated with two-fold serially diluted 
unlabelled MepS from 30 µM to 0.916 nM. The experiment yielded a concentration-
dependent fluorescence enhancement which was confirmed as due to ligand binding using an 
SD test (figure 5.16). The raw fluorescence values were used to generate an estimated KD of 
940 ± 127 nM (figure 3.16B). 
 
Figure 3.16 MepS interacts with MepM and PBP1A in vitro 
A. FL-MepM (at amine residues) at 125 nM was titrated with two-fold serially diluted MepS from 30 µM – 
0.916 nM. A KD of 1175 ± 390 nM was estimated using accompanying software. MST power 20%, LED power 
40%. The values are the mean ± standard deviations of two independent experiments. B. FL-PBP1A (at amine 
residues) at 41.5 nM was titrated with two-fold serially diluted MepS from 30 µM – 0.916 nM. A KD of 940 ± 
127 nM was estimated using accompanying software. MST power 40%, LED power 20%. The values are the 
mean ± standard deviations of two independent experiments. Raw MST data are shown in figures 5.15 and 5.16. 
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3.2.5.2 MepS - Non-interacting proteins or contradictory interactions  
There appears to be a weak, yet direct interaction between MepS and PBP1A. We therefore 
tested for an interaction between MepS and LpoA, using MST (section 2.5.1.7). FL-MepS (at 
amine residues) was used at a concentration of 62.5 nM and was titrated with two-fold serially 
diluted unlabelled LpoA from 30 µM to 0.916 nM. No interaction was observed (figure 
3.17A).  
Using the same FL-MepS concentrations, we saw no interaction upon titration of unlabelled 
PBP4 from 50 µM to 1.526 nM (figure 3.17B). Unfortunately, this is in contradiction to a 
Ni2+ bead pull-down assay that was performed in which His-MepS was able to retain native 
PBP4 on Ni2+ beads (figure 3.17C) (section 2.5.2.2).  
The final potential MepS interaction partner tested was EnvC. Again, FL-MepS was titrated 
with serially diluted unlabelled EnvC from 15 µM to 0.458 nM, and no interaction was 
observed (figure 3.17D).  
 
 
 
  
117 
 
  
 
Figure 3.17 MepS – Non-interacting proteins or contradictory interactions  
A. MST of FL-MepS (at amine residues) at 62.5 nM titrated with two-fold serially diluted unlabelled LpoA from 
30 µM – 0.916 nM. MST power 40%, LED power 20%. Raw MST data are shown in figure 5.17. B. MST as 
above using unlabelled PBP4 from 50 µM – 1.526 nM. MST power, LED power 40%. Raw MST data are shown 
in figure 5.18. C. In vitro Ni2+ bead pull-down assay using His-MepS and native PBP4. Proteins were cross-
linked with formaldehyde and an applied (A) sample taken prior to incubation with Ni2+ beads. After thorough 
washing, proteins were eluted (E), and cross-linking reversed, by boiling with SDS buffer. Proteins were 
separated by 12% SDS-PAGE and visualised by Coomassie staining. D. MST as above using unlabelled EnvC 
from 15 µM – 0.458 nM. MST power 20%, 20% LED power. Raw MST data are shown in figure 5.19.   
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3.2.5.3 MepM - Non-interacting proteins  
In this section we have shown that MepM interacts with MepS (figure 3.16A) and does not 
interact with PBP7 (figure 3.15B). We present here two other negative MepM interaction 
partners; PBP4 and LpoA. 
We performed MST to test for an interaction between PBP4 and MepM and showed that there 
is no interaction. FL-MepM (at amine residues) at a constant concentration of 125 nM was 
titrated with two-fold serially diluted unlabelled PBP4 from 30 µM to 0.916 nM. The negative 
MST measurement is shown in figure 3.18A.  
We have shown that each of the hydrolases so far has an association to the elongasome 
through a direct interaction with PBP1A, LpoA or both. We therefore tested for an interaction 
between MepM and LpoA. Using the His-tagged form of MepM and an untagged version of 
LpoA we performed an in vitro Ni2+ bead pull-down assay and observed no retention of tag-
less LpoA (figure 3.18B).  
 
 
Figure 3.18 Non-interacting protein of MepM  
A. FL-MepM (at amine residues) at a concentration of 125 nM was titrated with two-fold serially diluted PBP4 
from 30 µM – 0.916 nM and tested for interaction by MST. Conditions were 20% MST power and 20% LED 
power. Raw MST data are shown in figure 5.20. B. In vitro Ni2+ bead pull-down assay using His-MepM and 
native LpoA. Proteins were cross-linked with formaldehyde and an applied (A) sample taken prior to incubation 
with Ni2+ beads. After thorough washing, proteins were eluted (E) and cross-linking was reversed by boiling with 
SDS buffer. Proteins were separated by 12% SDS-PAGE and visualised by Coomassie staining. 
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3.2.6 Conclusions and discussions 
The data presented in this section followed from the results in section 3.1, primarily the 
characterisation of the structure of the OM-anchored lipoprotein LpoA, and the identification 
of multiple TPR-like motifs within LpoAN. None of the interactions/activity effects in this 
section had been reported or published previously. 
 
Interactions between LpoA, PBP1A and PBP4 
A proteomics-based search for LpoA interaction partners identified PBP4. We confirmed this 
as a direct interaction in vitro using SPR. Unfortunately the sensorgrams generated were not 
suitable for KD determination due to a ‘biphasic’ binding pattern. After consultation with an 
SPR analyst we hypothesised that a dimer of PBP4 was binding to the LpoA surface to cause 
the first increase in response units before disassociation of a PBP4 monomer. We speculate 
that the released monomer re-associated to the LpoA surface, causing the unique binding 
curve observed. To confirm the interaction by a second in vitro method, and to estimate a KD 
value for the interaction, we performed MST.  
The interaction between unlabelled PBP4 and FL-LpoA generated a concentration-dependent 
fluorescence enhancement. After confirmation that the change occurred as result of ligand 
binding by SD test, the raw fluorescence data was used to estimate a KD of 315 ± 38 nM. The 
concentration-dependant fluorescence enhancement implies the interaction occurs close to 
sites of LpoA labelling. The two cysteine residues of LpoA are located in LpoAC, implying it 
is this domain that is the primary interaction site of PBP4. We were also able to confirm the in 
vivo interaction using co-immunoprecipitation.  
We tested the relevance of this interaction in vitro by showing that LpoA had a moderate 
inhibitory effect on both the EPase and CPase activities of PBP4. However, we hypothesise 
that the primary role of this interaction is spatio-temporal. LpoA may interact with PBP4 in 
order to coordinate hydrolase activity with ongoing PG synthesis, to create the space required 
for nascent PG insertion by the core PG synthesis complex during elongation. Due to the lack 
of a strong effect on activity we hypothesise that LpoA acts to target PBP4 activity, rather 
than regulate activity, however, localisation studies will have to be undertaken to test this 
hypothesis.  
We continued to investigate this interaction using truncated versions of both proteins (LpoAC, 
LpoAN, and PBP4ΔD3) in MST experiments. We show that full length LpoA interacts with 
both PBP4 and PBP4ΔD3, the resulting binding curves generating estimated dissociation 
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constants of 315 ± 38 nM and 153 ± 31 nM, respectively. As the interaction takes place with 
similar affinity, the LpoA interaction sites of PBP4 likely lie in domains 1 and/or 2. As 
discussed earlier the interaction between full length LpoA and full length PBP4 inferred that 
the PBP4 interaction sites of LpoA lie in LpoAC. We continued to search for information 
regarding interaction sites using the truncated versions of LpoA. 
We show that LpoAC interacts with full length PBP4 with an estimated KD of 226 ± 15 nM, 
and with PBP4ΔD3 with an apparent KD of 315 ± 21 nM. These dissociation constants are 
within the same range as that of full length LpoA and indicate firstly, that the interaction may 
indeed take place primarily through LpoAC, and secondly, that domain 3 of PBP4 is likely not 
important for the interaction with LpoA. It is interesting to note that binding of PBP4 to full 
length fluorescently-labelled LpoA at cysteine residues caused a concentration-dependent 
fluorescence enhancement, but the binding of PBP4 to cysteine-labelled LpoAC did not. 
LpoAN does not contain any cysteines, and implies multiple PBP4 binding sites within 
LpoAC, involving the cysteines when the protein is in its full length form, and not requiring 
the cysteine residues in the truncated form. The cysteines of LpoAC are not present in the 
‘wing’-like domains of LpoA indicating these may not be important interaction sites when the 
full length versions of both proteins interact. However, we speculate that these ‘wing’-like 
domains become more important when the need to stabilise an interaction arises, in this case 
with roughly 30% of its structure missing. This means the interaction would not take place 
through the labelled cysteine residues, as with full length LpoA, leading to the standard MST 
binding curve observed, rather than the concentration-dependent fluorescence enhancement 
observed for full length LpoA and full length PBP4.  
We also used LpoAN in MST to test for the interaction with full length PBP4 and PBP4ΔD3. 
While the interaction of LpoAN took place with both PBP4 versions, the interaction between 
LpoAN and full length PBP4 occurred with three times less affinity than full length LpoA, at 
954 ± 52 nM. This indicated again that LpoAC is primarily responsible for the interaction with 
PBP4.  
However, the interaction between LpoAN and PBP4ΔD3 occurred with the highest affinity 
observed in this work with an estimated KD of 17 ± 4 nM. We hypothesise that the interaction 
between LpoAN and PBP4 is dependent on the conformational state of domain 3. A 
conformational change in this domain, or in this case a deletion, may reveal a larger 
interaction site promoting an interaction with LpoAN with ~50 times higher affinity. This 
conformational change may occur upon binding of another PBP4 interaction partner, which 
may reveal more of the active site and thus increase activity, the affinity for LpoAN may then 
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increase in order to exert the inhibitory effect observed in this work, thus moderating the 
activity of PBP4. This also implies that the two domains of LpoA may have different primary 
functions; perhaps LpoAN acts to control PBP4 activity where LpoAC acts to recruit PBP4 to 
sites of ongoing PG synthesis. More work is required to test these hypotheses. 
In addition to LpoA, we show that PBP4 interacts directly in vitro and in vivo with PBP1A. 
We applied the same interaction assays as used to confirm the LpoA-PBP4 interaction 
including SPR, which again yielded a binding curve not suitable for KD determination. The 
lack of dissociation of PBP4 over the PBP1A surface, and absence of a concentration-
dependent response over the control surface, indicates that the specific interaction of PBP4 
with PBP1A takes place with high affinity. MST was performed using unlabelled PBP4 and 
FL-PBP1A to estimate a KD value for the interaction of 66.8 ± 9.1 nM. This high affinity 
interaction correlates with the lack of PBP4 dissociation observed in the SPR experiment.  
Like the interaction between LpoA and PBP4, we hypothesise that the role of this interaction 
is to recruit PBP4 to sites of ongoing PG synthesis during cell growth, however, localisation 
studies will be required to confirm these hypotheses. 
 
Interactions of PBP7 with LpoA, PBP1A and PBP4 
Using purified PBP7 as both the labelled protein (at amine residues) and unlabelled serially 
diluted ligand in MST, we identified interactions between PBP7 and both PBP1A and LpoA. 
The estimated KD values generated were 78.5 ± 8.24 nM and 217 ± 92.5 nM, respectively, 
strikingly similar affinities to those observed for PBP4 with PBP1A and LpoA. The 
interaction between PBP1A and PBP7 was observed by MST only, showing no interaction by 
Ni 2+ bead pull-down. It is speculated that the lack of interaction by pull-down assay may be 
due the hexahistidine tag that may either occlude interaction sites with PBP1A or cause PBP7 
to be immobilised to the Ni2+ resin in such a way that prevents PBP1A binding, a situation 
that would not occur in solution, as with MST. We aim to optimise another in vitro technique, 
such as SPR with which to confirm this interaction.  
These data infer that PBP7 may also be recruited to the elongasome through direct 
interactions with the core synthesis complex. In addition, we observed a direct interaction 
with PBP4 using a Ni2+ bead pull-down assay and MST experiments, by which we estimated a 
KD value of 332 ± 85.8 nM. We have yet to show any effect of PBP7 on the activity of 
PBP1A or the stimulation of PBP1A by LpoA, and thus hypothesise, that like PBP4, the 
  
122 
 
  
primary role of these interactions could be spatio/temporal. If both PBP4 and PBP7 are 
recruited to sites of ongoing PG synthesis by PBP1A/LpoA, this could allow a greater degree 
of hydrolase activity during elongation. PBP4 and PBP7 have implicated auxiliary roles in the 
maintenance of cell morphology [121]. We speculate that upon deletion of both of these 
proteins, there is an imbalance in PG synthesis and hydrolysis during elongation leading to 
the morphological changes observed.  
Interactions of MepM and MepS  
We have observed the interaction between PBP4 and PBP7 and thus hypothesised the 
existence of interactions between the other hydrolases. We showed the negative interactions 
of both PBP4 and PBP7 with MepS and MepM, however, we showed that MepS and MepM 
interact directly by MST, with an estimated KD of 1175 ± 390 nM.   
We hypothesise that these four EPases are all associated to the PG synthesis complex, yet 
exist as two separate hydrolase complexes. Both PBP4 and PBP7 interact with each other and 
with LpoA and PBP1A, and thus may associate through these interactions. We observe the 
interaction between MepS and PBP1A, with an estimated KD of 940 ± 127 nM, and thus 
hypothesise that a complex of MepS and MepM could associate this way. The PG hydrolase 
complexes may be recruited to the elongasome at different conditions or possess different 
substrate specificities to allow for a robust system of hydrolysing activity at sites of ongoing 
PG synthesis. More experiments will be required to test this hypothesis.   
We continued by showing that MepS does not interact with LpoA or EnvC. However, using a 
Ni2+ pull-down assay, we obtain inconsistent results for the interaction between PBP4 and 
MepS. We observed no interaction between MepS and PBP4 by MST, yet showed that His-
MepS was able to retain native PBP4. It is possible that a weak interaction takes place and 
was strengthened by the addition of the formaldehyde cross-linker, or that the fluorophore of 
the labelled MepS prevented binding of PBP4. We aim to test this interaction using another 
method, for example ITC, SPR or AUC. 
We also show the negative interaction of MepM and LpoA; however we have yet to test the 
interaction of MepM and PBP1A. We therefore propose that any association of MepM to the 
PG synthesis complex would be indirect, facilitated by the interaction of MepS and PBP1A. 
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Final word 
In this section we have employed in vitro and in vivo approaches to characterise a number of 
novel interactions. We significantly enhance the knowledge of how the PG synthases and 
hydrolases could be coordinated as members of a multi-enzyme complex. The interactions 
and activities identified in this section, and subsequent sections, are summarised in figure 3.28 
at the end of the section 3.4. 
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3.3 Biochemical characterisation of PBP4 
3.3.1 Introduction 
Before this work there were no known PBP4 interaction partners, or regulators of activity. As 
described in the previous section, we have now identified at least three novel interaction 
partners; two members of the PG synthesis complex during cell elongation, PBP1A and 
LpoA, and another Class C PBP with EPase activity, PBP7. The crystal structure of PBP4 has 
been elucidated, alone and with covalently bound β-lactam antibiotics [115]. It is comprised 
of three domains each embedded in the other; the active site serine-containing domain 1 is 
embedded with the non-catalytic domain 2, which in turn is embedded with the globular, non-
catalytic domain 3. This Russian doll-like architecture is thought to prevent flexibility 
between the three domains. PBP4 crystallises as a tight face-to-face dimer [115]. 
In section 3.2 we showed that domain 3 is not required for the interaction with LpoA. To 
further characterise PBP4, biochemically and structurally, we investigated the substrate 
binding capabilities and activities of the full length protein in comparison to the truncated 
form of PBP4, PBP4ΔD3.  
 
3.3.2 PBP4 is a dimer in solution 
As mentioned above, the published data predicts that PBP4 exists as a dimer, however, we 
sought to determine the oligomeric state of PBP4 in solution at the conditions used for 
interaction and activity assays. We therefore performed analytical ultracentrifugation (AUC) 
in collaboration with Dr. Alexandra Solovyova, Newcastle University. Purified PBP4 was 
dialysed o/n against 25 mM HEPES/NaOH, 150 mM NaCl, pH 7.5 and was analysed using 
the fringe displacement (interference) technique at 20°C to determine the sedimentation 
velocity of PBP4 at varying concentrations (5.6, 11.68, 17.27, 19.38 and 20.82 mg/ml) (figure 
3.19). Results were corrected for the viscosity/density of H2O at 20°C. The amino acid 
sequence and the known crystal structure data were used to predict the sedimentation velocity 
of a PBP4 dimer as 5.54 S with a molecular weight of 98.6 kDa. The experimental data 
collected had a sedimentation velocity of 5.35 S which corresponded to a dimer with a 
different monomer orientation than the published crystal structure. These data, and the 
absence of a PBP4 monomer peak, suggests that PBP4 is a dimer in solution with a different 
structure than that determined by X-ray crystallography.  
  
125 
 
  
 
Figure 3.19 Analytical ultracentrifugation shows that PBP4 exists as a dimer in solution 
Size distribution plots showing the sedimentation velocity of PBP4. The calculated sedimentation velocity by 
fringe displacement interference and subsequent estimation of molecular weight suggests PBP4 forms a dimer in 
solution with a different monomeric orientation to that of the published crystal structure. s20,wS (Sedimentation 
coefficient corrected for the viscosity and density of the solvent, relative to that of water at 20°C) plotted against 
absorbance (280 nM). 
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3.3.3 Domain 3 of PBP4 is crucial for activity  
 
Substrate binding of PBP4 versions 
Domain 3 of PBP4 is predicted to be globular with a strong hydrophobic core suggesting that 
the domain can be removed without loss of structural integrity to the rest of the protein [115]. 
The purification and subsequent use in interaction assays of PBP4ΔD3 was addressed in 
section 3.2.  
The successful purification of PBP4ΔD3 indicated that the protein was correctly folded. 
However, we performed Circular Dichroism (CD), in comparison to full length PBP4, to 
further study the structural integrity of the truncated version, in collaboration with Prof. 
Jeremy Lakey, Newcastle University. Proteins were dialysed o/n against 10 mM NaPO4, pH 
7.5 and concentrated/diluted to 0.4 mg/ml. CD measurements were taken using a Jasco J-810 
spectropolarimeter using a wavelength range of 180-250 nm. The average of 10 runs was 
taken for each protein with a buffer control subtraction. For a direct comparison, correcting 
for the differing amino acid sequences, the collected data was converted to molecular CD and 
plotted against wavelength (nm). The resulting CD spectra are compared in figure 3.20A and 
show that PBP4 lacking domain 3 is folded, consisting of both α-helices (~190 nm) and β-
sheets (~210 nm).  
To investigate the folding of the active site, an FL-bocillin binding assay was performed 
(section 2.5.2.1). The catalytically inactive version of PBP4, containing a single base 
substitution of serine 52 to alanine (S52A), was also purified as a negative control (section 
2.4.4). All PBP4 versions (10 µg) were incubated in 50 μl with 20 ng/μl of a fluorescently-
labelled version of the β-lactam bocillin (FL-bocillin) (Sigma). As a negative control, 
penicillin G was pre-incubated with protein samples at 1 ng/µl for 10 min to block the active 
site. Samples were resolved by 12% SDS-PAGE and fluorescence visualised using a Typhoon 
Fluoroimager (Excitation laser; 488 nm, emission filter; 520 BP20, PMT voltage; 400-800). 
As expected, full length PBP4 was capable of binding FL-bocillin, and the catalytically 
inactive version of PBP4 was not (figure 3.20B). However, we show that PBP4ΔD3 was also 
capable of binding FL-bocillin, which suggests that PBP4ΔD3 has a correctly folded active 
site. 
We also investigated whether domain 3 of PBP4 was crucial for PG binding. A PG-binding 
assay was performed (section 2.7.3) in which 100 μl of WT MC1061 PG was pelleted by 
centrifugation and resuspended in 100 μl binding buffer (10 mM Tris/maleate, 10 mM MgCl2, 
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50 mM NaCl, pH 7.5) and incubated with 10 µg of either PBP4 or PBP4ΔD3. Control 
samples were used for each PBP4 version which contained no PG. After a 30 min incubation, 
samples were centrifuged and washed with 200 µl of PG-binding buffer. A final SDS 
incubation was performed to release bound proteins before resolving the samples by SDS-
PAGE (figure 3.20C). We showed that both PBP4 and PBP4ΔD3 were retained by PG. In 
addition to the CD spectra and the FL-bocillin binding assays, these data indicate that the 
truncated version of PBP4 has a correctly folded secondary structure and active site, and is 
capable of substrate binding. 
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Figure 3.20 PBP4ΔD3 is folded and capable of binding substrates 
A. Circular Dichroism spectra of PBP4 and PBP4ΔD3 showing molecular CD against wavelength. Full length 
PBP4 and PBP4ΔD3 are folded, consisting of α-helices and β-sheets. B. PBP4 (full length), inactive PBP4 
(S62A) and PBP4ΔD3 were incubated 10 μg in 50 μl with FL-bocillin. Proteins were either pre-incubated with 
penicillin G (+) or not (-) before boiling with SDS-loading buffer. Proteins were separated by 12% SDS-PAGE 
and visualised using a Typhoon Fluoroimager (Excitation laser; 488 nm, emission filter; 520 BP20, PMT 
voltage; 400-800). C. The resuspended pellet of a 100 μl PG suspension was incubated with 10 µg of PBP4 (full 
length), inactive PBP4 (S62A) and PBP4ΔD3 for 30 min. Samples were centrifuged and the supernatant was 
retained (S) before being washed with binding buffer and centrifuged. The supernatant was retained (W) and the 
PG pellets were resuspended in 2% SDS solution and incubated for 1 h with stirring. Samples were centrifuged 
and the supernatant retained (P). Proteins were separated by 12% SDS-PAGE and visualised by Coomassie 
staining in comparison to samples lacking PG. 
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Hydrolytic activity of PBP4 versions    
In order to study the EPase and CPase activity of PBP4ΔD3, assays were performed with all 
three versions of PBP4. A HPLC-based muropeptide digestion assay was performed as 
described in section 2.5.2.2. Muropeptides from the MC1061 strain were incubated with each 
PBP4 version at 1 µM for 30 min at 37°C in standard EPase reaction buffer (10 mM 
HEPES/NaOH, 10 mM MgCl2, 150 mM NaCl, 0.05% Triton X-100, pH 7.5). The reaction 
was stopped by boiling, and the samples were reduced for analysis by reversed-phase HPLC 
(2.5.2.5). The relative percentages of Tetra-containing muropeptides (monomers and dimers) 
were calculated and plotted. The results show that despite its correctly folded active site, 
PBP4ΔD3 was inactive (figure 3.21A). This lack of inactivity was also demonstrated with 
intact sacculi from the MC1061 strain using 1 µM of each protein incubated for 4 h in EPase 
reaction buffer at 37°C (figure 3.21B). Using isolated muropeptides from the penta-peptide 
rich sacculi, CS703-1 at the same conditions as the MC1061 muropeptide digestion assay, we 
also observed the inactivity of PBP4ΔD3, while the full length protein was active on all 
substrates (figure 3.21C).  
To address the CPase activity of PBP4, a spectrophotometric D-Ala release assay was 
performed using all three PBP4 versions (section 2.5.2.3). Figure 3.21D shows the absorbance 
against time for each protein at 10 µM. The only activity observed is that of full length PBP4. 
Both the catalytically inactive version and PBP4ΔD3 have no activity. 
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Figure 3.21 Domain 3 of PBP4 is required for activity 
PBP4 versions were incubated at 1 µM with isolated muropeptides from MC1061 PG (A) for 30 min, or intact 
MC1061 sacculi (B) for 4 hours. Isolated muropeptides from the pentapeptide rich sacculi CS703-1 (C) were 
also used for 30 min at 37°C before boiling and reducing with sodium borohydride and analysis by HPLC. All 
assays were undertaken at 37°C with shaking. D. Spectrophotometric D-Ala release assay with PBP4 versions 
(10 µM) using UDP-MurNAc-pentapeptide as substrate. Absorbance read at 563 nm. 
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3.3.4 PBP4ΔD3 is a dimer in solution 
The data gathered thus far suggest that domain 3 has a crucial role in the hydrolytic activity of 
PBP4, yet the removal of this domain does not affect the binding of PG substrate or β-
lactams. Domain 3 constitutes ~40% of the dimer surface [115]. We therefore hypothesised 
that without this domain, PBP4 would remain in an inactive, yet substrate-binding, 
monomeric state.  
We performed AUC in collaboration with Alexandra Solovyova. Samples were dialysed o/n 
against 25 mM HEPES/NaOH, 150 mM NaCl, pH 7.5 and the fringe displacement 
(interference) technique was used at 20°C to determine the sedimentation velocity of varying 
concentrations of PBP4ΔD3 (5.9, 9.4, 17.3, 27.3 and 34.7 mg/ml). Results were corrected for 
the viscosity/density of H2O at 20°C. Using the amino acid sequence and the known crystal 
structure data, the predicted sedimentation velocity of PBP4ΔD3 in the dimeric state was 
predicted to be 5.3 S (figure 3.22). Like the full length version, there was no monomeric peak, 
predicted to have a molecular weight of ~45 kDa. At the higher concentrations, trimer and 
tetramer peaks could be observed. However, the dimer peak was the most prominent at all 
concentrations tested. These data support that PBP4ΔD3 is a dimer in solution, but that the 
monomers may arrange in a different orientation to those of full length PBP4.  
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Figure 3.22 Analytical ultracentrifugation shows that PBP4ΔD3 exists as a dimer in solution 
Size distribution plots showing the sedimentation velocity of PBP4ΔD3. The calculated sedimentation velocity 
by fringe displacement interference and subsequent estimation of molecular weight suggests PBP4ΔD3 forms a 
dimer in solution. s20,wS (Sedimentation coefficient corrected for the viscosity and density of the solvent, relative 
to that of water at 20°C) plotted against absorbance (280 nM). 
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3.3.5 Domain 3 of PBP4 is not required for interaction with PBP1A 
Domain 3 of PBP4 constitutes 15.3% of the amino acid sequence of the PBP4 monomer. We 
hypothesised that it could also be an interaction site for the PBP4 interaction partners 
identified in the section 3.2.  
In section 3.2.2.3 we show that PBP4ΔD3 was capable of binding full length LpoA. Here we 
performed MST in which PBP4ΔD3 was two-fold serially diluted and titrated as the 
unlabelled ligand from a starting concentration of 10 μM (section 2.5.1.7) and tested for 
interaction with FL-PBP1A (at amine residues), which was used at 41.5 nM. 
LpoA interacts with PBP4ΔD3 with similar affinity to that of the full length, with an apparent 
KD of 153 ± 31 nM compared to 315 ± 37.7 nM. PBP1A was also capable of interacting with 
PBP4ΔD3, with an apparent KD of 246 ± 49.7 nM compared to 66.8 ± 9.11 nM for full length 
PBP4 (figure 3.23). These data show that domain 3 is not a crucial interaction site for at least 
two of its known interaction partners implying it is domain 1 and/or 2 that possess the 
LpoA/PBP1A interaction sites. 
 
Figure 3.23 PBP1A interacts with PBP4 independently of domain 3 
MST of two-fold serially diluted PBP4ΔD3 (10 µM – 0.305 nM) with FL-PBP1A (at amine residues) at 41.5 nM 
(20% MST power, 80% LED power). The KD value was estimated to be 246 ± 49.7 nM and was calculated using 
the accompanying software. The values are the mean ± standard deviation of three independent experiments. 
Raw MST data are shown in 5.21. 
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3.3.6 Conclusions and discussion 
In this section we present further efforts to structurally and biochemically characterise full 
length PBP4 and a truncated form of the protein, PBP4ΔD3, in which the globular domain 3 
of the protein is removed. The structural model of the PBP4 dimer, presented in [115], 
suggests a tight face-to-face monomeric orientation which, using AUC, we predicted would 
sediment at 6.11 S. In concordance with the published data we show that PBP4 exists 
exclusively as a dimer in solution at the concentrations tested. However, our AUC data 
suggest a different orientation of the monomers. Instead of a face-to-face orientation the 
experimental data predicted an end-to-end monomer arrangement. This may highlight a 
hitherto uncharacterised oligomeric flexibility that we may see at the milder conditions of 
AUC rather than those required for X-ray crystallography. Nevertheless, our data showed that 
PBP4 is a dimer in solution. 
Using circular dichroism (CD) we show that domain 3 can be removed from PBP4, and the 
truncated version purified, without loss of secondary structure. Of note firstly is that the 
PBP4ΔD3 CD spectra corresponds to a folded protein consisting of both α-helices and β-
sheets. The crystal structure of PBP4 (figure 1.4) predicts that domain 3 consists mainly of β-
sheets, with the rest of the structure comprised of a mixture of β-sheets and α-helices. These 
data suggest that PBP4ΔD3 is folded but cannot predict whether the rest of the unaltered 
domains of the protein are the same as native PBP4.  
We showed that the active site of PBP4ΔD3 is folded using two substrate-binding assays. In 
comparison to full length PBP4 and the active site mutant PBP4S62A we show that 
PBP4ΔD3 binds a fluorescent form of the β-lactam bocillin, indicating that PBP4ΔD3 has a 
folded active site. Using a PG-binding assay we show that PBP4ΔD3 is able to bind high 
molecular weight sacculi, albeit with less efficiency, although this is not quantitative. 
Domain 3 has thus far been shown to be non-essential for structural integrity and substrate 
binding. We therefore directly assayed the in vitro activity of this truncated form in 
comparison to full length PBP4 and PBP4S62A. We showed in EPase activity assays using 
both isolated muropeptides and intact sacculi from the MC1061 WT strain, and muropeptides 
from a penta-peptide rich strain (CS703-1), that PBP4ΔD3 is inactive. Similarly, using a 
spectrophotometric D-Ala release assay, we show that PBP4ΔD3 has no CPase activity. 
Our initial hypothesis to explain this lack of activity, having studied the crystal structure 
which depicts domain 3 as a major dimer interface, was that domain 3 facilitates the correct 
dimerisation of PBP4, and that PBP4 is only active in a dimeric state. At the same conditions 
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as full length PBP4 we showed that PBP4ΔD3 also exists as a dimer by AUC, however with a 
slightly different monomeric orientation. Whether this is significant is yet to be determined, 
however, we speculate that the orientation of the dimers, whilst not preventing the binding of 
the substrate to the active site of PBP4ΔD3, could in some way abate activity. It is possible 
that PBP4ΔD3 monomers are capable of dimerising in a face-to-face orientation but, without 
domain 3, encloses the active sites of both monomers. While this may not prevent substrate 
binding we hypothesise that it could prevent degradation of bound material. Alternatively, if 
the PBP4ΔD3 monomers dimerise in a back-to-back fashion, with their active sites facing 
away from each other, this could allow substrate binding to the active site of each monomer, 
but for activity to occur, coordination of both monomers may be required. A third possibility 
is that, while not required for general substrate binding, domain 3 is required to correctly 
position substrate for degradation. 
In section 3.2.2.3 we showed that domain 3 is not required for an interaction with LpoA. 
LpoA interacts with full length PBP4 with an estimated KD of 315 ± 37.7 nM and with 
PBP4ΔD3 with an estimated KD of 153 ± 31 nM. We showed in this section that the 
interaction between PBP4 and PBP1A is also not reliant on domain 3, however, PBP1A 
interacts with PBP4ΔD3 with less affinity than full length PBP4, decreasing from 66.8 ± 9.11 
nM to 246 ± 49.7 nM when domain 3 is absent. We hypothesise that domain 3 may play an 
auxiliary role in the interaction with PBP1A, but its presence is not essential. These data 
suggest the interaction of LpoA and PBP1A with PBP4 occurs primarily through domain 1 
and/or 2 of PBP4. More detail regarding the LpoA/PBP4 interaction was shown in section 
3.2.2.3 using truncated forms of both proteins. Neither LpoA nor PBP1A have major 
enzymatic effects on the activity of PBP4 and neither require domain 3 as an interaction site, a 
domain which seems critical for activity. We therefore hypothesise that any regulator of PBP4 
activity would interact with domain 3.  
 
Final word 
The data presented in this section are the first to examine and dissect the domains of PBP4, 
with respect to investigating the mechanisms of the interactions and activities of this protein. 
We also present domain 3 of PBP4 as crucial for activity through an as-yet-unknown 
mechanism, but one that could represent a way of regulating hydrolase activity in E. coli.  
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3.4 The biochemical characterisation of MepA 
3.4.1 Introduction 
The LAS metallopeptidase MepA has no known interaction partners and in vitro activity has 
only been analysed using the sacculi and isolated muropeptides of P. putida [116,117], 
isolated [14C]-disaccharide tetrapeptide from E. coli [244] and DL-meso-[3H]-diaminopimelic 
acid labelled sacculi [245]. It was also not identified as a potential interaction partner of any 
protein in the proteomics screens carried out by the Typas group (Manuel Banzhaf, 
unpublished).  
In section 3.2, we presented a large number of interactions, regulatory or otherwise, between 
the PG hydrolases and the PG synthases. We identified the direct interaction between PBP7 
and PBP4 and between MepS and MepM. These data could imply an uncharacterised level of 
cooperative activity between the PG hydrolases. It was possible that there could be more 
interactions between the PG hydrolases.  
This section describes the characterisation of MepA, the last EPase successfully purified in 
this work, through novel interactions with other EPases, and the discovery of pH-dependent 
activity using unlabelled sacculi from E. coli. This work continues to investigate novel ways 
by which PG hydrolase activity is regulated in E. coli. 
 
3.4.2 MepA interacts with PBP4, PBP7 and MepS 
Native MepA was purified to homogeneity as described in section 2.4.8 and tested for 
interactions with many of the proteins in this project by MST. 
Figure 3.24 shows the interaction of MepA with PBP7, PBP4 and MepS using MST (section 
2.5.1.7). MepA was fluorescently-labelled at cysteine residues and used at a constant 
concentration of 125 nM. Two-fold serially diluted PBP7, from 50 µM to 1.53 nM, was 
titrated with FL-MepA to yield a binding curve that generated an estimated KD of 160 ± 23.7 
nM (figure 3.24A). PBP4 was titrated from a concentration of 30 µM to 0.916 nM to yield an 
estimated KD of 84 ± 14 nM (figure 3.24B). Finally, MepS was titrated from a concentration 
of 30 µM to 0.916 nM to yield an estimated EC50 of 101 ± 41.3 nM (figure 3.24C).  
The interaction between MepA and MepS yielded a binding curve that did not fit an 
equilibrium binding model. As such, the Hill model was applied to estimate the EC50 shown 
and a Hill coefficient of 2.57, indicating positive cooperativity upon binding.  
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Figure 3.24 MepA interacts with PBP7, PBP4 and MepS in vitro 
A. Purified MepA was labelled for MST at cysteine residues and used at a concentration of 125 nM. PBP7 was 
two-fold serially diluted from 50 μM – 1.526 nM and MST measured at 40% LED power and 60% MST power. 
An estimated KD of 160 ± 23.7 nM was determined using accompanying software. B. Using the same FL-MepA 
conditions, PBP4 was two-fold serially diluted from 30 μM – 0.916 nM and MST measured at 40% LED power 
and 60% MST power. An estimated KD of 84 ± 14 nM was determined using accompanying software. C. Again, 
using the same FL-MepA conditions, MepS was two-fold serially diluted from a concentration of 30 μM – 0.916 
nM and MST measured at 40% LED power and 60% MST power. The Hill model was applied and an EC50 of 
101 ± 41.3 nM was estimated using accompanying software. The interaction was calculated to have a Hill 
coefficient of 2.57. The values for each graph are the mean ± standard deviations of three independent 
experiments. Raw MST data are shown in figures 5.23-5.25.  
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3.4.3 MepA – Non-interacting proteins or contradictory interactions 
We performed Ni2+ bead pull-down assays as a second method of testing the in vitro 
interactions of MepA (section 2.5.1.5). Ni2+ bead pull-down assays were performed using His-
PBP4 and His-MepS to test for retention of native MepA. Figure 3.25A shows that His-PBP4, 
in the presence of formaldehyde, did not retain native MepA after washing. The same was 
true for the interaction between His-MepS and native MepA (figure 3.25B). Unfortunately, 
due to the similar sizes of MepA and PBP7, it was difficult to obtain a clear result after 
separation by SDS-PAGE.  
FL-MepA was used at the same conditions as previously and tested for interaction with 
serially diluted MepM from 20 µM to 0.61 nM using MST, by which we observed no 
interaction (figure 3.25C). A Ni2+ bead pull-down assay was performed using His-MepM and 
native MepA by which we also observed no interaction (figure 3.25D).  
 
Figure 3.25 MepA does not interact with PBP4 and MepS by Ni2+ bead pull-down or MepM 
A. In vitro Ni2+ bead pull-down assay using His-PBP4 and native MepA. Proteins were cross-linked with 
formaldehyde and an applied (A) sample taken prior to incubation with Ni2+ beads. After thorough washing, 
proteins were eluted (E) and cross-linking reversed by boiling with SDS buffer. Proteins were separated by 12% 
SDS-PAGE and visualised by Coomassie staining. B. Identical to above using His-MepS. C. MST of FL-MepA 
at 125 nM titrated with two-fold serially diluted unlabelled MepM from 20 µM – 0.61 nM. MST power 40%, 
LED power 40%. Raw MST data are shown in figure 5.26. D. Identical to A and B using His-MepM and native 
MepA. 
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3.4.4 MepA activity against intact sacculi is pH dependent 
To date, in vitro MepA activity assays have either used substrate from P. putida or 
radioactively-labelled E. coli substrate. We therefore sought to characterise MepA activity 
against purified high molecular weight unlabelled sacculi from E. coli (section 2.5.2.2). 
MepA was incubated with sacculi from the D456 E. coli strain at a concentration of 2 µM, o/n 
or for 2 h, at 37°C, alone or pre-incubated with 20 mM EDTA. Standard EPase reaction 
buffer was used (10 mM HEPES/NaOH, 150 mM NaCl, 0.05% Triton X-100, pH 7.5) and 
compared to that of a pH 5.0 reaction buffer (10 mM NaAcetate/acetic acid, 150 mM NaCl, 
0.05% Triton X-100, pH 5.0). Samples were inactivated by boiling in the presence of 20 mM 
EDTA, before an o/n cellosyl digestion. Released muropeptides were obtained by 
centrifugation, reduced with sodium borohydride and analysed by reversed-phase HPLC 
(section 2.5.2.5). The percentage of dimeric muropeptides was calculated and is shown in 
figure 3.26. 
MepA was almost inactive against sacculi at pH 7.5 and significantly more active at pH 5.0 at 
both incubation times tested. These data highlight a pH dependent activity not observed for 
the other EPases (see figure 5.27 and 5.28 for raw chromatograms of MepA activity assays) 
(see section 3.4 and figures 5.29-5.31 for PBP7, MepS and MepH activity at different 
conditions). 
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Figure 3.26 MepA has higher activity at lower pH 
MepA was tested for EPase activity at a concentration of 2 µM with intact D456 sacculi at pH 7.5 and pH 5.0, 
o/n or for 2 h, alone or in the presence of 20 mM EDTA. Samples were inactivated by boiling and the addition of 
20 mM EDTA before centrifugation and o/n cellosyl digestion of the supernatant. Samples were boiled and 
centrifuged. Released muropeptides were reduced for analysis by reversed-phase HPLC. The relative percentage 
of muropeptides in cross-links was calculated and plotted. The values are the mean ± standard deviation of three 
independent experiments. Raw chromatograms are shown in figures 5.27 and 5.28. 
 
To investigate the lack of activity on sacculi by MepA at pH 7.5, a PG-binding assay was 
performed (section 2.7.3) in comparison to the other EPases investigated in this work (figure 
3.27). Sacculi from the MC1061 strain (100 µl) were pelleted and resuspended in PG-binding 
buffer (10 mM Tris/Maleate, 10 mM MgCl2, 50 mM NaCl, pH 7.5) and mixed with 10 µg of 
each protein for 30 min on ice before centrifugation and retention of the supernatant (S 
sample). Pelleted PG was washed with 200 µl of PG-binding buffer before centrifugation and 
collection of the supernatant (W sample). SDS (2% solution) was used to resuspend the pellet 
with stirring for 1 h to release any bound protein before a final centrifugation (P sample). In 
parallel, control samples were used in which no PG was included. After resolving the samples 
by 12% SDS-PAGE, we found that all EPases studied in this work were retained by PG at pH 
7.5, except MepA.  
The assay was repeated using a pH 5.0 PG-binding buffer (10 mM NaAcetate/acetic acid, 10 
mM MgCl2, 50 mM NaCl, pH 5.0) to test if the binding of MepA to PG is pH dependent, 
which we show to be the case. It should be noted that NlpI and the other EPases have not yet 
been tested for PG binding at pH 5.0. 
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Figure 3.27 Peptidoglycan binding of EPases and NlpI at pH 7.5 and pH 5.0 
Pelleted and resuspended sacculi from the MC1061 strain were incubated with 10 µg of PBP4, PBP7, MepM, 
MepS and NlpI at pH 7.5 and MepA at pH 7.5 and pH 5.0. After a 30 min incubation, samples were centrifuged 
and the supernatant collected (S). Samples were washed and centrifuged with the supernatant retained (W). 
Pelleted sacculi were incubated with 2% SDS solution for 1 h to release any bound protein. Samples were 
centrifuged and the supernatant was retained (P). Control samples were carried out in parallel without PG. 
Proteins were separated by 12% SDS-PAGE and visualised by Coomassie staining.  
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3.4.5 Conclusions and discussion 
This section described the characterisation of three novel interaction partners of MepA; PBP4, 
PBP7 and MepS by MST, and the investigation into the activity of MepA against E. coli 
sacculi. 
MST was performed using FL-MepA and unlabelled PBP7, PBP4 and MepS. We showed the 
interaction with PBP7 has an apparent KD of 160 ± 23.7 nM, with PBP4, which has an 
apparent KD of 194 ± 39.5 nM and with MepS, which has an apparent EC50 of 101 ± 41.3 nM. 
However, we were unable to confirm these interactions by Ni2+ pull-down assays. We 
speculate that the presence of the His-tag may be preventing the interaction from being 
observed in this assay, either occluding an interaction site or immobilised to the nickel resin 
in such a way that prevents interaction. Unfortunately, we have no His-tagged version of 
MepA with which to test these interactions in the opposite way. We therefore aim to optimise 
a second in vitro method, for example SPR, and to test all interactions in vivo by co-
immunoprecipitation. 
Interestingly, the binding curve generated for the interaction between MepA and MepS was 
not an equilibrium binding event, therefore the Hill model was applied to estimate an EC50 of 
101 ± 41.3 nM and a Hill coefficient of 2.57. This value implies positive cooperativity; the 
binding of MepS to MepA may cause a conformational change to allow MepA to bind more 
protein. This also implies multiple MepS binding sites on MepA. As MepA exists as a dimer, 
it is possible that the binding of MepS to one of the monomers induces a conformational 
change that causes the other monomer to bind MepS, perhaps necessitated by the rapid 
turnover rate of MepS [108]. This observed positive cooperativity may not only be to promote 
subsequent interactions with MepS, but to prevent the binding of other MepA interaction 
partners. We speculate that under certain conditions the interaction between MepA and MepS, 
and presumably the coordination of their activity, could be more favourable than that of 
MepA with PBP4 or PBP7. We aim to test whether the interaction between MepA and MepS 
prevents the interaction of MepA with PBP4 and PBP7.  
MepM is the only EPase investigated here to not interact with MepA, but it is possible that in 
the cellular environment MepM is a member of this EPase subcomplex through its interaction 
with MepS. 
We have also characterised the pH dependent EPase activity of MepA. We sought to optimise 
a MepA activity assay similar to that of the other EPases studied in this work. Using the 
standard EPase conditions, i.e. pH 7.5, we observed high activity of MepA on isolated 
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muropeptides, with little to no activity on intact sacculi at high concentrations (20 µM) and 
long incubations (o/n) (figure 5.22). We investigated this using a MepA PG-binding assay in 
comparison to the other hydrolases used in this work. We showed that while the other 
hydrolases bound to PG at pH 7.5, MepA did not. If MepA activity was specific for 
muropeptides rather than high molecular weight material, this could be beneficial for the 
complete degradation of PG in the cell, and contribute to the robustness of the hydrolase 
network. However, we repeated the MepA PG-binding assay at different conditions and 
observed the retention of MepA by PG at pH 5.0. We hypothesised therefore that the binding 
and cleavage of PG by MepA could be pH dependent. Indeed, using the same HPLC-based 
sacculi digestion assay, but at pH 5.0, we observed almost complete digestion of dimeric 
muropeptides in an o/n incubation at 2 µM, and an intermediary digestion after 2 h. The 2 h 
incubation will be used to test the effect of the inactive interaction partners of MepA.  
 
Final word 
The data presented in this section describes three more interactions between the PG 
hydrolases of E. coli, deepening our understanding of how hydrolase activity could be 
coordinated in the cell. We also present the pH dependent activity of MepA, highlighting 
another method of how hydrolase activity could be controlled in E. coli. We speculate that the 
hydrolase redundancy observed in E. coli arises from conditional specificity, with enzymes 
having more or less activity at different intracellular and extracellular conditions. As the pH 
of the periplasm changes in relation to the external conditions [14], having an enzyme with an 
optimal activity at pH 5.0 could ensure correct PG breakdown in situations when other 
enzymes lose their activity. This could become important for example, when colonising the 
gastrointestinal tract, the pH of which varies between 5.5 and 7.5 [246]. A summary of all the 
interactions presented in this work so far is shown in figure 3.28.  
 
 
 
 
  
144 
 
  
 
Figure 3.28 Interactions within a PG synthesis/hydrolysis subcomplex 
Schematic to show the summary of interactions, and effects on activity, described in this work to this point. 
There exists a large number of interactions between the PG hydrolases, PBP4, PBP7, MepA, MepS and MepM 
which are directly or indirectly associated to two components of the PG synthesis complex during elongation, 
LpoA and PBP1A. The numbers are KD values given in nanomolar. Dissociation constant for the interaction 
between MepA and MepS was calculated using the Hill model (EC50).   
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3.5 New Lipoprotein I (NlpI) is a novel regulator of endopeptidases 
3.5.1 Introduction 
A number of papers have published data with respect to the possible functions of New 
Lipoprotein I (NlpI). It has been implicated in the regulation of cell division and the control of 
amidases because of a temperature sensitive filamentation upon deletion [228]; the regulation 
of hypervesiculation through control of PG turnover [230]; and may have a role in the 
mediation of complement-based cell death [247]. Most recently NlpI has been shown to 
regulate the proteolytic degradation of MepS [108]. E. coli possesses ~27 hydrolases that have 
no known regulators of activity. Intuitively therefore, there may be as-of-yet unidentified 
regulators for some of these proteins. In addition to the phenotypes described above, cells 
lacking nlpI are synthetically sick when combined with that of deletions in mrcB and lpoB 
indicating a role in the regulation of cell elongation (Manjula Reddy, unpublished). These 
data, and the recently published material regarding its regulation of the proteolytic 
degradation of MepS, led to our interest in the protein.   
NlpI was comprehensively investigated in this section using in vitro interaction assays to 
identify numerous direct, novel interactions with PG hydrolases. This work also explored the 
in vitro effects of these interactions and highlights the primary role of NlpI as a novel 
regulator of EPases. 
 
3.5.2 NlpI exists as a dimer in solution 
The crystal structure of NlpI predicts the formation of a strong dimer (see figure 1.10) [233]. 
However, we sought to determine the oligomeric state in solution at the conditions used for in 
vitro interaction assays. This would also allow us to infer stoichiometry should we find any 
novel interaction partners. AUC was performed in collaboration with Alexandra Solovyova 
using purified NlpI (section 2.4.9). NlpI was dialysed o/n against 25 mM HEPES/NaOH, 150 
mM NaCl, pH 7.5 and analysed using the absorbance optical system at 20°C to determine the 
sedimentation velocity of NlpI at varying concentrations (0.31, 0.46, 0.6, 0.75, 0.9, 1.05, and 
1.2 mg/ml). Results were corrected for the viscosity/density of H2O at 20°C. Using the amino 
acid sequence and the known crystal structure data, the sedimentation velocity of monomeric 
NlpI was predicted to be 2.83 S with a molecular weight of 30.35 kDa, and the dimer was 
predicted to sediment at 4.16 S with a molecular weight of 60.7 kDa. The size distribution 
plots obtained showed that NlpI exists exclusively as a dimer at these concentrations, with a 
sedimentation velocity of 4.52 S (figure 3.29).  
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Figure 3.29 Analytical ultracentrifugation reveals that NlpI exists as a dimer in solution 
Size distribution plots showing the sedimentation velocity of NlpI. Both the calculated molecular weight and the 
measured molecular weight for NlpI as a monomer or dimer are shown. s20,wS (Sedimentation coefficient 
corrected for the viscosity and density of the solvent, relative to that of water at 20°C) plotted against absorbance 
(280 nM) reveals NlpI exists exclusively as a strong dimer at these conditions. 
 
 
For use in interaction assays, such as MST, the experimental concentrations for proteins of 
interest are in the nanomolar range. We therefore sought to use NlpI in MST to determine the 
dissociation constant of dimer formation (section 2.5.1.7). A concentration of 62.5 nM of FL-
NlpI (at amine residues) was low enough to yield a good fluorescence signal and was 
estimated to be below the KD of dimerisation. Unlabelled NlpI was two-fold serially diluted 
from 30 μM to 0.916 nM, and titrated against the constant concentration of FL-NlpI. 
Normalised fluorescence readings were measured at 40% MST power and 50% LED power 
and the resulting MST binding curve is shown in figure 3.30. The KD of NlpI dimerisation 
was estimated to be 126 ± 9.14 nM using the accompanying software.  
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Figure 3.30 NlpI dimerisation by MST 
MST of FL-NlpI (at amine residues) at a concentration of 62.5 nM titrated with two-fold serially diluted 
unlabelled NlpI from 30 μM - 0.916 nM (40% MST power, 50% LED power). An apparent KD of 126 ± 9.14 nM 
was estimated using accompanying software. The values are the mean ± standard deviation of three independent 
experiments. Raw MST data are shown in figure 5.32. 
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3.5.3 NlpI interacts with PBP4 and stimulates its activity 
3.5.3.1 NlpI interacts with PBP4 in vitro  
NlpI was identified as potentially involved in PG synthesis/hydrolysis regulation through 
genetic studies performed by our collaborators at EMBL, Heidelberg (unpublished). These 
patterns identified NlpI as being associated with PBP1A/LpoA and/or PBP1B/LpoB. These 
findings were further substantiated by our collaborator Manjula Reddy in Hyderabad, India, 
who identified a synthetic sick phenotype when an NlpI deletion was combined with that of 
deletions in PBP1B/LpoB (unpublished). The Typas lab performed affinity chromatography 
using immobilised purified NlpI(sol), incubated with a combined membrane/periplasmic 
fraction from E. coli and identified a number of proteins enriched in comparison to a control 
column. PBP4 was identified as a potential interaction partner of NlpI. Like MepS, PBP4 had 
been implicated as being regulated by NlpI [230]. We therefore sought to test the specificity 
of this interaction with the purified proteins. 
SPR was performed in which NlpI (4 µg/ml) was immobilised to an SPR sensorchip surface 
by general amine coupling (2.5.1.6). PBP4 was applied at varying concentrations (0, 0.25, 0.5, 
1, 2, and 4 µM) as an analyte. The experiment yielded a concentration dependent increase in 
response units (RU) which was plotted against time (figure 3.31A). The equilibrium binding 
state was optimal for KD determination by Scatchard analysis (non-linear regression), in 
which the equilibrium response values (Req) were calculated using the accompanying software 
and plotted against analyte concentration. We estimated a KD of 310 ± 46 nM (figure 3.31B). 
A negative control lane was activated without immobilisation of NlpI.  
To test the interaction by another method, we performed MST (section 2.5.1.7). NlpI was 
fluorescently-labelled at amine residues and optimised to a concentration of 62.5 nM. 
Unlabelled PBP4 was two-fold serially diluted from 50 μM to 1.53 nM and titrated with FL-
NlpI. The binding curve generated an estimated KD of 177 ± 48.8 nM using the accompanying 
software (figure 3.31C).  
An in vitro Ni2+ bead cross-linking pull-down assay was performed in which His-NlpI and 
native PBP4 were incubated with Ni2+ beads before washing and elution (section 2.5.1.5). An 
applied sample was taken prior to bead incubation and compared to a sample taken after 
elution of retained proteins. Native PBP4 was only retained in the presence of His-NlpI 
(figure 3.31D).  
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Figure 3.31 NlpI interacts with PBP4 in vitro 
A. SPR sensorgrams of NlpI immobilised by general amine coupling, applied with varying concentrations of 
PBP4 in comparison to a surface activated without immobilisation of protein. B. Equilibration response (Req) 
values were obtained and plotted against analyte concentration for Scratchard analysis by non-linear regression. 
A KD of 310 ± 46 nM was estimated. C. MST of FL-NlpI (at amine residues) at a concentration of 62.5 nM was 
titrated with two-fold serially diluted PBP4 from 50 µM – 1.53 nM (20% MST power, 40% LED power). An 
apparent KD of 177 ± 49 nM was estimated using the accompanying software. The values are the mean ± 
standard deviation of three independent experiments. Raw MST data are shown in figure 5.33. D. In vitro Ni2+ 
bead pull-down assay using His-NlpI and native PBP4. An applied sample (A) was taken prior to incubation of 
cross-linked proteins with Ni2+ beads. After thorough washing and elution of bound proteins by boiling with 
SDS-loading buffer (E) proteins were separated by 12% SDS-PAGE and visualised by Coomassie staining. 
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3.5.3.2 NlpI stimulates the endopeptidase activity of PBP4 
The interaction characterised here could highlight NlpI as a novel regulator of hydrolase 
activity. Further, through this interaction with PBP4, NlpI could be linked to the multi-
enzyme PG-synthesising complex during cell elongation.  
To address our hypothesis of hydrolase regulation we investigated the effect of NlpI on PBP4 
activity using the EPase assay already established in this work. Intact MC1061 sacculi were 
incubated with 1 µM PBP4 in the presence and absence of 2 µM NlpI for 2 hours at 37°C 
with shaking (section 2.5.2.2). The reaction was stopped by boiling and centrifuged to obtain 
the released muropeptide-containing supernatant. Released muropeptides were reduced and 
analysed by reversed-phase HPLC (section 2.5.2.5). We show that in the presence of NlpI, the 
hydrolytic EPase activity of PBP4 is stimulated, cleaving virtually all TetraTetra dimers to 
Tetra monomers (figure 3.32). PBP4 alone reduced the percentage of dimeric muropeptides 
from 44.4% to 16.3%, but in the presence of NlpI, PBP4 cleaves virtually all dimeric 
muropeptides to yield a relative percentage of 0.52%. 
  
Figure 3.32 NlpI stimulates the endopeptidase activity of PBP4 on sacculi 
HPLC-based PBP4 sacculi digestion assay. Isolated sacculi from the E. coli WT strain, MC1061, were incubated 
with 1 µM PBP4 for 2 hours with shaking at 37°C either alone or in the presence of 2 µM NlpI. The reaction was 
stopped by boiling and the released muropeptides were obtained by centrifugation, reduced with sodium 
borohydride and analysed by reversed-phase HPLC. HPLC chromatograms are shown in figure 5.34. The values 
are the mean ± standard deviation of three independent experiments. 
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3.5.3.3 Domain 3 of PBP4 is likely the NlpI interaction site 
We sought to use the truncated version of PBP4, PBP4ΔD3, to elucidate potential binding 
sites. Our previous hypothesis was that a potential regulator of PBP4 activity would interact 
with domain 3, the domain seemingly crucial for both EPase and CPase activity. We therefore 
carried out a Ni2+ bead cross-linking pull-down assay using His-PBP4ΔD3 and an untagged 
version of NlpI (section 2.5.1.5). After thorough washing and elution of retained proteins, and 
comparison of the applied and elution samples, we showed that His-PBP4ΔD3 did not retain 
native NlpI, indicating that the proteins do not interact (figure 3.33A).  
We continued by showing that domain 3 of PBP4 is a major interaction site for NlpI using 
MST (section 2.5.1.7). FL-NlpI was used at a concentration of 62.5 nM and was titrated with 
two-fold serially diluted PBP4ΔD3 from a concentration of 10 µM to 0.31 nM (figure 3.33B). 
The absence of a concentration-dependent change in normalised fluorescence (FNorm) was 
indicative of the absence of an interaction. In section 3.3.5 we showed that domain 3 was not 
required for the interaction between PBP1A and LpoA, however, domain 3 seems to be 
crucial for the interaction with NlpI. 
 
 
Figure 3.33 Domain 3 of PBP4 is required for interaction with NlpI 
A. In vitro Ni2+ bead pull-down assay using His-PBP4ΔD3 and native NlpI. After an o/n incubation with Ni2+ 
beads, His-PBP4ΔD3 was unable to retain untagged NlpI. B. MST measurement of FL-NlpI (at amine residues) 
at a concentration of 62.5 nM titrated with serially diluted unlabelled PBP4ΔD3 from a concentration of 10 µM – 
0.31 nM (20% LED power and 40% MST power). Raw MST data are shown in figure 5.35. 
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3.5.3.4 NlpI can interact with PBP4 in the presence of PBP1A/LpoA  
In this work, we have identified five novel PBP4 interaction partners; LpoA, PBP1A, PBP7, 
MepA and NlpI. Here we tested the possibility that PBP4 may possess multiple binding sites 
for its interaction partners with particular interest in NlpI, the regulator of its hydrolytic 
activity, and PBP1A and LpoA which we hypothesise act to recruit PBP4 to sites of ongoing 
PG synthesis. As shown in previous sections we predicted that domain 3 of PBP4 is the main 
interaction site of NlpI, and domain 1 and/or 2 the likely interaction site for PBP1A and 
LpoA. We therefore hypothesised that the presence of NlpI should not prevent the binding of 
PBP4 to PBP1A. The standard MST protocol was modified such that an unlabelled ligand 
was not titrated with the fluorescently-labelled protein, but an appropriate concentration 
chosen that would reach the ‘bound state’ upon application, as determined using the standard 
MST protocol. A third protein that interacted with the unlabelled protein, but not the 
fluorescently-labelled protein, was pre-incubated in excess with the unlabelled ligand, prior to 
addition to the fluorescently-labelled protein. We predicted this pre-incubation would saturate 
all potential binding sites and would allow us to measure the formation of multi-protein 
complexes and provide insight into interaction sites, shared or otherwise. Using this protocol, 
PBP4 (0.5 µM) was applied to FL-PBP1A (at amine residues) at a concentration of 20.8 nM, 
and we observed an increase in FNorm, indicative of an interaction (figure 3.34A). We show 
in figure 3.48 that NlpI was capable of interacting with PBP1A (discussed in more detail in 
section 3.5.9), we therefore used a concentration of NlpI lower than that of the KD of 
interaction with PBP1A, but in excess of PBP4. As such, we observed no interaction upon 
application of 1 µM NlpI. NlpI was incubated with PBP4 at the same concentrations as used 
individually to block the NlpI binding sites of PBP4. Upon application of this mixture, the 
increase in FNorm was the same as that of PBP4 alone, indicating the presence of NlpI did 
not disrupt the interaction of PBP1A with PBP4.  
The experiment was repeated in the same way using FL-LpoA. Using the regular MST 
protocol we observed no interaction between FL-LpoA and NlpI (figure 3.45A discussed in 
more detail in section 3.5.9) and we reproduced this using FL-LpoA (166 nM) (at cysteine 
residues) and 30 µM NlpI (figure 3.35A). The interaction observed previously between FL-
LpoA and PBP4 yielded a concentration-dependent fluorescence enhancement (figure 3.10B). 
In the presence of 5 µM PBP4, the fluorescence signal is enhanced, indicative of an 
interaction (figure 3.35A). PBP4, in the presence of excess NlpI, caused the same 
fluorescence enhancement observed for that of PBP4 alone. These data indicate that the 
presence of NlpI does not prevent the interaction of PBP4 with LpoA. 
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Figure 3.34 PBP4 possesses different interaction sites for PBP1A and NlpI  
A. End-point normalised fluorescence (FNorm) showing the presence of NlpI does not prevent binding of PBP4 
to PBP1A. The MST of FL-PBP1A (20.8 nM) was measured either alone, or in the presence of PBP4 (0.5 µM) 
or NlpI (1 µM). The same concentrations were used to pre-incubate NlpI with PBP4, before addition to FL-
MepS. MST measurements were carried out with 80% LED power, 40% MST power. The values are the mean ± 
the standard deviation of three independent experiments. B. MST time traces of the experiments shown in A. 
The values are the mean of three independent experiments. 
 
 
Figure 3.35 PBP4 possesses different interaction sites for LpoA and NlpI  
A. Raw fluorescence values showing the presence of NlpI does not prevent binding of PBP4 to LpoA. MST 
measurements were taken of FL-LpoA (166 nM) alone, or in the presence of PBP4 (5 µM) or NlpI (30 µM). The 
same concentrations were used to pre-incubate NlpI with PBP4, before addition to FL-LpoA. MST 
measurements were carried out with 100% LED power, 20% MST power. The values are the mean ± the 
standard deviation of three independent experiments B. Pre-experiment capillary scans of A.  
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3.5.4 Interaction of NlpI with PBP7 
3.5.4.1 NlpI interacts with PBP7 in vitro 
Having confirmed the in vitro interaction of NlpI with PBP4, we hypothesised that NlpI may 
interact with other EPases. PBP7, one of the other Class C PBP hydrolases, was tested for 
interaction. Our initial hypothesis was that NlpI could be a global regulator of EPases. PBP7 
was also identified as a potential interaction partner by affinity chromatography by Manuel 
Banzhaf, Heidelberg (unpublished). 
His-PBP7 was purified by Hamish Yau from the Vollmer group and a Ni2+ bead cross-linking 
pull-down assay was performed using a tagless form of NlpI (section 2.5.1.5). We show that 
NlpI is only retained by Ni2+ beads in the presence of His-PBP7 (figure 3.36A).  
We continued by testing this interaction using MST. NlpI was fluorescently-labelled at amine 
residues and used at a concentration of 62.5 nM. Unlabelled PBP7 was two-fold serially 
diluted from 30 µM to 0.916 nM and titrated with FL-NlpI. The binding curve generated did 
not correspond to an equilibrium binding event. Instead, the Hill model was applied to 
determine an EC50 of 422 ± 25 nM (figure 3.36B). The Hill model also generated an estimated 
Hill coefficient of 3.06, implying positive cooperativity.  
Interestingly, when we analysed the same interaction using unlabelled NlpI and FL-PBP7, the 
MST measurements generated a standard equilibrium binding curve which yielded an 
estimated KD of 90 ± 8.9 nM (figure 3.36C). In this instance, FL-PBP7 was used at a 
concentration of 62.5 nM and was titrated with two-fold serially diluted NlpI from a 
concentration of 10 µM to 0.31 nM.  
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Figure 3.36 NlpI interacts with PBP7 in vitro 
A. In vitro Ni2+ bead pull-down assay using His-PBP7 and native NlpI. After an o/n incubation with Ni2+ beads, 
His-PBP7 was able to retain native NlpI. B. MST measurement of FL-NlpI (at amine residues) at a concentration 
of 62.5 nM and serially diluted unlabelled PBP7 from a concentration of 30 µM – 0.916 nM (50% LED power 
and 10% MST power). The Hill model was applied and an apparent EC50 of 422 ± 25 nM was estimated using 
accompanying software. A Hill coefficient of 3.06 was determined, implying positive cooperativity. Raw MST 
data are shown in figure 5.36. C. MST measurement of FL-PBP7 (at amine residues) at a concentration of 62.5 
nM titrated with serially diluted unlabelled NlpI from a concentration of 10 µM – 0.31 nM (40% LED power and 
20% MST power). An apparent KD of 90 ± 8.9 nM was estimated using accompanying software. Raw MST data 
are shown in figure 5.37. The values for each MST graph are the mean ± standard deviation of three independent 
experiments. 
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3.5.4.2 NlpI has no effect on PBP7 activity 
In section 3.5.3.2 we show a stimulatory effect of NlpI on PBP4. We therefore tested the 
effect of NlpI on the EPase activity of PBP7, to determine whether there is a broader role of 
NlpI in hydrolase regulation. 
An EPase assay was performed using muropeptides from the MC1061 strain (section 2.5.2.2). 
Muropeptides were incubated with 2 µM PBP7 and/or 4 µM NlpI for 4 h at 37°C with 
shaking, before stopping the reaction by boiling. Reactions were carried out in standard EPase 
reaction buffer (10 mM HEPES/NaOH, 10 mM MgCl2, 150 mM NaCl, 0.05% Triton X-100, 
pH 7.5). Muropeptides were reduced with sodium borohydride and analysed by HPLC 
(section 2.5.2.5). The Tetra-containing muropeptides were integrated and the relative amount 
of TetraTetra dimers was calculated as a percentage of the total amount of Tetra-containing 
muropeptides. There was no effect of NlpI on the EPase activity of PBP7 (figure 3.37). We 
also performed the reaction at four different conditions, including low/high salt and pH, and 
observed no effect of NlpI (figure 5.29). PBP7 activity was highest at 150 mM NaCl at pH 7.5 
with activity affected at lower pH and higher NaCl concentration, but in all cases the presence 
of NlpI had no effect on the percentage of TetraTetra dimers.   
 
Figure 3.37 NlpI has no effect on the endopeptidase activity of PBP7  
Isolated muropeptides from the WT E. coli strain MC1061 were incubated with PBP7 (2 µM) and/or NlpI (4 
µM) for 4 hours at 37°C with shaking prior to stopping the reaction by boiling, reduction of muropeptides with 
sodium borohydride and analysis by HPLC. Peaks corresponding to the Tetra monomer and TetraTetra dimer 
muropeptides were integrated using the accompanying Laura software. The relative percentage of TetraTetra- 
containing muropeptides was plotted as a representation of EPase activity. The values are the mean ± standard 
deviation of three independent experiments.   
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3.5.5 Interaction of NlpI and MepS 
3.5.5.1 NlpI interacts with MepS in vitro 
The deletion of nlpI causes a hypervesiculation phenotype, which is suppressed when 
combined with a deletion in mepS [230]. A recent paper from the group of our collaborator 
Manjula Reddy, Hyderabad, shows that NlpI facilitates the proteolytic degradation of MepS 
[108]. However, these proteins may be functionally linked. As-of-yet there have been no data 
characterising the direct interaction between the two proteins, and we therefore sought to test 
the interaction in vitro. We hypothesised that NlpI may interact or regulate the activity of 
more than the just the Class C PBP hydrolases PBP4 and PBP7.  
Using the established in vitro Ni2+ bead cross-link pull-down assay (section 2.5.1.5), we 
showed that His-MepS retained native NlpI after incubation with Ni2+ beads and thorough 
washing (figure 3.38A). Native NlpI alone was not retained. 
MST was performed to confirm this in vitro interaction and to estimate a dissociation constant 
(section 2.5.1.7). MepS was fluorescently-labelled (at amine residues) and used at a 
concentration of 62.5 nM. Unlabelled NlpI was two-fold serially diluted from 50 µM to 1.53 
nM and titrated with FL-MepS. The binding curve yielded an apparent KD of 145 ± 51.6 nM 
using the accompanying software (figure 3.38B). 
 
 
Figure 3.38 NlpI interacts with MepS in vitro 
A. In vitro Ni2+ bead pull-down assay using His-MepS and native NlpI. After o/n incubation with Ni2+ beads and 
thorough washing, His-MepS retained native NlpI. B. MST measurement of FL-MepS (at amine residues) at a 
concentration of 62.5 nM titrated with serially diluted unlabelled NlpI from a concentration of 50 µM – 1.53 nM 
(20% LED power and 40% MST power). An apparent KD of 145 ± 51.6 nM was estimated using accompanying 
software. The values are the mean ± standard deviation of three independent experiments. Raw MST data are 
shown in figure 5.38. 
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3.5.5.2 MST saturation test of MepS and NlpI 
We attempted to determine the stoichiometry of this interaction using a modified version of 
the MST protocol. MepS exists as a monomer [131] and we show in this work that NlpI has a 
dissociation constant for dimerisation of 126 nM (figure 3.31). We used a higher 
concentration of FL-MepS than the standard MST protocol and a narrow, linear range of 
unlabelled NlpI, to observe saturation of FL-MepS and thus infer stoichiometry. FL-MepS 
was used at a constant concentration of 125 nM and was titrated with a linear concentration 
gradient of unlabelled NlpI from 0 – 300 nM. This concentration range allowed for saturation 
in 1:1 and 1:2 ratios.  
The saturation curve is shown in figure 3.39 in which the TJump data was chosen for analysis 
as this gave the clearest saturation point. The increase in TJump value correlates with the 
increasing concentrations of NlpI until saturation of FL-MepS was achieved. Using Microsoft 
Excel, the gradient of the exponential TJump phase and the saturation plateau was calculated. 
Using the values generated we calculated the NlpI concentration which saturates 125 nM FL-
MepS as 197.3 nM, which corresponds to a ratio of 1:1.6.  
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Figure 3.39 Saturation of MepS with NlpI by MST 
A constant concentration of 125 nM FL-MepS (at amine residues) was mixed with a narrow, linear range of 
unlabelled NlpI (0 – 300 nM). The initial TJump from the MST analysis and Microsoft Excel were used to 
determine the concentration at which NlpI saturates 125 nM of FL-MepS. MST measurements taken at 40% 
LED power and 20% MST power. The values are the mean ± standard deviation of three independent 
experiments.   
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3.5.5.3 NlpI activates MepS on muropeptides 
Having obtained the first evidence of a direct interaction between NlpI and MepS, we sought 
to test the effect of NlpI on MepS activity using intact sacculi. MepS is only weakly active 
against isolated muropeptides, even at high concentrations (5 µM) and long incubations (o/n) 
[129]. The NMR structure of MepS shows a structurally closed active site, which may 
occlude ready access of substrate [131]. We hypothesised that NlpI may activate MepS by 
causing a conformational change and cause the active site to open.  
To study the effect of NlpI on MepS activity, we performed a sacculi-based EPase assay. 
MepS was incubated at a concentration of 5 μM in the presence or absence of 10 μM NlpI, 
o/n at 37°C with shaking, in standard EPase reaction buffer (section 2.5.2.2). The reaction 
was stopped by boiling and the sample was subjected to cellosyl digestion. Samples were 
centrifuged and the muropeptide-containing supernatant was retained and reduced with 
sodium borohydride for HPLC analysis (2.5.2.5). The relative percentage of TetraTetra-
containing muropeptides was calculated from the total amount of Tetra-containing 
muropeptides and plotted. Even at these high concentrations and long incubation time, no 
activity was observed of MepS alone or in the presence of NlpI (figure 5.39). This assay was 
completed at four different conditions including high and low NaCl (300 mM and 150 mM) 
and pH (pH 7.5 and pH 5.0) with no activity observed (figure 5.39).  
We performed the same assay using isolated muropeptides from the MC1061 WT strain in 
which MepS, with and without NlpI, was incubated at the same concentrations and conditions 
as above. The relative percentage of TetraTetra-containing muropeptides was calculated as 
before. Figure 3.40 shows the results of this assay using the standard EPase buffer (25 mM 
HEPES/NaOH, 150 mM NaCl, 0.05% Triton X-100, pH 7.5). Figure 5.30 shows the assay 
performed at four different conditions. We again did not detect any activity of MepS alone at 
any of the four conditions tested, which is contrary to the published data which show MepS to 
be active after an o/n incubation with muropeptides [129]. However, in the presence of NlpI, 
MepS was activated. MepS alone did not significantly reduce the percentage of muropeptides 
in cross-links, remaining at 42.6%. However, in the presence of NlpI, the percentage of 
TetraTetra dimers was 16.8%. We show that NlpI activated MepS EPase activity at three of 
the conditions tested (figure 5.30). MepS remained inactive at low pH and high salt. At 150 
mM NaCl and pH 7.5 the stimulation of activity was most drastic and is shown in figure 3.40. 
These data provide evidence for a functional interaction between NlpI and MepS, and is 
further evidence of NlpI being a regulator of EPases.  
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Figure 3.40 NlpI activates MepS on muropeptides 
Isolated muropeptides from the cellosyl digestion of the WT E. coli strain, MC1061, were incubated o/n at 37°C 
with 5 μM MepS alone or in the presence of 10 μM NlpI (standard EPase reaction buffer was used here; 25 mM 
HEPES/NaOH, 150 mM NaCl, 0.05% Triton X-100, pH 7.5). Samples were inactivated by boiling and 
centrifuged. The digested muropeptides were reduced with sodium borohydride and analysed by HPLC. The 
relative amounts of TetraTetra dimer were calculated as a percentage of the total number of Tetra-containing 
muropeptides. The values are the mean ± standard deviation of three independent experiments. Raw HPLC 
chromatograms are shown in figure 5.40. 
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3.5.5.4 Deletion of mepS suppresses a ΔnlpI phenotype 
To investigate the relationship between NlpI and MepS in vivo, we analysed the growth 
curves of single or double deletions in both genes, in the presence of various concentrations of 
the β-lactam, imipenem. Briefly, as it will be discussed in section 3.6, we showed that NlpI is 
crucial for induction of β-lactamase in response to imipenem. This could be consistent with a 
role of NlpI in regulating the EPases and/or lytic transglycosylases, whose hydrolytic 
products are crucial for the induction of the AmpC β-lactamase (section 1.6).  
BW27783 cells lacking NlpI, MepS or both, provided by the Reddy lab, were grown to an 
OD578 of 0.2 in LB media before inoculation with varying concentrations of imipenem (0, 0.5, 
1, 3 and 5 µg/ml). Growth was monitored using a spectrophotometer (578 nm) every 30 min 
for 4 h and plotted against time (min). A deletion in MepS had little effect on cell growth 
(figure 3.41A) in comparison to WT (figure 5.41). However, growth of cells lacking NlpI was 
impaired, most drastically with 1 µg/ml imipenem (figure 3.41B). In an nlpI-mepS- strain, the 
nlpI- phenotype was supressed and the cells were no longer susceptible to the antibiotic 
(figure 3.41C). 
We performed a β-lactamase induction assay using the same deletion strains in comparison to 
WT (section 2.6.1). The same strains used for the aforementioned growth curves were 
cultivated to an OD578 of 0.5-0.6. Equal volumes of these strains were added to tubes 
containing the same volume of fresh, pre-warmed LB containing 1 µg/ml of imipenem. In 
parallel, cells were also added to fresh LB containing no antibiotic. Samples were incubated 
for a further 30 min before being placed on ice. Cells were harvested by centrifugation and 
washed with sodium phosphate buffer, before being centrifuged again. Cell pellets were 
resuspended in 1 ml of sodium phosphate buffer and 50 µl of the cell suspension was lysed by 
osmotic shock. After centrifugation and retention of the supernatant, the protein concentration 
of the lysate was estimated using a BCA kit (section 2.2.3). The lysate was then tested for its 
ability to hydrolyse the chromogenic β-lactam nitrocefin, using a spectrophotometer. Pure β-
lactamase from P. aeruginosa, Vim4, was used to determine maximal hydrolytic activity. The 
rate of nitrocefin hydrolysed per min per mg of protein was calculated and β-lactamase 
induction was expressed as the fold difference over the control, containing no imipenem. The 
deletion of mepS had no effect on the induction of β-lactamase in response to imipenem and 
cells lacking NlpI were incapable of inducing a response (figure 3.41D). However, cells with 
deletions in both nlpI and mepS showed no impaired β-lactamase induction, correlating with 
the growth curve experiments.  
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Figure 3.41 Deletion of mepS rescues ΔnlpI phenotypes 
BW27783 strains lacking mepS (A), nlpI (B) or both (C) were grown to an OD578 of 0.2 before inoculation with 
varying concentrations of imipenem (0, 0.5, 1, 3, 5 µg/ml). Growth was measured using a spectrophotometer 
every 30 min for 4 hours. BW27783 WT growth curves shown in figure 5.41. D. β-lactamase induction assay of 
the same strains transformed with the ampR/ampC operon-containing plasmid, pJP1. Fold difference calculated 
against a control not subjected to imipenem stress. The values are the mean ± standard deviation of three 
independent experiments.   
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3.5.6 Interaction of NlpI and MepM 
3.5.6.1 NlpI interacts with MepM in vitro 
We have identified interactions between NlpI and three EPases. Two EPases belong to the 
Class C group of PBPs, PBP4 and PBP7, and the other belonging to the NlpC/P60 family of 
peptidases, MepS. The latter also belongs to a group of recently identified redundantly 
essential EPases for cell elongation, together with MepM and MepH. Unfortunately, we have 
been unable to purify MepH. However, we were able to purify MepM, belonging to the M23 
LytM family of metallopeptidases, to homogeneity and test for an interaction with NlpI.   
His-MepM was purified by a past member of the Vollmer group, Astrid Schwaiger (section 
2.4.7). An in vitro cross-linking pull-down assay was performed using His-MepM and native 
NlpI (section 2.5.1.5). NlpI was only retained in the presence of His-MepM, indicative of an 
interaction (figure 3.42A). 
We confirmed this in vitro interaction using MST in which 125 nM of FL-NlpI (at amine 
residues) was titrated with two-fold serially diluted MepM from 30 µM to 0.915 nM (figure 
3.42B). The binding of MepM caused a concentration-dependent fluorescence enhancement 
which was confirmed as due to ligand binding using an SD test (figure 5.42). The raw 
fluorescence data was used to generate a binding curve which yielded an apparent KD of 152 
± 42.1 nM.  
 
Figure 3.42 NlpI interacts with MepM in vitro 
A. In vitro Ni2+ bead pull-down assay using His-MepM and native NlpI. After o/n incubation with Ni2+ beads, 
His-MepM is able to retain native NlpI. Proteins were separated by 12% SDS-PAGE and visualised by 
coomassie staining. B. Raw fluorescence measurement of FL-NlpI (at amine residues) at a concentration of 125 
nM and serially diluted unlabelled MepM from a concentration of 30 µM – 0.915 nM (100% LED power and 
20% MST power). An apparent KD of 152 ± 42.1 nM was estimated using accompanying software. The values 
are the mean ± standard deviation of three independent experiments. Raw MST data are shown in figure 5.42. 
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3.5.6.2 NlpI inhibits the endopeptidase activity of MepM 
To determine whether NlpI was a regulator of MepM EPase activity, a HPLC-based sacculi 
digestion assay was performed (2.5.2.2). Purified sacculi from the WT E. coli strain MC1061 
were incubated with 2 μM MepM in the presence and absence of 4 μM NlpI for 4 hours with 
shaking at 37°C. Standard EPase reaction buffer was used (25 mM HEPES/NaOH, 150 mM 
NaCl, 0.05% Triton X-100, pH 7.5). The reaction was stopped by boiling and samples were 
centrifuged to collect the released muropeptide-containing supernatant. Muropeptides were 
reduced with sodium borohydride and analysed by HPLC (section 2.5.2.5). The relative 
percentage of TetraTetra-containing muropeptides was calculated from the total amount of 
Tetra-containing peptides and plotted (figure 3.43). 
NlpI had an inhibitory effect on the EPase activity of MepM (figure 3.43). MepM alone 
reduced the relative percentage of dimeric muropeptides from 43.6% to 22.2%. In the 
presence of NlpI, MepM only reduced the percentage of dimeric muropeptides to 36.4%. We 
show that like PBP7 and MepS, the degree of activity was dependent on which conditions 
were applied (figure 5.31). However, MepM was active at each condition, and its activity was 
inhibited in the presence of excess NlpI.  
 
Figure 3.43 MepM endopeptidase activity is inhibited in the presence of NlpI 
MepM was incubated with isolated intact sacculi from the WT strain, MC1061, at a concentration of 2 µM alone 
or in the presence of 4 µM NlpI for 4 hours at 37°C. Samples were inactivated by boiling and centrifuged to 
obtain released muropeptides. Muropeptides were reduced with sodium borohydride and analysed by HPLC. The 
relative amount of TetraTetra dimers were plotted as a percentage of the total number of Tetra-containing 
muropeptides. The values are the mean ± standard deviation of three independent experiments. See figure 5.43 
for raw HPLC chromatograms. 
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3.5.7 Interaction of NlpI and MepA 
3.5.7.1 The interaction of NlpI and MepA is pH dependent 
In section 3.4 we showed that MepA has a pH dependent EPase activity and substrate 
binding. At pH 7.5 MepA does not bind intact PG and exerts no EPase activity, whereas at pH 
5.0, it is capable of both. The interaction between NlpI and MepA was firstly tested at pH 7.5. 
FL-MepA (at cysteine residues) was used at a concentration of 125 nM and was titrated with 
two-fold serially diluted unlabelled NlpI from 30 µM to 0.916 nM. The MST experiment 
showed no interaction (figure 3.44B). 
We therefore reasoned that some interactions of MepA may also be pH dependent. The MST 
experiment was repeated, however, both the unlabelled NlpI and FL-MepA were diluted 
against pH 5.0 buffer (10 mM NaAcetate/Acetic acid, 150 mM NaCl, 0.05% Triton X-100, 
pH 5.0). Measurements were taken at the same conditions as previously and an interaction 
was observed, generating a binding curve that was used to generate an estimated KD of 140 ± 
21.9 nM (figure 3.44). The experiment was repeated using the same stock of unlabelled NlpI 
and FL-MepA, diluted in pH 7.5 buffer, and again no interaction was observed.  
 
Figure 3.44 Interaction between NlpI and MepA is pH dependent 
A. MST measurement of FL-MepA (at cysteine residues) at a concentration of 125 nM titrated with serially 
diluted unlabelled NlpI from a concentration of 30 µM – 0.916 nM (60% LED power and 40% MST power). 
Unlabelled NlpI and FL-MepA were diluted into pH 5.0 MST buffer. An apparent KD of 140 ± 21.9 nM was 
estimated using accompanying software. The values are the mean ± standard deviation of three independent 
experiments. B. MST measurement of FL-MepA (at cysteine residues) at a concentration of 125 nM titrated with 
serially diluted unlabelled NlpI from a concentration of 30 µM – 0.916 nM (60% LED power and 40% MST 
power). Unlabelled NlpI and FL-MepA were diluted into pH 7.5 MST buffer. Raw MST data are shown in 
figures 5.44 and 5.45. 
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3.5.7.2 NlpI has no effect on MepA activity at pH 5.0 
As the activity of MepA and the interaction between MepA and NlpI are both pH dependent, 
we performed an activity assay, as described in section 2.5.2.2, using pH 5.0 EPase reaction 
buffer. Section 3.4.4 shows the optimisation of the MepA EPase assay on intact sacculi. 
MepA was incubated with D456 sacculi at 2 µM, with and without 4 µM NlpI, for 2 h at 
37°C. The reaction was stopped by boiling with 20 mM EDTA and digested with cellosyl o/n. 
The sample was boiled again and centrifuged. The released muropeptide-containing 
supernatant was retained and analysed by reversed-phase HPLC and the total number of 
muropeptides in dimers were calculated (section 2.5.2.5). We show in figure 3.45 that NlpI 
had no effect on the activity of MepA at pH 5.0. 
 
 
Figure 3.45 NlpI has no effect on the activity of MepA at pH 5.0 
MepA was incubated with D456 sacculi at a concentration of 2µM in the presence or absence of 4 µM NlpI. 
Samples were incubated for 2 h at 37°C before stopping the reaction by boiling with 20 mM EDTA. Samples 
were digested o/n with cellosyl and boiled again. Released muropeptides were obtained by centrifugation, 
reduced with sodium borohydride and analysed by reversed-phase HPLC. D456 sacculi contain Tetra and Penta 
monomers as well as TetraTetra and TetraPenta dimers. The relative percentage of dimeric muropeptides was 
calculated and plotted. The values are the mean ± standard deviation of three independent experiments. Raw 
HPLC chromatograms are shown in figure 5.46. 
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3.5.8 NlpI has multiple EPase interaction sites  
NlpI has been shown to interact with five enzymes with EPase activity; PBP4, PBP7, MepA, 
MepM, and MepS, which themselves are connected by multiple direct and indirect 
interactions. We questioned whether NlpI would preferentially interact with a particular 
EPase in the presence of another, or if NlpI had different interaction sites for each EPase. We 
sought to test these hypotheses by challenging interactions with the presence of other 
interaction partners using modified MST (described in section 3.5.3.4) and Ni2+ bead pull-
down assays. We used these methods to test if NlpI could interact with more than one EPase 
simultaneously. 
 
NlpI, MepS and PBP4 
FL-MepS (at amine residues) was used at a concentration of 62.5 nM and was tested for 
interaction using 3 µM NlpI, a concentration within the bound state for the interaction (figure 
3.38B). An increase in the FNorm was indicative of an interaction with MepS (figure 3.46A). 
PBP4 has been shown not to interact with MepS by MST but interacts with NlpI with an 
apparent KD of 177 ± 49 nM (figure 3.31C). Here, the addition of PBP4 (30 µM) to FL-MepS 
did not produce a change in FNorm significant enough to indicate an interaction. NlpI was 
mixed with 30 µM PBP4, which we predicted would saturate all PBP4 binding sites of NlpI. 
The mixture was then added to FL-MepS and the FNorm recorded. An increase in FNorm was 
observed indicative of an interaction, and was significantly larger than that of NlpI alone. 
These data indicate that the presence of excess PBP4 did not prevent the binding of NlpI to 
FL-MepS and that a larger complex formed that slowed the thermophoretic movement of FL-
MepS (figure 3.46B). As a control, we showed that 12 µM of BSA did not incur the same 
thermophoretic effect as excess PBP4 indicating that the ternary complex formed between 
MepS, NlpI and PBP4 was specific. 
These MST data were verified using an in vitro Ni2+ bead pull-down assay with His-MepS 
and untagged forms of NlpI and PBP4. Figure 3.46C shows that His-MepS retained both NlpI 
and PBP4 individually, but also retained both proteins simultaneously.  
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Figure 3.46 NlpI, MepS and PBP4 form a ternary complex 
A. End-point normalised fluorescence (FNorm) showing the ternary complex of MepS, NlpI and PBP4. FL-MepS 
(62.5 nM) was measured either alone, or in the presence of NlpI (3 µM) or excess PBP4 (30 µM). The same 
concentrations were then used to pre-incubate NlpI with PBP4 before addition to FL-MepS. MST measurements 
were carried out with 20% LED power and 40% MST power. The values are the mean ± the standard deviation of 
three independent experiments. B. MST time traces of the experiments shown in A. The values are the mean of 
three independent experiments. C. An in vitro Ni2+ bead pull-down assay was used to show that His-MepS was 
able to retain both NlpI and PBP4 individually and at the same time. All proteins were used at 2 µM. A, applied 
sample taken prior to addition to beads; E, elution sample of bound proteins after washing. Proteins were 
separated by 12% SDS-PAGE and visualised by Coomassie-staining.  
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NlpI, MepS and PBP7 
We used the same modified MST protocol to test the potential trimeric complex formation of 
MepS, NlpI and PBP7. FL-MepS and unlabelled NlpI were used at the same concentration as 
above; however, unlabelled NlpI was pre-incubated with unlabelled PBP7 (30 µM) prior to 
addition to FL-MepS, instead of PBP4.  
The addition of NlpI (3 µM) to FL-MepS again caused a significant change in FNorm, 
indicative of an interaction (figure 3.47A). We observed no significant change upon the 
addition of PBP7 (30 µM), consistent with the regular MST protocol which showed that these 
proteins do not interact (figure 3.15A). Upon addition of NlpI saturated with PBP7, the 
observed change in FNorm was the same as with NlpI alone, showing that the presence of 
PBP7 bound to NlpI did not prevent the binding of NlpI to MepS (figure 3.47A/B).  
 
 
Figure 3.47 NlpI possesses different interaction sites for MepS and PBP7 
A. End-point normalised fluorescence (FNorm) showing the presence of PBP7 does not prevent binding of NlpI 
to MepS. FL-MepS (62.5 nM) was measured either alone, or in the presence of NlpI (3 µM) or excess PBP4 (30 
µM). The same concentrations were then used to pre-incubate NlpI with PBP7, before addition to FL-MepS. 
MST measurements were carried out with 20% LED power and 40% MST power. The values are the mean ± the 
standard deviation of three independent experiments. B. MST time traces of the experiments shown in A. The 
values are the mean of three independent experiments. 
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Larger complexes involving NlpI 
Described and observed in this work are the interaction of NlpI with at least five EPases 
(PBP4, PBP7, MepS, MepM and MepA). In addition, work undertaken by Hamish Yau from 
the Vollmer group identified the interactions of Slt with four of the same EPases as NlpI 
(PBP4, PBP7, MepS and MepM) (Unpublished). Investigations are underway into the ability 
of NlpI and Slt to interact with their shared EPases in the presence of the other protein to 
determine preferential or competitive binding.  
Using the Ni2+ bead pull-down assay, larger complexes than previously tested were attempted 
to observe direct or indirect interactions. Here, a five protein complex was tested using four 
unlabelled proteins, NlpI, PBP4, PBP7 and Slt, and one His-tagged, MepS. 
Figure 3.48 shows that His-MepS was able to pull down NlpI, PBP4 and Slt. As there are 
shared interactions between all four of these proteins, we cannot say that MepS is interacting 
with all of these proteins simultaneously, but these data do infer that a large complex between 
these proteins is occurring in vitro. Large complexes, such as this have not been regularly 
observed, and this technique could be important for proteins with multiple direct or indirect 
interaction partners. For example, in this situation, PBP7 is not retained. More controls will 
need to be undertaken to determine whether PBP7 can be retained whilst one of the other 
proteins is not present and this would provide information on selective or preferential 
interactions of proteins with multiple interaction partners.  
 
 
Figure 3.48 His-MepS retains PBP4, NlpI and Slt by in vitro Ni2+ bead pull-down 
In vitro Ni2+ bead pull-down assay using His-MepS and untagged NlpI, PBP4, PBP7 and Slt. An applied sample 
was taken prior to addition to beads (A). Beads were washed and eluted and a sample taken (E). Proteins were 
separated by 12% SDS-PAGE and visualised by Coomassie staining.   
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3.5.9 Other NlpI interactions partners  
 
Positive interactions 
Characterised is this work are the shared interaction partners, PBP4 and PBP7, of NlpI, LpoA 
and PBP1A. We hypothesised therefore that NlpI may be capable of interacting directly with 
the core PG synthesis machinery during elongation.  
Using MST we observed a weak interaction between NlpI and PBP1A (figure 3.49A) (section 
2.5.1.7). FL-PBP1A (at amine residues) was used at a concentration of 41.5 nM and was 
titrated with two-fold serially diluted unlabelled NlpI from a concentration of 100 µM to 3.05 
nM. The binding curve generated an apparent KD of 1470 ± 138 nM.  
Using an in vitro TPase assay we showed that NlpI had no effect on the activity of PBP1A 
and no effect on the stimulation of activity by LpoA (figure 5.47) (section 2.5.2.4).    
We speculated that NlpI may interact exclusively with hydrolases possessing EPase activity. 
To test this we used the monofunctional CPases PBP6B and PBP5 (purified by Katharina 
Peters from the Vollmer group). Using in vitro cross-linking pull-down assays we confirm the 
absence of an interaction between His-NlpI and native PBP5 (figure 3.51C). However, His-
NlpI was able to retain native PBP6B (figure 3.49B). 
During an in vitro affinity chromatography search for potential NlpI interaction partners, our 
collaborators from the Typas group found EnvC and AmiC. These data infer that NlpI could 
have an additional role in the regulation of the activity of amidases.  
Here we show the in vitro interaction between NlpI and EnvC using MST and a Ni2+ bead 
cross-linking pull-down assay (figure 3.49C/D). FL-NlpI (at amine residues) was used at a 
constant concentration of 166 nM. Unlabelled EnvC was two-fold serially diluted from a 
concentration of 10 µM to 0.305 nM and titrated with FL-NlpI. The resulting binding curve 
yielded an estimated KD of 252 ± 47.5 nM. We confirmed this in vitro interaction by showing 
that His-NlpI retained untagged EnvC on Ni2+ beads after thorough washing (section 2.5.1.5).  
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Figure 3.49 NlpI interacts with PBP1A, PBP6B and EnvC in vitro 
A. MST showing the interaction between FL-PBP1A (at amine residues) at a constant concentration of 41.5 nM 
titrated with two-fold serially diluted unlabelled NlpI from a concentration of 100 µM – 0.35 nM. MST power 
20%, LED power 80%. An apparent KD of 1470 ± 138 nM was estimated using accompanying software. The 
values are the mean ± standard deviation of three independent experiments. Raw MST data are shown in figure 
5.48. B. In vitro Ni2+ bead pull-down assay using His-NlpI and untagged PBP6B. An applied sample was taken 
prior to addition to beads (A). Beads were washed and eluted and a sample taken (E). Proteins were separated by 
12% SDS-PAGE and visualised by Coomassie staining. C. MST of FL-NlpI, (at amine residues) at a 
concentration of 166 nM, titrated with two-fold serially diluted EnvC from a concentration of 10 µM – 0.305 
nM. MST power 20%, LED power 80%. A KD of 252 ± 47.5 nM was estimated using accompanying software. 
The values are the mean ± standard deviation of three independent experiments. Raw MST data are shown in 
figure 5.49. D. In vitro Ni2+ bead pull-down assay using His-NlpI and untagged EnvC. An applied sample was 
taken prior to addition to beads (A). Beads were washed and eluted and a sample taken (E). Proteins were 
separated by 12% SDS-PAGE and visualised by Coomassie staining.   
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Non-interacting proteins 
After observing the interaction between NlpI and PBP1A, we tested an interaction between 
NlpI and LpoA. LpoA was fluorescently-labelled (at cysteine residues) and used at a 
concentration of 62.5 nM. Unlabelled NlpI was two-fold serially diluted from 100 µM to 3.05 
nM and titrated with FL-LpoA (figure 3.50A). We also performed an in vitro Ni2+ pull-down 
assay using His-NlpI and native LpoA (figure 3.51A). Both assays concluded that there was 
no interaction between NlpI and LpoA.  
In addition, NlpI did not interact with the soluble LT, Slt. FL-NlpI (at amine residues), at a 
concentration of 62.5 nM, was titrated with two fold serially diluted unlabelled Slt from 15 
µM to 0.458 nM (figure 3.50B). We also performed an in vitro pull-down assay using His-Slt 
and native NlpI (figure 3.51B). In both assays we did not detect an interaction between NlpI 
and Slt.   
NlpI also did not interact with LpoB. FL-NlpI (at amine residues), at a concentration of 62.5 
nM, was titrated with two fold serially diluted LpoB from 50 µM to 1.526 nM to show no 
interaction (figure 3.50C).  
Using in vitro Ni2+ bead pull-downs, we showed that there was no interaction between PBP5 
and NlpI, using His-NlpI and thrombin-cleaved PBP5, purified by Katharina Peters from the 
Vollmer lab (figure 3.51C).  
A deletion of nlpI and pal was shown to be synthetically lethal in vivo by Manuel Banzhaf 
(unpublished) implicating a functional relationship. However we not did not detect a direct 
interaction between the proteins by in vitro Ni2+ pull-down assay, using His-Pal and thrombin-
cleaved NlpI (figure 3.51D).  
Finally, we showed by an in vitro Ni2+ pull-down assay that there was no interaction between 
NlpI and CpoB. His-CpoB and thrombin-cleaved NlpI were used (figure 3.51E). 
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Figure 3.50 NlpI does not interact with LpoA, Slt or LpoB by MST 
A. MST measurement of FL-LpoA (at cysteine residues) at 62.5 nM titrated with two-fold serially diluted 
unlabelled NlpI from 100 µM – 3.05 nM. MST power 40%, LED power 40%. B. MST measurement of FL-NlpI 
(at amine residues) at 62.5 nM titrated with two-fold serially diluted unlabelled Slt from 15 µM – 0.458 nM. 
MST power 40%, LED power 40%. C. MST measurement of FL-NlpI (at amine residues) at 62.5 nM titrated 
with two-fold serially diluted unlabelled LpoB from 50 µM – 1.526 nM. MST power 20%, LED power 40%. 
Raw MST data are shown in figures 5.50-5.52. 
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Figure 3.51 NlpI does not interact with LpoA, Slt, PBP5, Pal or CpoB by Ni2+ pull-down assay 
A. In vitro Ni2+ bead pull-down assay using 2 µM of His-LpoA and untagged EnvC. A, applied sample taken 
prior to addition to beads; E, elution sample of bound proteins after washing. B. In vitro Ni2+ bead pull-down 
assay using 2 µM of His-Slt and untagged NlpI. C. In vitro Ni2+ bead pull-down assay using 2 µM of His-NlpI 
and untagged PBP5. D. In vitro Ni2+ bead pull-down assay using 2 µM of His-CpoB and untagged NlpI. Proteins 
were separated by 12% SDS-PAGE and visualised by Coomassie-staining. 
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3.5.10 Conclusions and discussions 
The data presented in this section comprehensively characterised the role of New Lipoprotein 
I (NlpI), of previously debated cellular function, as a regulator of EPase activity. We have 
characterised the interactions of NlpI with five of the seven known PG EPases of E. coli and 
used MST to estimate the KD value of each interaction. We showed that NlpI has differential 
effects on the activity of three of these EPases.  
 
Oligomeric state of NlpI 
After purification to homogeneity of the soluble form, we used AUC to determine the 
oligomeric state of NlpI in solution in collaboration with Alexandra Solovyova, Newcastle 
University. The results yielded one peak, corresponding to the estimated size of the dimeric 
form of the protein (~60 kDa). The published crystal structure predicted strong dimerisation 
between two large surfaces in a face-to-face formation. At the high concentrations used in 
AUC, we did not detect a monomeric form of NlpI. The AUC data showed a slight 
discrepancy between the predicted and the measured sedimentation velocities. We 
hypothesised that this was due to the dimer having a slightly more elongated shape than 
determined by crystallography, or an uncharacterised degree of flexibility between the 
monomers. 
To determine the KD of dimerisation, we used NlpI at much lower concentrations than 
required for AUC. Using MST we tested for the interaction between FL-NlpI, at 62.5 nM 
(predicted to be lower than the KD for dimerisation), and serially diluted unlabelled NlpI. The 
binding curve generated an estimated KD for dimerisation of 126 ± 9.1 nM. These MST data 
explain why no NlpI monomer was observed using AUC, and will provide a basis for the 
determination of stoichiometry in future interaction experiments.      
 
NlpI is a novel regulator of endopeptidase activity 
NlpI and PBP4  
Our collaborators in Heidelberg used affinity chromatography to identify PBP4 as highly 
enriched after incubation of a combined E. coli membrane/periplasmic fraction with beads 
containing immobilised NlpI, compared to that of a control column. We confirmed the 
interaction by SPR which generated an equilibrium binding plateau. Using Scatchard analysis 
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by non-linear regression we estimated a KD of 311 ± 46 nM. We further confirmed the in vitro 
interaction using MST, to generate an estimated KD of 177 ± 49 nM. The dissociation 
constants calculated by the two methods closely correlate. In addition we used a Ni2+ bead 
cross-linking pull-down assay as a third method of confirming the in vitro interaction. 
Attempts have been made to observe the interaction in vivo using co-immunoprecipitation, but 
have been unsuccessful thus far.  
Using a sacculi-based EPase activity assay we could show that, unlike the other interaction 
partners of PBP4 presented in this work (LpoA, PBP1A, PBP7 and MepA), NlpI is able to 
stimulate the activity of PBP4. We observe almost complete degradation of dimeric 
muropeptides by PBP4 in the presence of NlpI. We hypothesise that LpoA and PBP1A act to 
spatio-temporally coordinate PBP4 activity with ongoing PG synthesis, where NlpI acts to 
regulate this activity. It is possible that in vitro we only observe stimulation by NlpI where, in 
vivo, NlpI may be able to both stimulate and inhibit PBP4 activity when required. In vivo 
experiments are currently being undertaken by the Typas group regarding all of the EPases 
and NlpI.  
In section 3.3.5 we showed that domain 3 is not an interaction site for LpoA or PBP1A. Using 
a Ni2+ bead pull-down assay and MST, we showed that PBP4ΔD3 does not interact with NlpI. 
These interaction and activity data correlate with the observed lack of activity upon deletion 
of domain 3. We speculate that the interaction between NlpI and PBP4 takes place primarily 
through domain 3 which causes a conformational change revealing or concealing the active 
site, thus regulating activity. As the conditions of the periplasm are not constant, NlpI may be 
bound to PBP4, via domain 3, to allow NlpI to alter the activity of PBP4 in response to these 
changing conditions.  
Domain 3 of PBP4 may have a similar role as the regulatory α-helix of AmiB which is 
removed upon interaction with EnvC to allow activity (section 1.4.6). The mechanism of how 
and why domain 3 of PBP4 is essential for activity is not yet known. Co-crystallisation 
studies would help elucidate this function and have been undertaken in this project, however 
these have been unsuccessful so far, having only been able to obtain crystals of NlpI.  
In the absence of domain 3, there is no interaction with NlpI, however the interaction between 
PBP4 and PBP1A and LpoA can still take place. Here we used a modified MST protocol to 
test whether PBP4 can interact with PBP1A and LpoA in the presence of excess NlpI. PBP1A 
is a shared interaction partner of PBP4 and NlpI, however the KD for the interaction between 
NlpI and PBP1A is significantly higher (~1000 nM) than that of PBP4 and PBP1A (~60 nM). 
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This allowed us to use FL-PBP1A in the presence of a low concentration of PBP4 and an 
excess of NlpI without causing an interaction between NlpI and FL-PBP1A. We used 0.5 µM 
of unlabelled PBP4, which is within the bound state of the interaction observed for FL-
PBP1A and PBP4, and 1 µM of NlpI, which is in excess of PBP4 but below the estimated KD 
of interaction for PBP1A. We observed the binding of PBP4 to FL-PBP1A alone and in the 
presence of excess NlpI, supporting our hypothesis that PBP4 has different binding sites for 
its different interaction partners, which we predict to be domain 1 and/or 2 for PBP1A and 
domain 3 for NlpI.  
This hypothesis is further supported using FL-LpoA and testing for interaction with PBP4 in 
the presence or absence of excess NlpI. The interaction between FL-LpoA (at cysteine 
residues) and PBP4 caused a concentration-dependent fluorescence enhancement, while LpoA 
does not interact with NlpI. We show again that the interaction between FL-LpoA and PBP4 
caused a fluorescence enhancement, and that excess NlpI did not. The presence of excess NlpI 
also did not prevent the interaction of PBP4 and LpoA. Thus, these data support previous in 
vitro work in this project that infer that PBP4 interacts with LpoA and PBP1A via domain 1 
and/or 2, (section 3.2.2.3 and 3.3.5) and interacts with NlpI via domain 3 (section 3.5.3.3). 
 
NlpI and PBP7 
We hypothesised that NlpI may have more than one interaction partner. We chose to firstly 
test one of the other members of the Class C PBPs, PBP7. We confirmed the interaction in 
vitro using a Ni2+ bead pull-down assay and MST. FL-PBP7 was titrated with serially diluted 
NlpI which generated an equilibrium binding event with an estimated KD of 90 ± 8.9 nM, one 
of the strongest interactions observed in this work. However, when testing the interaction 
using FL-NlpI and unlabelled PBP7, the binding was no longer in equilibrium. We therefore 
applied the Hill model to estimate an apparent EC50 of 422 ± 25 nM, a significantly weaker 
interaction than before. Using this model, we also generated a Hill coefficient of 3.06, 
implying positive cooperativity. This indicates that the binding of PBP7 may cause a 
conformational change in NlpI leading to an increase in affinity for subsequent interactions 
with PBP7. This also suggests that NlpI may possess more than one PBP7 binding site. As 
NlpI was used as the fluorescently-labelled protein, it was below the concentration calculated 
for dimerisation. We speculate that the increased affinity for PBP7 observed for monomeric 
NlpI may be to prevent interactions with other EPases. In the cell, monomeric NlpI may exist 
at certain conditions in which an interaction with PBP7 is more favourable than the other 
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EPases. When NlpI is in its dimeric state it may be able to bind to all EPases simultaneously. 
We aim to thoroughly test the ability of NlpI to bind more than one EPase at the same time. 
Unlike PBP4, NlpI had no effect on the EPase activity of PBP7 at all conditions tested. 
However, we should not exclude an effect on activity in the cell. It is also possible that PBP7 
may not require regulation of activity, or that another interaction partner is involved. The role 
of NlpI here may be to coordinate EPase activity with the other EPases as part of a 
hydrolase/regulator complex, or activity may be only regulated when it is recruited to sites of 
ongoing PG synthesis.  
 
NlpI and MepS 
While inferred in recent publications [100,236], we present here the first evidence of the 
direct in vitro interaction between NlpI and MepS, a member of the NlpC/P60 peptidase 
superfamily. We showed the interaction using His-tagged MepS and untagged NlpI in a Ni2+ 
bead pull-down assay and MST, which we used to estimate a KD of 145 ± 51.6 nM, an affinity 
which closely matches that of NlpI and PBP4.  
Aramini et al (2008) used NMR spectroscopy and AUC to show that MepS exists as a 
monomer in solution. The high concentrations required for use as the serially diluted 
unlabelled ligand in MST means that NlpI is most likely in a dimeric state. We therefore 
initially hypothesised that MepS interacts with NlpI with a stoichiometry of 1:2.  
We performed a saturation binding experiment by MST to test this hypothesis. We modified 
the MST protocol to estimate the concentration of NlpI required to saturate a constant 
concentration of FL-MepS. A narrow linear range of NlpI concentrations (0-300 nM) was 
added to a constant concentration of 125 nM FL-MepS and was analysed by MST. The linear 
range of NlpI reached a saturation plateau at 197.3 nM which corresponded to a stoichiometry 
of MepS to NlpI of 1:1.6. We predict that the ratio generated, being halfway between 1:1 and 
1:2, is due to the presence of both monomeric and dimeric forms of NlpI present, monomeric 
at lower concentrations and dimeric at higher. Attempts to reverse this experiment using a 
constant concentration of FL-NlpI and a linear range of MepS have been unsuccessful thus 
far. Nevertheless, this adapted protocol is promising for investigating the stoichiometry of 
future interactions by MST.  
The NMR structure of MepS predicted that the active site, while conserved within a putative 
substrate binding groove, is buried within the protein. We hypothesise this is the reason for 
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the low activity observed in the published data, and the lack of activity observed in this work. 
We predicted that the interaction of NlpI with MepS may cause a conformational change in 
such a way that the active site becomes more accessible for substrate and thus stimulate 
activity. When tested on intact sacculi, this was not the case at any of the conditions tested 
and NlpI did not affect activity. On muropeptides however, the presence of NlpI stimulated 
MepS activity at each condition tested, excluding high NaCl (300 mM) and low pH (pH 5.0), 
most obviously at 150 mM NaCl and pH 7.5. At present we do not know whether the binding 
of NlpI causes a conformational change in MepS, but efforts to co-crystallise the complex are 
planned. As discussed earlier, a recent publication by our collaborator [108] highlighted the 
role of NlpI in facilitating the proteolytic degradation of MepS. Our current hypothesis is that 
the effect on activity by NlpI is secondary to this regulation of degradation.  
Phenotypically, we also confirmed the findings of [230] by showing that a deletion of mepS 
suppresses an nlpI- phenotype. We used growth curves of varying concentrations of 
imipenem, and a β-lactamase induction assay. The induction of β-lactamase relies on the 
turnover products of LTs and EPases (section 1.6). We show that in the absence of NlpI, cells 
are incapable of inducing a β-lactamase response upon imipenem stress (discussed in more 
detail in section 3.6). This implies that NlpI is involved in the in vivo activity of PG 
hydrolases. We show that there was no effect on β-lactamase induction upon deletion of 
mepS, which is unsurprising due to the redundant nature of the PG hydrolases. However, upon 
deletion of mepS in an nlpI- background, we observe suppression of this impaired induction. 
These data indicate that it is the unregulated activity of MepS that contributes to the impaired 
ability to induce β-lactamase in response to imipenem in the absence of NlpI, and perhaps the 
unregulated activity of the other EPases, although this has not been tested.  
 
NlpI and MepM 
In our lab so far we have been unsuccessful in the purification of MepH. However, we tested 
for the interaction between NlpI and MepM. Using His-MepM and native NlpI we showed an 
in vitro interaction by Ni2+ bead pull-down assay. By MST, we estimated a KD of 152 ± 42.1 
nM. This affinity is in close concordance with that of the four other hydrolase interaction 
partners of NlpI. The addition of unlabelled MepM to FL-NlpI (at amine residues) caused a 
concentration-dependent fluorescence enhancement, and the raw fluorescence values were 
used to estimate the dissociation constant.  
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NlpI inhibited the EPase activity of MepM on intact sacculi. As with the other EPases 
(excluding MepA), MepM activity was weaker at lower pH and at a higher concentration of 
NaCl, however, the inhibition by NlpI was observed at all conditions tested. Inhibition was 
most drastically observed at standard EPase reaction conditions (150 mM NaCl and pH 7.5). 
 
NlpI and MepA 
NlpI has now been shown to interact with four EPases at our standard pH 7.5 interaction 
conditions. MepA was the only EPase studied in this work to initially not interact with NlpI. 
The characterisation of the pH dependent activity and substrate binding ability of MepA in 
section 3.4 prompted us to test this interaction at pH 5.0. Using MST we observed an 
interaction with an estimated KD of 140 ± 21.9 nM. In section 3.4 we concluded that the pH 
dependent activity of MepA could be another way of how the hydrolases of E. coli are 
regulated. We speculate that the redundancy of the hydrolases arises from differing optimal 
conditions and substrate specificities. Now we show the interaction between NlpI and MepA 
correlates with this pH dependency. The shared interactions of MepA and NlpI with PBP7, 
PBP4 and MepS at pH 7.5 suggests that MepA is also a part of this larger complex of 
hydrolases. However, when conditions are optimal for MepA activity, i.e. pH 5.0, this 
facilitates the interaction with NlpI. We observed no effect of NlpI on the activity of MepA at 
pH 5.0, however we hypothesise that in vivo NlpI may have a regulatory role.   
 
Other NlpI interactions 
NlpI and PBP1A 
We investigated the possibility of NlpI interaction partners which do not possess EPase 
activity but exist within the multi-enzyme PG-synthesising complex. We firstly tested 
PBP1A, which shares at least three interaction partners with NlpI; LpoA, PBP4 and PBP7.  
We confirmed an in vitro interaction using MST with FL-PBP1A and unlabelled NlpI to 
estimate an apparent KD of 1470 ± 138 nM. This affinity is significantly weaker than any NlpI 
interaction partner identified so far. There is also no effect of NlpI on PBP1A activity, alone, 
or in the presence of LpoA. We have no further data as-of-yet regarding the importance of this 
interaction but hypothesise that it is yet another way of associating hydrolase activity to PG 
synthesis during cell elongation.  
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NlpI and EnvC 
Our collaborators from the Typas group identified EnvC as a potential interaction partner of 
NlpI. We present here the in vitro interaction between NlpI and EnvC using a Ni2+ bead pull-
down assay and MST, which was used to estimate a KD of 252 ± 47.5 nM. The aberrant cell 
division phenotypes observed upon deletion of NlpI [228] could indicate a role in regulating 
amidase activity, which may be facilitated through an interaction with EnvC. Presently, we 
have no activity data regarding the effect of NlpI on the regulation of amidase activity by 
EnvC. Future work will investigate direct interactions between NlpI and the amidases AmiA 
and AmiB, which are regulated by EnvC, as well as AmiC which was also identified as a 
potential interaction partner by affinity chromatography. We hypothesise that NlpI could be a 
global regulator of hydrolase activity, regulating EPase activity during elongation and 
amidase activity during cell division.  
 
NlpI and PBP6B 
Using a Ni2+ bead pull-down assay we also observed an interaction between NlpI and PBP6B. 
No activity assays have been undertaken thus far, and the interaction has not been tested by 
another method. As PBP6B is a monofunctional CPase, it is possible that NlpI may regulate 
more than just EPase activity. PBP6B has been shown to be upregulated at pH 5.0 in 
comparison to pH 7.5, and although present and weakly active at pH 7.5, has higher activity at 
pH 5.0 (Peters et al,. 2016. in press). MepA may have a similar role for EPase activity at 
lower pH conditions and NlpI may interact and regulate both in the cell at these conditions.  
 
NlpI has multiple EPase interaction sites 
We tested for formation of ternary complexes in vitro using modified MST and Ni2+ pull-
down protocols. These modified protocols could be used to infer whether a protein has one 
interaction site for multiple proteins, or that the binding of one protein prevents the binding of 
another. We tested if NlpI possesses multiple EPase interaction sites or is restricted to one 
interaction partner at a time. We have shown in this work that PBP4 and MepS do not interact 
by MST and that the bound state for the interaction between NlpI and MepS begins at ~1 µM. 
Unlabelled NlpI was pre-incubated with an excess of PBP4 and the pre-formed complex was 
tested for interaction by MST with FL-MepS. The interaction between MepS and NlpI-PBP4 
takes place with a much larger thermophoretic movement than that of NlpI alone, indicative 
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of a larger complex binding to FL-MepS, causing a slower movement along the temperature 
gradient. Although no interaction was observed between MepS and PBP4 by MST, His-MepS 
retained native PBP4 in Ni2+ bead cross-linking pull-down assays. We hypothesise that the 
binding of NlpI to PBP4 may cause a conformational change in PBP4 to allow for a stronger 
interaction with MepS, or that the presence of NlpI strengthens this interaction and facilitates 
the formation of a trimeric complex. Using the Ni2+ bead cross-linking pull-down assay we 
show that His-MepS is able to retain PBP4 and NlpI separately, as observed previously, but 
could also retain both proteins simultaneously, complementing the MST data. We can 
therefore conclude that; MepS can interact with NlpI in the presence of excess PBP4, 
indicating that MepS and PBP4 do not share the same binding site on NlpI, and that NlpI, 
MepS and PBP4 can form a ternary complex.  
Similarly, we observed that MepS and PBP7 do not interact, which allowed us to challenge 
the interaction between MepS and NlpI with excess PBP7. Using the same concentration of 
FL-MepS we see no indication of an interaction with PBP7. After pre-incubation of NlpI with 
excess PBP7, we still see the interaction between NlpI and MepS, thus inferring that NlpI 
possesses different interaction sites for MepS and PBP7. In contrast to the experiments using 
MepS, NlpI and PBP4, there was no cumulative increase in FNorm from FL-MepS upon 
addition of NlpI pre-incubated with PBP7. This could imply that while NlpI may have 
different interaction sites for MepS and PBP7, it is unable to interact with both proteins as a 
trimeric complex and may preferentially bind to FL-MepS, or, that the change in size/charge 
of FL-MepS upon addition of NlpI bound to PBP7 did not significantly alter the properties of 
FL-MepS compared to NlpI alone. We also aim to test the interaction of NlpI with EPases at 
different conditions, which could allow us to determine if NlpI conditionally binds to certain 
EPases.  
 
Non-interacting proteins 
Separate to this work and unpublished, Hamish Yau (Vollmer group) has shown that Slt is 
capable of interacting with four of the same EPases as NlpI (PBP4, PBP7, MepS and MepM). 
We show here that there is no direct interaction between NlpI and Slt. We hypothesise that, 
although we have seen no regulation of EPase activity by Slt, that it may also be a regulator of 
EPase activity, or localisation. It is possible, in the absence of one of NlpI or Slt, the other 
takes over as the primary interaction partner. Another model is that these hydrolases and 
regulators exist as a large complex by which the activity or localisation of these enzymes 
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could be tailored to the conditions of the cell, or what substrate is available. This could 
explain the robustness of the hydrolases and the lack of phenotype upon single gene deletions. 
The lack of interaction observed of NlpI with LpoB, Pal and CpoB, indicates that the 
hydrolase regulation of NlpI may be coordinated with the elongasome rather than the 
divisome. However, as discussed, the inferred interactions with the amidases may be evidence 
of an indirect and uncharacterised association to the divisome.   
 
Final word 
In this section we found that NlpI was able to interact with five of the seven known EPases of 
E. coli and differentially alter the activity of at least three (figure 3.52). We believe we have 
characterised the primary function of NlpI, whose cellular function is still debated, as a 
regulator of hydrolase activity and/or spatio-temporal localisation. The differential in vitro 
effects of NlpI on EPase activity suggests the ability to coordinate individual hydrolase 
activity at different stages of cell growth. The identification of the pH dependent interaction 
of NlpI and MepA is a prime example of this. While the other interaction partners of NlpI 
have lower activity at lower pH, in situations when the cell is in a low pH environment, NlpI 
may be able to ‘choose’ MepA as the primary active EPase. We have not shown conditional 
activity of the other EPases, but predict that there are conditions at which each will be most 
efficient at degrading PG, and that, like MepA, NlpI will be able to preferentially interact and 
regulate activity for each. The Typas group are currently testing the effect of NlpI on EPase 
activity in vivo and the next section details the attempts to phenotypically characterise the role 
of NlpI using the aforementioned β-lactamase induction assay. Through our collaboration 
with Tanneke den Blaauwen, University of Amsterdam, we are localising the EPases in the 
presence and absence of NlpI. In this section we have modified the established MST protocol 
for the observation of ternary interactions, to provide insight into the ability of one protein to 
interact with multiple proteins simultaneously. While we have identified no protein that 
prevents the interaction of another thus far, this assay could be used for the identification of 
proteins sharing interaction sites. Efforts are underway to study more potential trimeric 
complexes, particularly by Hamish Yau (Vollmer group). A summary of the interactions 
identified in this section and section 3.4 is shown in figure 3.52. 
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Figure 3.52 Interaction network of NlpI and the endopeptidases 
Schematic to show the characterisation of novel interactions between NlpI and the PG hydrolases. KD values are 
given in nanomolar. *Dissociation constant calculated using the Hill model as an EC50. **Interaction only occurs 
at pH 5.0. 
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3.6 NlpI and the elongasome are required for correct β-lactamase induction  
3.6.1 Introduction 
The functional redundancy of the PG hydrolases complicates the in vivo analysis of protein 
interactions and activities. However, one of the few phenotypes observed upon a single 
deletion of PBP4 is the diminished induction of the β-lactamase AmpC in response to the 
broad-spectrum carbapenem, imipenem [112]. As discussed in section 1.6, AmpC induction 
in response to antibiotic stress is dependent on the amount of PG turnover products generated 
by EPases and LTs. We reasoned that proteins interacting with PBP4, and/or involved in the 
regulation of PBP4 activity, may have similar phenotypes and thus reveal the relevance of the 
interactions observed in vitro. To do so, we adapted the β-lactamase induction assay described 
in [224] and section 2.6.1 and tested multiple deletion and overexpression strains.  
In doing so, we were able to optimise an assay for the future identification and 
characterisation of proteins involved in bacterial cell wall elongation, PG hydrolysis and PG 
hydrolysis regulation, and proteins involved either directly or indirectly with LT activity. 
The strains in this section were obtained from the Keio collection available in the Vollmer 
group, or supplied by the Typas and Reddy laboratories. Prior to use in this assay all strains 
were transformed with the pJP1 plasmid, containing the ampR/ampC operon from E. cloacae, 
and subjected to growth curves to ensure a sub-lethal concentration of imipenem would be 
used (see table 5.2 for the list of strains used, growth curves not shown). 
 
3.6.2 An intact elongasome is required for β-lactamase induction  
The first strain tested was that of BW25113ΔdacB in comparison to WT BW25113. The 
method is as described in section 2.6.1.  
Sanders et al observed a ~50% diminished β-lactamase induction in the absence of PBP4 
[112] and we could reproduce this result (figure 3.53). Cells lacking PBP4 show an average 
fold difference over the control of 4.9 compared to a fold difference of 12.7 for WT. With the 
assay working as expected, we continued by testing the cells lacking the interaction partners 
of PBP4. 
The first PBP4 interaction partner identified in this work was LpoA. In strains lacking LpoA, 
induction is as similarly diminished as cells lacking PBP4, with an average fold difference of 
4.2 (figure 3.53). We continued by testing a strain lacking PBP1A and observed a complete 
inhibition in β-lactamase induction in response to imipenem (figure 3.53). The effect was 
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much more dramatic than in a deletion strain of PBP4. Cells lacking PBP1A had an average 
fold difference of 1.2. These data infer that the role of PBP1A in the induction of β-lactamase 
in response to imipenem is more important for the cell than that of PBP4. We speculated that 
a degenerate elongasome may actually be responsible for the impaired induction observed. A 
dysregulation of PG synthesis and hydrolysis through deletions in the core PG synthesis 
complex (PBP1A and LpoA) and/or PBP4 may alter the levels of the intracellular turnover 
products required for induction.  
To test whether this effect is exclusive to the elongasome we performed the assay using a 
strain lacking PBP1B. We observed no significant changes in β-lactamase induction. A fold 
difference over the control of 9.9 was calculated (figure 3.53). In comparison to strains 
lacking components of the elongasome, cells were significantly less affected. 
 
3.6.3 NlpI is required for β-lactamase induction  
In the last section we characterised NlpI as an interaction partner of at least five EPases and a 
regulator of activity of at least three. As discussed, the turnover products of EPase activity are 
crucial for correct AmpC induction. We sought to use this β-lactamase assay to observe the 
intrinsic connection of NlpI and EPase activity and highlight the in vivo relevance of NlpI. 
Prior to use in the β-lactamase induction assay, growth curves of each strain were taken at 
varying concentrations of imipenem. This is to ensure the concentration of imipenem used in 
the assay was sub-lethal. Figure 3.41 shows the growth curves of cells lacking NlpI. We 
observed that cells are more susceptible to imipenem, with growth showing a significant 
difference to WT after a 1 h exposure to 1 µg/ml of imipenem (figure 5.41). We showed that 
this growth impairment was due to an inability to induce an AmpC response (figure 3.53). 
Cells lacking NlpI produced a fold difference of 1.5. Conversely, in cells containing the 
overexpression plasmid pCL1920-NlpI, the average fold difference over the control was 24.2, 
3.5 times that of WT cells containing the empty overexpression plasmid (BW27783-
pCL1920) (figure 3.53). Using single deletions in the genes encoding two of the other NlpI 
interaction partners, MepS and MepM, we showed there to be no significant change in β-
lactamase induction (figure 3.53). The tail-specific protease, Prc, cleaves the 12 C-terminal 
residues of NlpI and has been hypothesised to ‘activate’ NlpI [248]. However, a deletion or 
overexpression of Prc also had no effect on β-lactamase induction (figure 3.53).  
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Figure 3.53 β-lactamase induction assay in response to imipenem 
BW25113 strains were obtained from the Vollmer laboratory Keio collection.BW27783 strains were provided by 
the Reddy laboratory. The pCL1920 plasmid is an IPTG dependent overexpression plasmid. All strains were 
transformed with the pJP1 plasmid carrying the ampR/ampC operon from E. cloacae. Cells were exposed to sub-
lethal concentrations (1 µg/ml) of imipenem. Cells were lysed by osmotic shock and β-lactamase induction 
measured using the chromogenic β-lactam nitrocefin. Hydrolysis of nitrocefin was measured using a 
spectrophotometer (555 nm) and the amount of nitrocefin hydrolysed per min per milligram of protein in the 
lysate was measured and compared to that of a control sample not exposed to imipenem. The purified β-
lactamase Vim4, from P. aeruginosa, was used as a positive control. The fold difference was calculated and 
plotted. For overexpression strains (BW27783-pCL1920) 1 mM IPTG was used during the initial growth period.  
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3.6.4 Conclusions and discussion 
We have adapted and optimised an in vivo assay, initially with the intention of providing 
relevance to the interaction partners of PBP4 characterised in this work. We continued by 
highlighting a potential secondary role of the elongasome as crucial for correct β-lactamase 
induction. We also provide in vivo relevance to the role of NlpI as a global regulator of PG 
hydrolase activity.  
 
An intact elongasome is required for correct β-lactamase induction 
We initially confirmed the assay as working optimally using a strain lacking PBP4 to replicate 
the data presented in [112], who showed cells lacking PBP4 were ~50% impaired in their 
ability to induce β-lactamase in response to imipenem. We proceeded by testing the 
interaction partners of PBP4 and discovered that cells lacking LpoA had a similarly poor 
induction response to that of cells lacking PBP4, with both mutant strains having ~60% 
impaired AmpC induction in comparison to WT. Contrary to the in vitro data, this indicates 
that LpoA may have a more important regulatory role when interacting with PBP4 in the cell. 
These data suggest that without LpoA regulating the activity of PBP4 the amount of turnover 
products is altered leading to the diminished induction observed. It is possible that the 
conditions used in vitro are not optimal to observe such an effect, for example we did not take 
into account the effect of periplasmic protein crowding.  
However, when we analysed the induction response in cells lacking PBP1A we found a much 
more significant reduction in AmpC induction than observed in dacB- cells. We hypothesise 
therefore that PBP1A may play a more important role than PBP4 in β-lactamase induction in 
the cell.   
This could be due to the strong interaction observed between PBP1A and PBP7 as well as 
PBP4, a deletion in PBP1A may lead to the unregulated activity of both PBP7 and PBP4 
causing the larger effect observed. However, when Sanders et al published the data 
implicating PBP4 in the induction of β-lactamase, they showed there was no effect on 
hydrolysis of nitrocefin in strains lacking PBP7 and no cumulative change when both PBP4 
and PBP7 were absent [112]. Of the mutant strains tested we found diminished induction in 
those associated with the elongasome; PBP1A, LpoA and PBP4. If β-lactamase induction 
relies on the amount of PG turnover products from EPase and LT activity, then maintaining 
the balance between PG hydrolysis and PG synthesis could be crucial to eliciting a successful 
response to β-lactam stress.  
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The divisome has recently been shown to have a secondary role in the coordination of 
membrane constriction through shared interactions with the Tol/Pal system [91]. We 
hypothesise β-lactamase induction in response to antibiotic stress may be a secondary role of 
the elongasome. As such, we tested the effect of a deletion in PBP1B which showed only a 
minor decrease in β-lactamase induction. We are continuing tests to confirm this hypothesis 
and, if successful, this assay could be modified to screen a large number of strains for the 
identification of novel members of the elongasome. 
  
NlpI is required for correct β-lactamase induction 
We show here that an nlpI mutant becomes susceptible to imipenem through an inability to 
induce a β-lactamase response. We have confirmed in this work the interactions of at least 
five EPases with NlpI. We hypothesise that the phenotype observed here is due to the 
unregulated activity of these EPases in the absence of NlpI. We showed that a strain 
overexpressing NlpI has a highly stimulated induction response, highlighting the role of NlpI 
in regulating EPase, and potentially LT, activity. 
As previously mentioned, Hamish Yau (Vollmer group) has identified interactions between 
Slt and four of the same EPases that interact with NlpI (PBP4, PBP7, MepS and MepM). We 
hypothesise that in the absence of NlpI, not only is the activity of the EPases unregulated but, 
in addition, the activity of the other EPase interaction partners is also affected, for example 
Slt. We are yet to observe any regulatory effect of Slt on the EPases in vitro, or vice versa, 
and there is no direct interaction between NlpI and Slt. However, in the absence of NlpI the 
affinity of interaction between the EPases and the LTs could be altered, thus leading to more 
or less regulation of activity of both sets of enzymes. Thus, directly through the regulation of 
EPase activity, and indirectly through the activity of the LTs, a single deletion in NlpI could 
cause the phenotype presented here.  
 
Final word 
The data presented in this section described the characterisation of the in vivo relevance of 
some of the interactions identified in this project. In doing so we optimised a β-lactamase 
induction assay which highlighted the connections between the PG synthases and the PG 
hydrolases and potentially discovered a novel secondary function of the elongasome. We also 
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utilised this assay to show the importance of NlpI in the regulation of hydrolytic turnover 
products in a cellular environment.  
Presently, we are designing a large scale screen of the Keio collection using a modified 
version of the plasmid used in this assay. We hypothesise that we will be able to use this 
assay to discover and characterise proteins involved with PG turnover and putative members 
of the elongasome, which could lead to the identification of novel antibiotic targets.  
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The regulation of peptidoglycan hydrolysis in Escherichia coli 
The data presented in this work significantly enhances our knowledge of how the potentially 
autolytic PG hydrolases are coordinated and controlled in E. coli and presumably other Gram-
negative organisms. As many of the members of the PG-synthesising/hydrolysing proteins 
investigated in this work, including NlpI, are conserved among other Gram-negative 
organisms it is likely that some of the mechanisms can be transferred to other related species. 
However, as exemplified by the comparison between E. coli and H. influenzae LpoA, some of 
the proteins involved may have alternative primary roles.  
Using combinations of state of the art in vitro and in vivo interaction assays we present the 
interactions of over 10 proteins participating in PG synthesis and hydrolysis as well as other 
cell envelope proteins. The methods of coordinating hydrolase activity in E. coli, discovered 
or elaborated upon in this project, can be summarised into four categories, which will be 
discussed and summarised below; 
1. An interaction network associated to PG synthesis.  
2. Conditional activity of hydrolases. 
3. Hydrolase domains crucial for activity. 
4. Regulation of activity by lipoproteins. 
 
Hydrolase interaction network associated to PG synthesis 
The high resolution structure of the N-terminal domain of the OM-anchored lipoprotein, 
LpoA was determined by NMR spectroscopy. In combination with SAXS and AUC of the 
full length protein, and modelling of the C-terminal domain based on the crystal structure of 
LpoA from H. influenzae, we present a full length structural model. It is predicted that LpoA 
is long enough to reach through pores in the PG layer to interact with the ODD domain of 
PBP1A. In comparison to H. influenzae, E. coli LpoA possesses C-terminal flexible ‘wing’-
like domains preventing structure determination by NMR spectroscopy. As LpoAC is 
sufficient for interaction and stimulation of PBP1A activity our hypothesis was that these 
domains could be interaction sites. However, we showed that these are not crucial for the in 
vivo interaction with PBP1A. Purification of LpoA versions lacking these domains have been 
unsuccessful which we hypothesise is due to intrinsic instability. Attempts to optimise the 
purification of these constructs are planned and we aim to use them to study the interaction 
and stimulation of PBP1A, and other LpoA interaction partners.  
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The ‘wing’-like domains of LpoA from E. coli are not present in H. influenzae. LpoA from 
both organisms and LpoB from E. coli, were tested for effects on the activity of PBP1A and 
PBP1B from both organisms. PBP1A from H. influenzae was as active as E. coli PBP1A 
when stimulated by its cognate LpoA. In contrast, the activity of PBP1B from H. influenzae 
has a very low level of TPase activity, alone or in the presence of any Lpo protein tested. 
There is no PBP stimulation by any non-cognate Lpo protein tested. The small size and slow 
generation time of H. influenzae in comparison to E. coli may explain why there is no 
requirement for stimulation and the low cross-linking activity of PBP1B. As LpoA is essential 
in H. influenzae, we predict a different primary role of LpoA in each organism. A CpoB-
related function of E. coli LpoA has been described [91]. It is suggested that there is a partial 
redundancy between CpoB and LpoA in the tethering of the Tol-Pal system to the PG 
synthesis machinery for coordination with OM constriction during cell division. As PBP1A in 
H. influenzae is already as active as LpoA-stimulated PBP1A in E. coli, we hypothesise that 
the primary role of H. influenzae LpoA is this CpoB-related function, however, further 
experiments are required to address this hypothesis.  
Continuing in E. coli, the in vitro interaction between LpoA and PBP1A was thoroughly 
investigated by SPR and MST. Using MST, a KD of 852 ± 146 nM was determined. This 
affinity closely correlates with that of the interaction between LpoB and PBP1B which has a 
KD of 810 ± 80 nM [75].  
The NMR spectra of LpoAN revealed an elongated shape comprised exclusively of α-helices 
organised into canonical TPR motifs, between which are conserved residues. It was 
hypothesised that this domain could facilitate novel LpoA interaction partners. 
Through a proteomics-based search for these proteins using LpoAN we discovered the 
functional relationship between LpoA and PBP4. The interaction sites between the two 
proteins likely include domain 1 and/or domain 2 of PBP4, and while both domains of LpoA 
can interact with PBP4, it is likely that LpoAC is the primary PBP4 interaction site. A direct in 
vitro and in vivo interaction between PBP4 and PBP1A was also discovered. It is LpoAC that 
interacts with PBP1A, and as stated above, we predict LpoAC is also primarily responsible for 
the interaction with PBP4. This could indicate that the three proteins interact as a trimeric 
complex. LpoA moderately inhibits the activity of PBP4 and stimulates the activity of PBP1A 
but there was no effect of PBP4 on PBP1A activity, or vice versa. It was concluded that these 
interactions may take place to recruit PBP4 to sites of ongoing PG synthesis by the core 
synthesis complex during elongation. Localisation studies will be required to test this 
hypothesis and whether this recruitment of PBP4 is exclusive to the elongation machinery. 
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PBP7 was also discovered to have direct interactions with LpoA, PBP1A, and PBP4. Again, 
we hypothesise that PBP7 is recruited as a space-making enzyme to facilitate the insertion of 
nascent PG, and whose activity may be coordinated with that of PBP4.    
A direct interaction between two of the three recently discovered EPases, MepS and MepM 
was also observed, as was the interaction of MepS and PBP1A. No interactions between 
PBP4 and PBP7 with MepS or MepM have been observed and we hypothesise that MepS and 
MepM are recruited to the elongasome as a separate hydrolase complex to PBP7 and PBP4. 
Direct interactions between MepA and PBP4, PBP7 and MepS were also identified.  
We have identified multiple direct interactions traversing four different groups of EPases; the 
Class C PBPs, PBP4 (also possessing CPase activity) and PBP7; the NlpC/P60 superfamily, 
MepS; the M23 LytM metallopeptidases, MepM; and the LAS family of metallopeptidases, 
MepA, with direct or indirect associations to the PG synthesis machinery. The data presented 
in this work suggests that the PG hydrolases of E. coli exist as large protein complexes of 
enzymes belonging to different protein families. We speculate that the hydrolases involved 
possess different substrate specificities, and different optimal conditions. The identification of 
the pH dependent activity of MepA supports this hypothesis and will be discussed below. To 
have a set of coordinated enzymes with the same cleavage site, but conditional activities and 
different substrate specificities, would provide the cell with a large degree of hydrolytic 
functional redundancy. This could explain why no single deletion of the E. coli hydrolases has 
a strong phenotype. The direct or indirect interactions of multiple hydrolases, between each 
other and the PG synthesis machinery, highlights a flexible yet well controlled PG hydrolase 
system for the safe insertion of nascent PG into the pre-existing layer.  
 
Conditional activity of hydrolases 
As alluded to above, conditional PG hydrolase activity is particularly highlighted in the case 
of MepA. We show that MepA is inactive on intact sacculi at pH 7.5, unlike the other EPases 
investigated in this work, whereas at pH 5.0, MepA is active. It was shown that this is due to 
an inability to bind to intact sacculi at pH 7.5.  
It is speculated that this pH dependent hydrolase activity could be present in other protein 
families possessing hydrolase activity, for example the six redundant DD-CPases of E. coli. 
The monofunctional CPase PBP6B has recently been shown to be expressed in greater 
amounts at pH 5.0 than at pH 7.5 and to show more activity at pH 5.0 (Peters et al. 2016. in 
press). Conditional specificity has also been observed for the hydrolases possessing LT 
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activity, with MltA expressing optimal activity at pH 4-4.5 and at 30°C [249]. We therefore 
hypothesise that hydrolases across different families may have conditional specificity to allow 
efficient hydrolase activity at many different conditions.  
 
Hydrolase domains crucial for activity   
The amidases AmiB and AmiC are known to possess an α-helix which occludes the active site 
which prevents activity. Upon interaction with their cognate activators EnvC and NlpD, 
respectively, this α-helix is removed to allow activity. This is potentially a method of 
controlling aberrant hydrolase activity at sites other than at cell division.  
Similarly, the biochemical investigation into the structure and activities of PBP4 identified the 
globular, non-catalytic domain 3 as crucial for activity, but not for substrate binding. Two 
possible explanations are that domain 3 acts to correctly position substrate for degradation, or, 
that without domain 3, PBP4 dimerises in such a way that substrate cannot be processed once 
bound. Interestingly, while domain 3 is not an interaction site for LpoA or PBP1A, which 
have little to no effect on activity, it is crucial for the interaction with NlpI, which stimulates 
activity in vitro. It is speculated that conformational changes in domain 3 may reveal or 
conceal more of the active site of PBP4 thus modulating activity. This, and a hypothesised 
complementary modulation of PBP4 activity by LpoAN, is discussed in more detail below.  
 
Regulation of activity by lipoproteins 
There are currently two regulators of hydrolase activity in E. coli described in appreciable 
detail; EnvC and NlpD, the regulators of amidase activity during daughter cell separation. E. 
coli possesses ~30 hydrolases that have no known regulators of activity. Characterised in this 
work is the identification of NlpI, an OM-anchored lipoprotein, as a novel regulator of EPases 
in E. coli. 
NlpI interacts with five of the seven known EPases of E. coli; PBP4, PBP7, MepS, MepM, 
and MepA, themselves linked by direct interactions with each other and the core PG synthesis 
complex during elongation. NlpI differentially affects the activity of PBP4, MepS and MepM 
in vitro. It was shown that NlpI possesses different binding sites for at least MepS, PBP4 and 
PBP7, being able to interact with each in the presence of excess concentrations of another, for 
example NlpI can still interact with MepS in the presence of PBP4. NlpI, MepS and PBP4 
were also shown to form a ternary complex in vitro. It will be interesting to test if NlpI 
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preferentially binds to certain EPases at different conditions, for example the pH dependent 
interaction with MepA.  
The first NlpI interaction partner confirmed was PBP4, which we continued to investigate by 
showing that it is domain 3 of PBP4 that is the main NlpI interaction site. As NlpI stimulates 
PBP4 activity in vitro, and domain 3 is essential for activity, it is hypothesised that the 
interaction causes a conformational change in domain 3 to alter its activity. In comparison to 
the interaction between PBP4 and LpoA where it is likely that domain 1 and /or 2 is the main 
LpoA interaction site. However, a potential modulatory role of LpoAN was identified, 
complementing that of NlpI; in the absence of domain 3, the KD of the interaction between 
LpoAN and PBP4 decreases more than 50 fold. We speculate that these interactions could 
represent a putative modulation of PBP4 activity. NlpI may interact with domain 3 of PBP4 to 
stimulate activity by inducing a conformational change in domain 3, causing the affinity for 
LpoAN to increase in order to exert an inhibitory effect. This could be a novel method of 
modulating the potentially autolytic activity of PBP4 in response to the changing conditions 
of the cell. Using a modified version of the MST assay it was shown that the presence of 
excess NlpI does not prevent the interaction of PBP4 with PBP1A or LpoA. These data 
support the hypothesis that NlpI interacts with PBP4 primarily through domain 3 of PBP4 and 
that PBP1A/LpoA interact with PBP4 through domain 1 and/or 2.   
Cells transformed with pJP1 and lacking NlpI are incapable of inducing a β-lactamase 
response when exposed to the antibiotic imipenem. These data support the in vivo regulation 
of EPase activity by NlpI, as well as potentially LT activity. More in vivo experiments are 
currently underway to observe the regulation of EPase activity by NlpI in the cellular 
environment. Localisation assays of the EPases in the presence and absence of NlpI are also 
underway in order to observe any spatio-temporal role of NlpI. As discussed above, we 
hypothesise that the hydrolases investigated in this work exist as a larger complex which can 
be recruited to sites of ongoing PG synthesis. We hypothesise that NlpI also exists as part of 
this complex and can differentially modulate the activity of the hydrolases when required. An 
example presented in this work is the pH dependent interaction of NlpI and MepA, whose 
activity is also pH dependent. 
Differences in substrate specificity, and conditional optimal activity across the multiple 
hydrolase families present in this multi-enzyme complex, could provide the cell with the 
robustness required for growth at different conditions, and explain the high redundancy of the 
PG hydrolases. Some may be tailored to the digestion of intact sacculi, and some to the 
digestion of muropeptides, this would provide the cell with the tools required for the efficient 
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and complete breakdown and turnover of PG during growth. Others may be pH dependent, for 
example MepA, or more active at higher NaCl conditions. The role of NlpI in this complex 
may be to coordinate which hydrolases will be more or less active at which time. A schematic 
of all the interactions characterised in this work, as well as the effects on activity of these 
interactions, is summarised in figure 4.1 and table 4.1. 
 
Summary 
Höltje proposed that for the successful and safe enlargement of the bacterial cell wall in rod-
shaped bacteria, PG synthases and hydrolases would be active within multi-enzyme 
complexes [57]. Since then, the identification of protein complexes specialised for the 
elongation and division phases of bacterial growth have been characterised [4,238]. More 
recently, prokaryotic cytoskeletal elements have been shown to spatio-temporally localise 
these complexes from the cytoplasm [23,238]. Later, it was discovered that PG synthesis is 
also regulated by OM-anchored lipoproteins; LpoA and LpoB [25,26]. While the mechanisms 
of PG synthesis have been studied in recent years, the molecular interplay with the PG 
hydrolases and how this activity is regulated remains poorly understood.  
In this work we continued to dissect the known interaction between the major PG synthase 
during cell elongation, PBP1A and the OM-anchored regulator LpoA, identifying novel wing-
like domains of LpoA through the high resolution NMR structure of LpoAN and subsequent 
modelling of the full length protein, drawing comparisons with LpoA from H. influenzae.  
The search for novel LpoA interaction partners lead to the discovery of a potential trimeric 
complex consisting of a PG synthase (PBP1A) a PG hydrolase (PBP4) and a lipoprotein 
regulator (LpoA). This formed the basis of the search and discovery of a large number of 
direct and novel interactions between the PG synthases and hydrolases.  
Four methods of controlling PG hydrolases in E. coli were concluded in this work; the 
identification of a network of interactions between the PG hydrolases and synthases providing 
support for the hypothesised multi-enzyme complexes for PG growth; pH dependent 
hydrolase activity, inferring conditional activity of PG hydrolases at different stages of the 
cell cycle; non-catalytic domains crucial for activity, but not for substrate binding, indicating 
intrinsic feedback within individual proteins; and the identification of a global regulator of 
EPase activity, NlpI. 
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Final word 
The growth of the PG layer remains one of the most promising sources of novel antibiotic 
targets. This work provides major insights into the understanding of the regulation of 
peptidoglycan hydrolysis and its coordination with PG synthesis in E. coli. Improving the 
understanding of essential prokaryotic processes is paramount for the future identification of 
novel antibiotics, highlighted by the increasing prevalence of antibiotic resistant bacteria.  
 
 
Figure 4.1 Network of interactions between the PG synthases, hydrolases and regulators  
Summary of interactions and their affinities identified in this work, and by the Typas group which have not yet 
been tested in vitro. Interaction and KD of NlpD and AmiC shown by [159].  
 
 
 
 
No effect
Stimulatory
Inhibitory
Type of interaction
Dimer
< 100
100 - 300
300 - 1000
> 1000
not known
KD/EC50 of Interaction
MepA
YebA
Spr
LpoA
EnvC
NlpI
PBP7PBP1A
PBP4
AmiA AmiC
AmiB NlpD
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Table 4.1 Project interaction summary 
 
 
 
 
 
 
 
 
PBP4
PBP4 
ΔD3
LpoA PBP1A NlpI
NlpI 
ΔC11
Spr PBP7 YebA MepA Slt Pal CpoB EnvC LpoB PBP5 PBP6B
PBP4 M/A M/P/S/C M/P/S/C M/P/S/A P M/P M/P M/P M/P M/P P M/P P/C
PBP4 
ΔD3
M M M/P M
LpoA M/S/C M/P M/P M P M M/P P P P
PBP1A M M M/P
NlpI M/A M/P M/P/A M/P M/P M/P/A P P M/P P P P
NlpI 
ΔC11
M/P
Spr M/P M M/P M/P M
PBP7 A M M/P M/P M
YebA M M/P
MepA M M/P
Slt A P P
Pal
CpoB
EnvC
LpoB
PBP5
PBP6B
M
P
S
A
C In vivo  co-immunoprecipitation
Positive interaction
Contradictory results/needs repeating
Negative interaction
Not tested
Microscale thermophoresis
Ni-bead pull -downs
Surface Plasmon Resonance
Analytical Ultracentrifugation
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5.1 Antibodies 
Table 5.1 List of antibodies used in this project 
 
1Newcastle University, Vollmer group 
 
5.2 Plasmids 
Table 5.2 List of plasmids used in this project 
Plasmid Strain(s) 
Resistance 
cassette 
Remarks Source 
pET28-His-
LpoA(sol)Δ1-27 
BL21(DE3) 
DH5α 
Kan • N-terminal His-tag 
• Purification of full 
length His-
LpoA(sol) 
Katrin Beilhartz 
pET28-His-LpoAN BL21(DE3) 
DH5α 
Kan • N-terminal His-tag 
• Purification of 
His-LpoAN  
Katrin Beilhartz 
pET28-His-LpoAC BL21(DE3) 
DH5α 
Kan • N-terminal His-tag 
• Purification of 
His-LpoAC  
Katrin Beilhartz 
pET28-His-LpoA  
(H. influenzae) 
BL21(DE3) 
DH5α 
Kan • N-terminal His-tag 
• Purification of full 
length His-LpoA 
from H. influenzae  
Manuel Banzhaf 
Antibody Working dilution Source 
α-LpoA 1 in 5000 Manuel Banzhaf1 
α-PBP1A 1 in 5000 Manuel Banzhaf1 
α-PBP1B 1 in 5000 Ute Bertsche1 
α-PBP4 1 in 2000 This work 
α-NlpI 1 in 5000 This work 
α-MepA 1 in 5000 This work 
α-MepS 1 in 2000 This work 
α-MepM 1 in 5000 Astrid Schwaiger1 
α-PBP7 1 in 5000 Hamish Yau1 
Goat α-rabbit-HRP conjugated 1 in 10000 Sigma 
TrueBlotTM α-rabbit 1 in 2000 eBioscience/Rockford 
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pET28-His-
LpoB(sol)Δ1-20 
BL21(DE3) 
DH5α 
Kan • N-terminal His-tag 
• Purification of full 
length His-
LpoB(sol) 
[31] 
pTK1A-His MC1061 Kan • N-terminal His-tag 
• Purification of full 
length His-PBP1A  
Sylvia Liebscher 
    pET28-His-
PBP1A     (H. 
influenzae) 
BL21(DE3) 
DH5α 
Kan • N-terminal His-tag  
• Purification of full 
length His-PBP1A 
from H. influenzae 
Manuel Banzhaf 
pDML924 BL21(DE3) 
DH5α 
Kan • N-terminal His-tag  
• Purification of full 
length His-PBP1B  
[251] 
    pET28-His-PBP1B     
(H. influenzae) 
BL21(DE3) 
DH5α 
Kan • N-terminal His-tag 
• Purification of full 
length His-PBP1A 
from H. influenzae 
Manuel Banzhaf 
pQE30-His-ODD MC1061 Kan • N-terminal His-tag  
• Purification of 
His-ODD of 
PBP1A 
Athanasios Typas 
pET21b-PBP4Δ1-60 BL21(DE3) 
DH5α 
Amp • Native                       
• Purification of 
native PBP4  
Manuel Pazos 
pET21b-His-PBP4   
Δ1-60 
BL21(DE3) 
DH5α 
Amp • N-terminal His-tag  
• Purification of 
His- PBP4  
Manuel Pazos 
pET21b-PBP4 S62A    
Δ1-60 
BL21(DE3) 
DH5α 
Amp • Native                       
• Purification of 
native PBP4 active 
site mutant                      
Manuel Pazos 
pBAD18-His-
PBP4ΔD3 
BL21(DE3) 
DH5α 
Amp • N-terminal His-tag  
• Purification of 
His- PBP4 lacking 
domain 3  
Ann-Kristin Hov 
pET21b-His-
PBP4S62AΔ1-60 
BL21(DE3) 
DH5α 
Amp • N-terminal His-tag    
• Purification of 
His-PBP4 active 
site mutant 
Manuel Pazos 
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pET28-His-PBP7 BL21(DE3) 
DH5α 
Kan • N-terminal His-tag    
• Purification of 
His- PBP7  
Ann-Kristin Hov 
pET28-His-PBP7 
S67A 
BL21(DE3) 
DH5α 
Kan • N-terminal His-tag  
• Purification of 
His- PBP7 active 
site mutant 
Manuel Banzhaf 
pET28-His-EnvC BL21(DE3) 
DH5α 
Kan • N-terminal His-tag    
• Purification of 
His- EnvC 
Manuel Banzhaf 
pJFK-MepA MC1061 Kan • Native                       
• Purification of 
native MepA                 
Vollmer group 
strain collection 
pET28-His-MepM BL21(DE3) 
DH5α 
Kan • N-terminal His-tag    
• Purification of 
His- MepM 
Manjula Reddy 
pET28-His-MepM 
H314A 
BL21(DE3) 
DH5α 
Kan • N-terminal His-tag  
• Purification of 
His- MepM active 
site mutant 
Manjula Reddy 
pET28-His-MepS BL21(DE3) 
DH5α 
Kan • N-terminal His-tag    
• Purification of 
His- MepS 
Manjula Reddy 
pET28-His-MepS 
C68A 
BL21(DE3) 
DH5α 
Kan • N-terminal His-tag  
• Purification of 
His- MepS active 
site mutant 
Manjula Reddy 
pCP20 DH5α Cam/Amp • Removal of FRT- 
flanked Kan 
resistance cassette 
in E. coli via yeast 
Flp recombinase 
[234] 
pJP1 MC1061 Kan • ampR/ampC 
operon from E. 
cloacae 
Vollmer group 
strain collection 
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5.3 Materials 
5.3.1 Chemicals 
30% Acrylamide (Rotipherese)    Roth 
Acetic acid       Sigma 
Agar        Fluka 
Ammonium Peroxodisulphate (APS)    Serva 
Amplex Red       Sigma 
Bromphenol blue      Sigma 
Bovine Serum Albumin     Pierce 
Calcium Chloride      Sigma 
Casein        VWR 
Chloroform       Fisher 
CNBr-activated sepharose     GE Healthcare 
Coomassie Brilliant Blue R-250    Roth 
D-amino acid oxidase      Sigma 
DMSO        Sigma 
DTSSP       Pierce/Thermo Scientific 
DTT        Sigma 
EDTA        Sigma 
EGTA        Sigma 
Ethanol       Fisher 
Glycerol       Sigma 
Glucose       Sigma 
Glycine       Sigma 
HEPES       VWR 
Horseradish peroxidase     Sigma 
Hydrochloric acid       Sigma 
Imidazole       Sigma 
Isopropanol       Sigma 
Magnesium chloride      VWR 
Lennox LB        Fisher Scientific 
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β-mercaptoethanol      Sigma 
Methanol       Fisher 
Methylene blue      Sigma 
MilliQ H2O       Millipore dispenser 
Phosphoric acid      Sigma 
Protease inhibitor cocktail (P8465)    Sigma 
Rotiphorese        Roth 
Rubidium chloride      Sigma 
Sodium acetate      Sigma 
Sodium azide       Merck 
Sodium borate       Sigma 
Sodium borohydride      Sigma 
Sodium chloride      VWR 
Sodium dihydrogenphosphate    VWR 
di-Sodium orthophosphate     VWR 
Sodium dodecyl sulphate     Melford 
Sodium hydroxide      Sigma 
Sodium phosphate      Sigma 
TEMED       Sigma 
Thrombin       Novagen 
Triton X-100       Roche 
TrizmaTM base (Tris)      Sigma 
Tryptone       VWR 
Tween 20       Serva 
Yeast extract       Deutshe Hefewerke  
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5.3.2 Antibiotics 
Ampicillin       Sigma 
Aztreonam       Sigma 
Bocillin FL       Molecular probes 
Chloramphenicol      Sigma 
Imipenem monophosphate     Santa Cruz Biotechnology  
Kanamycin       Sigma 
Nitrocefin       Sigma 
Streptomycin       Hoescht 
 
5.3.3 Enzymes for PG analysis and assays 
α-amylase (Bacillus subtilis)     Fluka 
Cellosyl (Streptomyces coelicolor)    Hoescht 
DNase (Bovine pancreatic)     Sigma 
Pronase E (Streptomyces grisens)    Boehringer 
Vim4 β-lactamase (Pseudomonas aeruginosa)  Adeline Derouaux  
 
5.3.4 Molecular weight markers 
PageRulerTM prestained marker    Thermo Scientific 
SpectraTM high range marker     Thermo Scientific 
 
5.3.5 Kits 
Monolith protein labelling kit (red-malaimide)  Nanotemper 
Monolith protein labelling kit (red-NHS)   Nanotemper 
Pierce BCA protein assay kit     Thermo Scientific 
ProteONTM HP general amine coupling kit   Biorad 
GeneluteTM HP plasmid midi-prep kit   Sigma 
Zinc staining kit      BioRad 
 
 
 
  
209 
 
  
5.3.6 Other materials 
BioscaleTM Mini-CHTTM hydroxyapatite cartridge (5 ml) BioRad 
Chemiluminescence (ECL) reagents    GE Healthcare 
Dialysis cassettes MWc.o 6-8 kDa    Novagen 
Dialysis tubing MWc.o 6-8 kDa    Spectrum labs 
[14C]-GlcNAc lipid II      Eefjan Breukink 
Dansyl-lipid II      Eefjan Breukink, Jules Phillipe 
FloScint III liquid scintilant     Perkin Elmer  
HisTrap HP (5 ml)      GE healthcare 
HiTrap Q HP (5 ml)      GE healthcare 
HiTrap SP HP (5 ml)      GE healthcare 
Ni2+-NTA superflow beads     QIAGEN  
Nitrocellulose membrane     BioRad 
ProteONTM GLC sensorchip     BioRad 
Protein G-coupled agarose      Pierce/Thermo Scientific 
Superdex75 HiLoad 16/60     GE healthcare 
Superdex75 10/300 GL     GE healthcare 
Superdex200 HiLoad 16/60     GE healthcare 
Superdex200 10/300 GL     GE healthcare 
VivaSpin 6 columns (MWc.o 5 kDa)    Sartorius Stedim 
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5.3.7 E. coli strains   
Table 5.3 List of E. coli strains used in this project 
Strain Property  Source 
MC1061 Laboratory strain [252] 
BW25113 Keio laboratory strain [239,240] 
BL21(DE3) Expression strain F- ompT, dc hsdS 
(rB- mB-) gal (λDE3 
Novagen 
XL1-Blue Expression strain recA1, endA1m 
gyrA96, thi-1, hsdR17, supE44, 
relA1, lac 
Stratagene 
DH5α Non-expression strain huA2, 
lavU169, phoA, glnV44, φ80 
Invitrogen 
BW25113ΔdacB dacB deletion strain [239,240] 
BW25113ΔlpoA lpoA deletion strain [239,240] 
CAG70778  BW25113. LpoA lacking wing 1 
(Δ294-351) 
Andrew Gray 
CAG70779  BW25113. LpoA lacking wing 2 
(Δ501-523)  
Andrew Gray 
CAG70780  BW25113. LpoA lacking wing 1 and 
wing 2 (Δ294-351 and Δ501-523) 
Andrew Gray 
CAG70169  BW25113. LpoA lacking TPR 
domain (Δ58-252) 
Andrew Gray 
CAG70777  BW25113. LpoA lacking the C-
terminal domain (Δ257-679) 
Andrew Gray 
BW25113ΔmrcA mrcA deletion strain [239,240] 
BW25113ΔmrcB mrcB deletion strain [239,240] 
BW25113ΔdacB dacB deletion strain [239,240] 
BW25113ΔnlpI nlpI deletion strain [239,240] 
BW27783 Laboratory strain Manjula Reddy 
BW27783ΔnlpI nlpI deletion strain Manjula Reddy 
BW27783Δprc prc deletion strain Manjula Reddy 
BW27783ΔmepS mepS deletion strain Manjula Reddy 
BW27783ΔmepM mepM deletion strain Manjula Reddy 
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BW27783 pCL1920  Laboratory overexpression strain Manjula Reddy 
BW27783 pCL1920 NlpI nlpI overexpression strain Manjula Reddy 
BW27783 pCL1920 Prc prc overexpression strain Manjula Reddy 
BW25113 pJP1 Keio laboratory strain containing 
ampR/ampC of E. cloacae 
This work 
BW25113ΔdacB pJP1 dacB deletion strain containing 
ampR/ampC of E. cloacae 
This work 
BW25113ΔlpoA pJP1 lpoA deletion strain containing 
ampR/ampC of E. cloacae 
This work 
BW25113ΔmrcA pJP1 mrcA deletion strain containing 
ampR/ampC of E. cloacae 
This work 
BW25113ΔmrcB pJP1 mrcB deletion strain containing 
ampR/ampC of E. cloacae 
This work 
BW25113ΔdacB pJP1 dacB deletion strain containing 
ampR/ampC of E. cloacae 
This work 
BW25113ΔnlpI pJP1 nlpI deletion strain containing 
ampR/ampC of E. cloacae 
This work 
BW27783 pJP1 Laboratory strain containing 
ampR/ampC of E. cloacae 
This work 
BW27783ΔnlpI pJP1 nlpI deletion strain containing 
ampR/ampC of E. cloacae 
This work 
BW27783Δprc pJP1 prc deletion strain containing 
ampR/ampC of E. cloacae 
This work 
BW27783ΔmepS pJP1 mepS deletion strain containing 
ampR/ampC of E. cloacae 
This work 
BW27783ΔmepM pJP1 mepM deletion strain containing 
ampR/ampC of E. cloacae 
This work 
BW27783 pCL1920 pJP1 Laboratory overexpression strain 
containing ampR/ampC of E. cloacae 
This work 
BW27783 pCL1920 NlpI 
pJP1 
nlpI overexpression strain containing 
ampR/ampC of E. cloacae 
This work 
BW27783 pCL1920 Prc 
pJP1  
prc overexpression strain containing 
ampR/ampC of E. cloacae 
This work 
 
5.3.8 Laboratory equipment 
Agilent 1200 HPLC system     Agilent technologies 
Autoclave       Astell 
ÄKTA Prime+       GE Healthcare 
Avanti J-26 XP centrifuge     Beckman-Coulter 
β-RAM model5 scintillation flow-cell   LabLogic 
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Developer       Konica SRX-101A 
Digital sonifier      Branson 
Epson perfection 3490 scanner    Epson 
Gel tank, for SDS-PAGE     BioRad 
ImageQuant LAS4000mini     GE Healthcare 
J-810 spectropolarimeter     Jasco 
Kern EG balance      Kern 
Kern PFB balance      Kern 
Mettler Toledo Classic plus balance    Mettler 
FLUOstar Optima plate reader    BMG labtech 
Micro 200R microfuge     Hettich 
MilliQ PF plus water purification machine   Millipore 
Monolith NT.115TM series MST machine   Nanotemper technologies 
OptimaTM ultracentrifuge     Beckman-Coulter 
OptimaTM TLX ultracentrifuge    Beckman-Coulter 
pH meter       Jenway 
Prism microfuge      Labnet 
ProteONTM XPR36      BioRad 
ScanVac SpeedVac system     UniEqzip 
Sigma 3-16k centrifuge     Scientific Laboratory Supplies 
Spectrophotometer      Biochrom Libra S22 
Thermomixer       Eppendorf 
Typhoon scanner      GE Healthcare 
Water bath with thermostat     Clifton 
Wet-Blot transfer chamber     BioRad 
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5.4 Supplementary figures 
 
 
Figure 5.1 Raw MST data corresponding to figure 3.1B 
A. Pre-experiment capillary scans of FL-PBP1A + LpoA. B. MST measurements were taken at 90% LED power 
and 20% MST power.  
A
B
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Figure 5.2 HPLC chromatograms corresponding to figure 3.7 
Representative HPLC chromatograms corresponding to figure 3.7, showing counts per minute (CPM) against 
time (min). A; E. coli PBP1A + all Lpo proteins. B; E. coli PBP1B + all Lpo proteins. C; H. influenzae PBP1A + 
all LpoA proteins. C; H. influenzae PBP1B + all LpoA proteins. 
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Figure 5.3 Raw MST data corresponding to figure 3.10B 
A. Pre-experiment capillary scans of FL-LpoA + PBP4. B. Capillary scan after SDS-denaturation test of the 
three samples containing the highest concentration of unlabelled ligand and the three samples containing the 
lowest concentration. MST measurements were taken at 100% LED power and 20% MST power.  
1 2 3 14 15 16
High concentration Low concentration
Capillary
A
B
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Figure 5.4 Raw MST data corresponding to figure 3.11B 
A. Pre-experiment capillary scans of FL-LpoA + PBP4ΔD3 in triplicate. B. MST measurements were taken at 
100% LED power and 20% MST power.  
A
B
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Figure 5.5 Raw MST data corresponding to figure 3.11C 
A. Pre-experiment capillary scans of FL-LpoAC + PBP4 in triplicate. B. MST measurements were taken at 20% 
LED power and 40% MST power.  
A
B
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Figure 5.6 Raw MST data corresponding to figure 3.11D 
A. Pre-experiment capillary scans of FL-LpoAC + PBP4ΔD3 in triplicate. B. MST measurements were taken at 
20% LED power and 40% MST power.  
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Figure 5.7 Raw MST data corresponding to figure 3.11E 
A. Pre-experiment capillary scans of FL-LpoAN + PBP4. B. MST measurements were taken at 20% LED power 
and 40% MST power.  
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Figure 5.8 Raw MST data corresponding to figure 3.11F 
A. Pre-experiment capillary scans of FL-LpoAN + PBP4ΔD3 in duplicate. B. MST measurements were taken at 
20% LED power and 40% MST power.  
A
B
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Figure 5.9 Raw MST data corresponding to figure 3.13B 
A. Pre-experiment capillary scans of FL-PBP1A + PBP4 and MST timetrace taken at 20% MST power, 80% 
LED power. B. Repeat of the above. 
A
B
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Figure 5.10 Raw MST data corresponding to figure 3.14A 
A. Pre-experiment capillary scans of FL-PBP7 + LpoA in triplicate. B. Capillary scan after SDS-denaturation 
test of the three samples containing the highest concentration of unlabelled ligand and the three samples 
containing the lowest concentration. MST measurements were taken at 40% LED power and 20% MST power.  
A
B
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Figure 5.11 Raw MST data corresponding to figure 3.14B 
A. Pre-experiment capillary scans of FL-PBP7 + PBP1A in duplicate. B. MST measurements were taken at 80% 
LED power and 20% MST power.  
A
B
  
224 
 
  
 
Figure 5.12 Raw MST data corresponding to figure 3.14C 
A. Pre-experiment capillary scans of FL-PBP7 + PBP4 in triplicate. B. Capillary scan after SDS-denaturation 
test of the three samples containing the highest concentration of unlabelled ligand and the three samples 
containing the lowest concentration. MST measurements were taken at 40% LED power and 40% MST power.  
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Figure 5.13 Raw MST data corresponding to figure 3.15A 
A. Pre-experiment capillary scan of FL-MepS + PBP7. B. MST timetrace. MST measurements were taken at 
40% LED power and 40% MST power.  
 
 
 
Figure 5.14 Raw MST data corresponding to figure 3.15B 
A. Pre-experiment capillary scan of FL-MepM + PBP7. B. MST timetrace. MST measurements were taken at 
40% LED power and 40% MST power.  
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Figure 5.15 Raw MST data corresponding to figure 3.16A 
A. Combined pre-experiment capillary scans of FL-MepM + MepS. B. MST timetrace. MST measurements were 
taken at 40% LED power and 20% MST power.  
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Figure 5.16 Raw MST data corresponding to figure 3.16B 
A. Pre-experiment capillary scans of FL-PBP1A + MepS. B. Capillary scan after SDS-denaturation test of the 
three samples containing the highest concentration of unlabelled ligand and the three samples containing the 
lowest concentration. MST measurements were taken at 20% LED power and 40% MST power.  
 
 
Figure 5.17 Raw MST data corresponding to figure 3.17A 
A. Pre-experiment capillary scan of FL-MepS + LpoA. B. MST timetrace. MST measurements were taken at 
40% LED power and 20% MST power.  
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Figure 5.18 Raw MST data corresponding to figure 3.17B 
A. Pre-experiment capillary scan of FL-MepS + PBP4. B. MST timetrace. MST measurements were taken at 
40% LED power and 40% MST power.  
 
 
 
Figure 5.19 Raw MST data corresponding to figure 3.17D 
A. Pre-experiment capillary scan of FL-MepS + EnvC. B. MST timetrace. MST measurements were taken at 
40% LED power and 20% MST power.  
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Figure 5.20 Raw MST data corresponding to figure 3.18A 
A. Pre-experiment capillary scan of FL-MepM + PBP4. B. MST timetrace. MST measurements were taken at 
20% LED power and 20% MST power.  
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Figure 5.21 Raw MST data corresponding to figure 3.23 
A. Pre-experiment capillary scans of FL-PBP1A + PBP4ΔD3. B. MST timetrace. MST measurements were 
taken at 80% LED power and 20% MST power.  
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Figure 5.22 MepA activity on sacculi and muropeptides at pH 7.5 
MepA was incubated o/n with intact sacculi (MC1061) at 20 µM, or for 90 min on isolated muropeptides (MPs) 
at 10 nM. The relative percentage of Tetra and TetraTetra-containing muropeptides after digestion was 
calculated and plotted. Assay was carried out at pH7.5 and 150 mM NaCl.   
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Figure 5.23 Raw MST data corresponding to figure 3.24A 
A. Pre-experiment capillary scans of FL-MepA + PBP7. B. MST timetrace. MST measurements were taken at 
40% LED power and 60% MST power.  
 
 
Figure 5.24 Raw MST data corresponding to figure 3.24B 
A. Combined pre-experiment capillary scans of FL-MepA + PBP4. B. MST timetrace. MST measurements were 
taken at 40% LED power and 60% MST power.  
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Figure 5.25 Raw MST data corresponding to figure 3.24C 
A. Combined pre-experiment capillary scans of FL-MepA + MepS. B. MST timetrace. MST measurements were 
taken at 40% LED power and 60% MST power.  
 
 
 
Figure 5.26 Raw MST data corresponding to figure 3.25C 
A. Combined pre-experiment capillary scans of FL-MepA + MepM. B. MST timetrace. MST measurements 
were taken at 40% LED power and 60% MST power.  
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Figure 5.27 HPLC chromatograms corresponding to figure 3.26, pH 7.5 
Representative HPLC chromatograms for pH 7.5 samples corresponding to figure 3.27 showing absorbance at 
205 nm against time (min).  
 
 
Figure 5.28 HPLC chromatograms corresponding to figure 3.27, pH 5.0 
Representative HPLC chromatograms for pH 5.0 samples corresponding to figure 3.27 showing absorbance at 
205 nm against time (min).  
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Figure 5.29 HPLC chromatograms corresponding to figure 3.35 
Relative percentages of TetraTetra dimers of the total amount of Tetra-containing muropeptides at four different 
conditions corresponding to figure 3.36 showing absorbance at 205 nm against time (min). PBP7 (2 µM) was 
incubated with MC1061 muropeptides in the presence or absence of NlpI (4 µM) for 2 h. 
 
Figure 5.30 HPLC chromatograms corresponding to figure 3.40 
Relative percentages of TetraTetra dimers of the total amount of Tetra-containing muropeptides at four different 
conditions corresponding to figure 4.39 showing absorbance at 205 nm against time (min). MepS (5 µM) was 
incubated with MC1061 muropeptides in the presence or absence of NlpI (10 µM) o/n. 
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Figure 5.31 HPLC chromatograms corresponding to figure 3.43 
Relative percentages of TetraTetra dimers of the total amount of Tetra-containing muropeptides at four different 
conditions corresponding to figure 4.42 showing absorbance at 205 nm against time (min). MepM (2 µM) was 
incubated with MC1061 sacculi in the presence or absence of NlpI (4 µM) for 4 h. 
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Figure 5.32 Raw MST data corresponding to figure 3.30 
A. Pre-experiment capillary scans of FL-NlpI + NlpI. B. MST timetrace. MST measurements were taken at 50% 
LED power and 40% MST power.  
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Figure 5.33 Raw MST data corresponding to figure 3.31C 
A. Pre-experiment capillary scans of FL-NlpI + PBP4. B. MST timetrace. MST measurements were taken at 
40% LED power and 20% MST power.  
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Figure 5.34 HPLC chromatograms corresponding to figure 3.32 
Representative HPLC chromatograms for PBP4 (1 µm) on MC1061 sacculi in the presence or absence of NlpI (2 
µm). Absorbance read at 205 nm shown against time (min).  
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Figure 5.35 Raw MST data corresponding to figure 3.33B 
A. Pre-experiment capillary scans of FL-NlpI + PBP4ΔD3. B. MST timetrace. MST measurements were taken at 
40% LED power and 20% MST power.  
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Figure 5.36 Raw MST data corresponding to figure 3.36B 
A. Combined pre-experiment capillary scans of FL-NlpI + PBP7. B. MST timetrace. MST measurements were 
taken at 50% LED power and 10% MST power.  
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Figure 5.37 Raw MST data corresponding to figure 3.36C 
A. Pre-experiment capillary scans of FL-PBP7 + NlpI. B. MST timetrace. MST measurements were taken at 
40% LED power and 20% MST power.  
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Figure 5.38 Raw MST data corresponding to figure 3.38B 
A. Pre-experiment capillary scans of FL-MepS + NlpI. B. MST timetrace. MST measurements were taken at 
20% LED power and 40% MST power.  
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Figure 5.39 NlpI does not activate MepS activity on intact sacculi 
Intact sacculi form the W/T E. coli strain, MC1061, was incubated o/n at 37°C with 5μM MepS alone or in the 
presence of 10 μM NlpI, at four different conditions. Samples were inactivated by boiling and centrifuged. The 
released muropeptide-containing supernatant was reduced with sodium borohydride and analysed by HPLC. The 
relative amounts of TetraTetra dimer were calculated as a percentage of the total number of Tetra-containing 
muropeptides.  
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Figure 5.40 HPLC chromatograms corresponding to figure 3.40 
Representative HPLC chromatograms for MepS (5 µm) on MC1061 muropeptides in the presence or absence of 
NlpI (10 µm). Absorbance read at 205 nm shown against time (min).  
 
 
Figure 5.41 WT Growth curves corresponding to figure 3.41 
BW27783 WT cells were grown to an OD578 of 0.2 before inoculation with varying concentrations of imipenem. 
Growth was monitored for 4 h every 30 min. Absorbance read at 578 nm shown against time (min).  
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Figure 5.42 Raw MST data corresponding to figure 3.42B 
A. Pre-experiment capillary scans of FL-NlpI + MepM. B. Capillary scan after SDS-denaturation test of the 
three samples containing the highest concentration of unlabelled ligand and the three samples containing the 
lowest concentration. MST measurements were taken at 100% LED power and 20% MST power.  
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Figure 5.43 HPLC chromatograms corresponding to figure 3.43 
Representative HPLC chromatograms for MepM (2 µM) on sacculi in the presence or absence of NlpI (4 µM). 
Absorbance read at 205 nm shown against time (min).  
 
 
Figure 5.44 Raw MST data corresponding to figure 3.44B 
A. Pre-experiment capillary scan of FL-MepA + NlpI at pH 7.5. B. MST timetrace. MST measurements were 
taken at 60% LED power and 60% MST power.  
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Figure 5.45 Raw MST data corresponding to figure 3.44A 
A. Pre-experiment capillary scans of FL-MepA + NlpI at pH 5.0. B. MST timetrace. MST measurements were 
taken at 60% LED power and 60% MST power.  
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Figure 5.46 HPLC chromatograms corresponding to figure 3.45 
Representative HPLC chromatograms for MepA (2 µM) in the presence or absence of NlpI (4 µM). Absorbance 
read at 205 nm shown against time (min).  
 
 
 
Figure 5.47 NlpI has no effect on the activity of PBP1A  
The percentage of peptides in cross-links in PG made by PBP1A (0.5 µM) alone, in the presence of LpoA (2 
µM), NlpI (2 µM) or both. 
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Figure 5.48 Raw MST data corresponding to figure 3.49A 
A. Pre-experiment capillary scans of FL-PBP1A + NlpI. B. MST timetrace. MST measurements were taken at 
80% LED power and 20% MST power.  
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Figure 5.49 Raw MST data corresponding to figure 3.49C 
A. Combined pre-experiment capillary scans of FL-NlpI + EnvC B. MST timetrace. MST measurements were 
taken at 80% LED power and 20% MST power.  
 
 
Figure 5.50 Raw MST data corresponding to figure 3.50A 
A. Pre-experiment capillary scan of FL-LpoA + NlpI B. MST timetrace. MST measurements were taken at 
100% LED power and 20% MST power.  
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Figure 5.51 Raw MST data corresponding to figure 3.50B 
A. Pre-experiment capillary scans of FL-NlpI + Slt.  B. MST timetrace. MST measurements were taken at 40% 
LED power and 40% MST power.  
 
 
Figure 5.52 Raw MST data corresponding to figure 3.50C 
A. Pre-experiment capillary scan of FL-NlpI + LpoB. B. MST timetrace. MST measurements were taken at 40% 
LED power and 20% MST power.  
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